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resumo 
 
 
O alumínio é o terceiro elemento mais abundante na Terra.  Uma vez que se 
encontra distribuído ubiquamente pelo meio ambiente e é utilizado em vários 
produtos e processos, a população humana está inevitavelmente exposta 
diariamente a este metal.  De facto, o alumínio tem sido relacionado com 
diversas doenças neurodegenerativas como: a esclerose lateral amiotrófica, a 
demência de Parkinson (DP), a doença de Alzheimer (DA) e a encefalopatia 
relacionada com a diálise. 
A fosforilação de proteínas é um dos principais mecanismos reguladores 
intracelulares da maior parte das vias de sinalização nas células eucarióticas.  
Este processo dinâmico regula o estado de fosforilação e/ou a actividade das 
proteínas através de um balanço entre as proteínas cinases, que fosforilam, e 
as proteínas fosfatases (PP) que desfosforilam as proteínas. 
A proteína fosfatase 1 (PP1) é uma fosfatase específica para serina/treonina 
que está envolvida em importantes mecanismos celulares tais como o ciclo 
celular, contracção muscular e apoptose, entre outros.  A PP1 tem três 
isoformas conhecidas, denominadas PP1α, PP1β e PP1γ,.  O gene que 
codifica para a isoforma gama pode sofrer splicing alternativo originando a 
isoforma ubíqua PP1γ1 e a isoforma enriquecida no testículo PP1γ2. 
A fosforilação anormal de proteínas tem sido associada a várias patologias, 
incluindo cancro, diabetes e várias doenças neurodegenerativas (DP, doença 
de Huntington e DA).  Uma das proteínas que se encontram anormalmente 
fosforiladas na DA são, por exemplo, os neurofilamentos (NF). 
Neste contexto, avaliou-se o efeito do alumínio na expressão de proteínas 
(PP1, NF) e realizou-se um estudo comparativo entre duas linhas celulares 
com características diferentes, as células PC12 e COS-1.  Observou-se que o 
alumínio induziu um decréscimo na viabilidade celular, assim como na 
expressão e actividade de ambas as isoformas da PP1 em ambas as linhas 
celulares.  Verificou-se que este efeito podia ser revertido retirando-se o 
alumínio.  Um estudo semelhante foi ainda realizado num sistema neuronal 
utilizando culturas primárias de neurónios corticais.  A expressão de ambas as 
isoformas da PP1 permaneceu inalterada após a exposição ao alumínio.  No 
entanto, o alumínio induziu um decréscimo da expressão dos NF e da 
sinaptofisina, uma proteína que marca os terminais sinápticos.  Por fim, 
estudou-se o efeito do alumínio na expressão de outras proteínas em sistemas 
in vitro e in vivo utilizando a tecnologia SELDI-TOF MS.  Esta tecnologia 
permitiu detectar várias proteínas cuja expressão foi alterada devido ao 
alumínio.  Com este trabalho pretendeu-se contribuir para um melhor 
conhecimento da neurotoxicidade do alumínio. 
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abstract 
 
Aluminium is the third most abundant element on Earth.  Aluminium is 
ubiquitous in the environment and is used in a variety of products and 
processes, thus, daily exposure of the general population to this metal is 
unavoidable.  Indeed, aluminium has been implicated with various 
neurodegenerative disorders like: amyotrophic lateral sclerosis 
(ALS)/Parkinson’s dementia (PD) complex of Guam, Alzheimer’s disease (AD) 
and dialysis encephalopathy.  Aluminium is known to interfere with several 
mechanisms of the nervous system, including alteration of cytoskeletal 
proteins, behavioural abnormalities, neurotransmission systems, oxidative 
damage, energy metabolism, second messengers, and also to induce neuronal 
apoptosis. 
Protein phosphorylation is a major intracellular regulatory mechanism of all 
signalling pathways in the eukaryotic cell.  This dynamic process regulates the 
net phosphorylation state and the activity of proteins by a balance between 
protein kinases, which phosphorylate, and protein phosphatases (PP), which 
dephosphorylate proteins.  Protein phosphatase 1 (PP1) is a serine/threonine 
specific phosphatase which is involved in the control of important cellular 
mechanisms such as the cell cycle, muscle contraction and apoptosis, among 
others.  PP1 has three known isoforms termed PP1α, PP1β and PP1γ.  The 
gene for PP1γ produces by alternative splicing a ubiquitously expressed PP1γ1 
and a testis-specific PP1γ2 isoform. 
Abnormal protein phosphorylation has been associated with various disorders, 
including cancer, diabetes, and several neurodegenerative disorders (PD, 
Huntington’s disease and AD).  Besides tau other proteins that are abnormally 
phosphorylated in AD are the neurofilaments (NF). 
In this context, the aluminium effect on the expression of proteins (PP1, NF) 
was evaluated.  A comparative study was performed using two cell lines with 
different characteristics, PC12 and COS-1 cells.  It was observed that 
aluminium induced a decrease in the cellular viability, as well as in the 
expression and activity of both PP1 isoforms in both cell lines.  This effect was 
reverted following aluminium withdrawal.  A similar study was also performed in 
a neuronal system, primary cortical neuron culture.  The expression of both 
PP1 isoforms remained unchanged after aluminium exposure.  However, 
aluminium induced a decrease in the expression of NF and of synaptophysin, a 
protein marker for synaptic terminals. 
Finally, the effect of aluminium on the expression of other proteins in in vitro 
and in vivo systems was evaluated using SELDI-TOF MS technology.  In this 
study, several proteins with altered expression due to aluminium were 
detected.  This work aimed to contribute to the better understanding of 
aluminium neurotoxicity. 
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I. GENERAL INTRODUCTION 
 
I.1. ALUMINIUM NEUROTOXICITY 
 
I.1.1. Aluminium bioavailability, human intake and bioprocessing 
 
 Aluminium is a ubiquitous element used extensively in contemporary life.  In spite 
of its abundance, aluminium is not an essential element and there is no known biological 
reaction that requires aluminium.  However, the neurotoxicity of aluminium has been 
recognized for many years.  Aluminium is highly abundant and the third most abundant 
element ubiquitously found in the natural environment, its bioavailability is high and is 
readily accessible.  Humans are exposed daily to aluminium from different sources.  Food 
is the main source of aluminium intake, while drinking water contributes only about 3% of 
total daily intake.  Aluminium in drinking water has two main sources: dissolved 
aluminium is present naturally as a result of leaching from minerals in the soil and bedrock 
in the catchment of the water source, this leaching can be greatly enhanced as a result of 
acid precipitation; and, aluminium is widely used in water treatment as a coagulant, to 
reduce the number of small particles and to improve the colour of the water.  It has been 
proposed that the safe amount of aluminium in drinking water should be lower than 0.1 
mg/l (Martyn et al., 1989).  Aluminium is found in beverages such as tea infusions which 
contain rather large amounts of aluminium, typically 2-6 mg/l (Flaten and Odegard, 1988), 
and is also found in processed food which contains aluminium-containing food additives.  
Food can also be contaminated with aluminium by contact through cooking devices, or 
when wrapped with aluminium foil, especially with the addition of acids such as lemon 
juice or vinegar.  Aluminium is also present in canned drinks and canned food coming 
from the package (Jagannatha and Valeswara, 1995; Jagannatha, 1994).  Humans are also 
in contact with aluminium through hygienic products like toothpaste and specially anti-
perspirants, which have considerable amounts of aluminium that can be absorbed through 
the skin (Exley, 2004).  In medicine, aluminium is used in several medications like 
Aluminium neurotoxicity and neuronal phosphorylation systems 
18 
 
buffered aspirin, but especially in antacids used for the treatment of gastric ulcers, with 
typical consumption in the order of 1 g per day (Lione, 1985; Reinke et al., 2003).  
Aluminium is also used in dental prothesis and as adjuvant in several vaccines (Brewer, 
2006).  Another potentially important source of exposure to aluminium is occupational 
exposure (McLachlan, 1995). 
 Exposure to aluminium is unavoidable during the entire life span.  Humans 
consume an average of 7.6 mg/day of aluminium from drinking water and food (Yokel and 
McNamara, 2001).  However, the absorption rate of aluminium is relative low, only 0.06-
0.1% of ingested aluminium is absorbed across the gastrointestinal tract (Moore et al., 
2000).  The gut is therefore the first barrier for aluminium uptake.  Aluminium absorption 
is limited by the presence of certain other dietary components such as citrate, which can 
form a complex with the metal increasing significantly its absorption (Whitehead et al., 
1997).  Age contributes to gut barrier impairment and so to the aluminium absorption.  
Indeed, it was reported that young individuals absorb much less aluminium from an 
aluminium citrate drink than older people (Taylor et al., 1992).  In the bloodstream, 
aluminium binds to the plasma proteins, transferrin (the main protein carrier) and albumin, 
the remainder complexes with citrate (the main small molecule carrier) (Martin et al., 
1987; Fatemi et al., 1991).  Aluminium in circulation may distribute through all the body.  
The main target for accumulation is the skeleton (Kerr et al., 1992), although, liver, 
kidney, muscle and heart also accumulate aluminium (Walker et al., 1994).  It has been 
proposed that aluminium could enter the brain from systemic circulation by three different 
routes: blood-brain barrier (BBB), nasal-olfactory pathway (by olfactory nerves) and 
cerebrospinal fluid (through the choroid plexus) (Perl and Good, 1987; Yokel et al., 1999).  
The BBB route is generally considered to be the most plausible mode of entry (Yokel, 
2002).  The potential mechanisms of distribution of substances across the BBB, the second 
barrier to aluminium, are the same as those across any cell membrane: diffusion, 
carrier/receptor mediated transport by facilitated diffusion and active transport.  One of the 
most probable mechanisms of aluminium access into the brain is by transferrin-receptor-
mediated endocytosis (Roskams and Connor, 1990), the iron transport protein by 
excellence.  Another important carrier for brain aluminium influx may be monocarboxylate 
transporter, a proton co-transporter located at the BBB (Gerhart et al., 1997; Yokel et al., 
2002).  However, aluminium alone affects the permeability of the BBB enhancing its 
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apparent lipophilicity, thus contributing to an increase of its transmembrane diffusion 
(Meiri et al., 1993), although this depends on the physicochemical properties of the metal 
coordination sphere (Favarato et al., 1992).  In the brain, aluminium competes with other 
elements, such as Fe, Ca and Mg, present in several proteins and enzymes altering their 
function.  Indeed, some aluminium persists in the brain for a long time.  Brain aluminium 
efflux, presumably Al-citrate, was suggested to be mediated by the monocarboxylate 
transporter, through the BBB (Yokel et al., 1999).  Absorbed aluminium is primarily 
eliminated via the kidneys and approximately 2% excreted in bile (Alfrey, 1986a; Yokel 
and McNamara, 2001). 
 
I.1.2. Aluminium speciation chemistry 
 
 The chemical speciation of aluminium in aqueous solution is of particular interest, 
as the form of aluminium regulates its solubility, bioavailability and consequently its 
toxicity.  One factor determining the form of aluminium in solution is pH (Figure I.1).  
Aluminium is a strong hydrolyzing element and is generally insoluble at neutral pH.  Its 
solubility is enhanced under acidic or alkaline conditions and in the presence of 
appropriate ligands.  Thus, in the range of physiologic pH values (between 6 and 8) 
aluminium is generally insoluble. 
 
 
Figure I.1 – Distribution of the hydrolysis products of aluminium as a function of pH (adapted from 
Meiri et al., 1993). 
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 In acidic solutions (pH<5), aluminium exists as an octahedral hexahydrate, 
Al(H2O)63+, usually abbreviated as Al3+ and sometimes referred in the literature as free 
aluminium.  As pH increases, Al(H2O)63+ undergoes successive deprotonations to yield 
different species such as Al(OH)2+ and Al(OH)2+ with decreasing solubility.  In neutral pH 
solutions, the amorphous Al(OH)3 is produced and precipitates.  At alkaline pH this 
precipitate redissolves to form tetrahedral aluminate, Al(OH)4-, the primary soluble 
aluminium species at a biological pH>6.2.  The main species at pH<5 is the octahedral 
hexahydrate, Al(H2O)63+ and at pH>6.2 the tetrahedral Al(OH)4-.  At pH between 5 and 6.2 
all species co-exist.  Thus, at pH 7.4 the main species is the insoluble Al(OH)3 although, 
the prominent soluble species is the Al(OH)4- (Martin, 1986; Meiri et al., 1993; Gupta, 
2005). 
 It should be pointed out that a solution of AlCl3 at physiological pH contains free 
aluminium (Al3+) at concentrations much lower than the indicating concentration, because 
AlCl3 forms insoluble hydroxyl complexes at that pH.  Indeed, when aluminium inorganic 
salts, such as chloride, sulphate, hydroxide or perchloride, are dissolved in water at a 
calculated concentration of 10 mM, the aluminium concentration is about 50 µM.  The use 
of Al-lactate or Al-aspartate increases the soluble aluminium concentration to 
approximately 55-330 µM and the use of Al-maltolate or gluconate increases the soluble 
aluminium concentration to 4-6 mM.  Aluminium complexes of low solubility can be 
biologically relevant; however, free aluminium is the species which is bioactive, the 
species that links to proteins or ligands, even at low concentration (Martin, 1986; Meiri et 
al., 1993; Gupta, 2005).  Thus, the solution concentration is merely informative, as at 
physiological pH the bioactive aluminium concentration is much lower. 
 Aluminium bioavailability, concerning diet and intestinal absorption, depends on 
which complexes it forms.  Several compounds in the diet, including ascorbic acid, citric 
acid, lactic acid and malic acid, may increase aluminium absorption in the intestine by 
elevating the pH of aluminium hydroxide precipitation (Partridge et al., 1989).  On the 
other hand, phosphate is also an important dietary factor, forming complexes even at low 
pH and making aluminium less available for absorption (Driscoll and Schecher, 1988).  It 
has been suggested that the presence of phosphates in the diet is probably the “natural” 
mechanism whereby aluminium is prevented from entering the circulation (Martin, 1986).  
Aluminium has also been reported to displace other ions of physiological relevance.  
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Aluminium is a small ion with an ionic radius of 54 pm and can replace divalent metals 
such as Ca, Mg and Zn, whose ionic radii are 72, 74 and 100 pm, respectively, and hence is 
thought to be responsible for executing various toxic effects (Martin, 1996). 
 Aluminium binds strongly to oxygen-donor ligands, particularly if they are 
negatively charged.  Inorganic or organic phosphates, carboxylate and deprotonated 
hydroxyl groups are strong Al3+ (aluminium) binders.  Thus, aluminium binds to the 
phosphor groups of DNA or RNA, influences DNA topology and affects gene transcription 
(Lukiw et al., 1998).  Phosphate groups of cell membranes are also targets for aluminium 
binding (Van Rensburg et al., 1995).  As well as phosphorylated proteins, aluminium has 
been reported to influence various functions of enzymes including protein kinases and 
phosphatases (Shetty et al., 1992; Amador et al., 2004).  Overall, the form and speciation 
of aluminium may be critical to its biological actions. 
 
I.1.3. Aluminium and neurodegenerative diseases 
 
 Acute aluminium exposure is of low toxicity.  In humans, oral doses up to 7.2 
mg/day are routinely tolerated without any signs of harmful short-term effects.  However, 
intake of large amounts of aluminium can lead to a wide range of toxic effects, including 
microcytic anaemia (Touam et al., 1983; Jeffery et al., 1996; Garbossa et al., 1998), 
osteomalacia (Bushinsky et al., 1995; Jablonski et al., 1996; Jeffery et al., 1996), glucose 
intolerance of uraemia (Banks et al., 1987) and cardiac arrest (Starkey, 1987).  Elderly 
persons with elevated serum aluminium levels exhibit impaired complex visual-motor co-
ordination and poor long-term memory (Bowdler et al., 1979). 
 Evidence suggests that trace metal homeostasis plays a crucial role in the normal 
functioning of the brain and any disturbance in it can exacerbate events associated with 
neurodegenerative disorders.  In fact, aluminium has been implicated in several 
neurological and other disorders, namely dialysis encephalopathy (Alfrey et al., 1976; 
Savory and Wills, 1984; Kerr and Ward, 1988), amyotrophic lateral sclerosis 
(ALS)/Parkinsonism-dementia (PD) complex of Guam (Perl et al., 1982; Kurland, 1988) or 
Alzheimer’s disease (AD) (Perl and Brody, 1980; Perl, 1988; Xu et al., 1992a). 
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I.1.3.1. Dialysis encephalopathy 
 
 Dialysis encephalopathy is a fatal brain disorder occurring in some patients with 
chronic renal failure undergoing inadvertent parenteral exposure to aluminium (Alfrey et 
al., 1980).  The chronic symptoms include speech disorders, neuropsychiatric 
abnormalities and multifocal myoclonus (Dewberry et al., 1980).  More subtle symptoms 
of the condition include disturbances of tetra-hydrobiopterin metabolism and abnormalities 
in a number of psycho-motor functions (e.g., visual spatial recognition memory), all 
occurring at mildly elevated serum aluminium levels (59 µg/l) and in the absence of 
chronic dementia (Altmann et al., 1989).  Patients with dialysis dementia were shown to 
have markedly elevated serum aluminium levels with increased concentrations in many 
tissues namely, kidney, liver, bone, heart and throughout the cerebral cortex (Alfrey et al., 
1980; Kerr and Ward, 1988; Meiri et al., 1993).  Investigators reported a correlation 
between the aluminium concentration in water used to prepare the dialysate fluid and the 
incidence of dialysis dementia (Savory and Wills, 1984).  Tissue accumulation of 
aluminium to levels high enough to cause toxicity is mainly due to a combination of high 
exposure, partly directly into bloodstream (thus bypassing absorption in the gastrointestinal 
tract) and these patients’ lack of kidney function, which is the main excretion route for 
aluminium.  The mechanism of neurotoxicity in dialysis encephalopathy has not been 
established.  However, severe acute aluminium intoxication cases have been reported to 
respond to chelation therapy with desferrioxamine to lower serum aluminium, combined 
with hemodialysis (Vaan Landeghem et al., 1997; Nakamura et al., 2000).  Indeed, 
desferrioxamine has been reported to accelerate clearance of brain aluminium (Yokel et al., 
2001).  It was also proposed that ascorbate, desferrioxamine and Ferralex-G in 
combination as a “molecular shuttle chelation” may provide a useful pharmacotherapy in 
the potential treatment of aluminium overload disease (Kruck et al., 2004).  Dialysis 
encephalopathy syndrome resulting from acute intoxication of aluminium caused by the 
use of an aluminium-containing dialysate was common occurrence prior to 1980.  
However, using modern techniques of water purification, such acute intoxication can now 
be avoided (Rob et al., 2001).  Nevertheless, aluminium toxicity is a known adverse effect 
in patients with end-stage renal disease due to oral intake of aluminium-containing 
phosphate binders (Wills and Savory, 1989).  Indeed, a fatal case of aluminium 
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encephalopathy in a patient with severe chronic renal failure not on dialysis but due to 
intake of large doses of antacids containing aluminium for at least 3 years, was recently 
reported (Zatta et al., 2004).  A similar report of an autopsy of a 59-year-old female 
aluminium encephalopathy patient who had chronic renal failure and took 3.0 g hydroxy-
aluminum gel per day for the control of serum phosphorus level during a 15-year period, 
was published by Shirabe and colleagues (2002).  Furthermore, it was reported recently 
significant aluminium toxicity in a non-hemodialysis patient who chronically injected 
intravenously oral methadone solution heated in an aluminium-based cooking utensil 
(Friesen et al., 2006). 
 The aluminium contamination of total parenteral nutrition (TPN) solutions is also a 
matter of great concern.  It was reported that the neurological development of premature 
infants who had received a TPN solution containing a high level of aluminium was 
impaired compared with infants who had received an aluminium-depleted TPN solution 
(Bishop et al., 1997).  Considering that aluminium in TPN solutions is highly bioavailable 
and that renal function of infants is impaired, the aluminium contamination of TPN 
solutions may cause serious brain damage (Kawahara, 2005). 
 
I.1.3.2. Amyotrophic lateral sclerosis and Parkinsonism-dementia complex of 
Guam 
 
 It has been postulated that aluminium plays a role in the aetiology of two severe 
neurodegenerative diseases, amyotrophic lateral sclerosis (ALS) and Parkinsonism-
dementia (PD) complex of Guam.  ALS/PD are characterized by the selective degeneration 
of motor neurons, the presence of neurofibrillary tangles (NFT) and neuropil threads in the 
brain, these features result in a clinical syndrome of progressive weakness, culminating in 
respiratory failure and death (Wakayama et al., 1993a).  Both diseases are observed at very 
high incidence among the Chamorro people of Guam (Garruto et al., 1990; Oyanagi, 
2005).  A high incidence of ALS is also found in two other areas, western New Guinea and 
the Kii Peninsula of Japan (Yase et al., 2001).  The soils and drinking water of Guam and 
the two other affected areas are very low in calcium and magnesium but very high in 
aluminium, iron and silicon (Gajdusek and Salazar, 1982).  Aluminium was found to 
accumulate in the tangle-bearing neurons in post-mortem brains of patients with ALS/PD 
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(Perl et al., 1982).  Garruto and Yase (1986) suggested that chronic nutritional deficiencies 
of calcium and magnesium may lead to increased absorption of aluminium (and other 
metals), resulting in the deposition of aluminium in neurons.  These deposits could 
interfere with the structure of neurons and eventually result in NFT (Garruto, 1989).  The 
elevated concentrations of aluminium in ALS/PD patients suggested that aluminium and 
the depletion of calcium and magnesium may play key roles in the pathogenesis of 
ALS/PD (Yase et al., 2001).  The dramatic decrease in the incidence of ALS/PD on Guam 
with a change in dietary habits and local water supplies has given support to this theory 
(Garruto et al., 1990).  Although, the remarkable clustering of motor neuron diseases 
(MND) was thought to have disappeared, the southern Kii Peninsula remains a high-risk 
area for MND, especially if the emigrants who developed MND one to four decades after 
leaving the focus are included (Yoshida et al., 1998).  It has been reported that 
experimental animals chronically fed a low-calcium and/or magnesium and high-
aluminium diet showed neuronal loss in the spinal anterior horn and cerebral cortices 
(Florence et al., 1994).  Further mice with a similar diet (low-Ca/Mg and high-Al) 
exhibited the deposition of aluminium, the deposition of hyperphosphorylated tau proteins 
(the basic structure of NFT) and neuronal loss (Kihira et al., 2002).  Recently, it was also 
reported that mice fed a similar diet also exhibited ALS-like skin and CNS changes (Kihira 
et al., 2004). 
 
I.1.3.3. Alzheimer’s disease 
 
 The association of aluminium with Alzheimer’s disease (AD) has more than 25 
years, however it is still a controversial issue and the mechanisms of aluminium toxicity in 
this disease are not yet established.  AD is a neurological disorder affecting elderly people, 
as first described by Alois Alzheimer in 1906.  Patients with AD exhibit progressive 
mental deterioration manifested by memory loss, inability to calculate, visual-spatial 
disturbances, confusion and disorientation.  The neuropathological characteristics include: 
cortical and subcortical atrophy; intraneuronal accumulation of neurofibrillary tangles 
(NFT), which are composed of paired helical filaments (PHF) of hyperphosphorylated tau 
proteins (Figure I.2); dystrophic neurites surrounding the extracellular deposits of amyloid 
beta-peptide (Abeta) in plaques (neuritic plaques or senile plaques) (Figure I.2); formation 
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of neuropil threads; loss of synaptic function; oxidative stress and apoptosis, leading to 
neuronal loss (Glenner and Wong, 1984; Grundke-Iqbal et al., 1986a; Markesbery, 1997; 
Christen, 2000; Dickson, 2004; LeBlanc, 2005).  These events are observed mostly in the 
hippocampal and cortical regions of AD brains.  The etiological factors of AD are not 
clearly elucidated, although current hypotheses include genetics, head trauma, oxidative 
stress, infectious agents and environmental factors, including aluminium toxicity. 
 
 
Figure I.2 – Neurofibrillary tangles and senile plaques.  In both AD hallmarks aluminium was found to 
accumulate. 
 
 One of the first studies relating aluminium with AD was published in 1973 by 
Crapper and colleagues (Crapper et al., 1973).  In this study they demonstrated that AD 
brain tissues showed a 2 to 3-fold increase in aluminium concentrations when compared to 
normal control tissues.  Later, it was reported that the aluminium content of human brain is 
around 6.2-9.8 µg/g (dry mass brain) (Xu et al., 1992a).  However, it has been reported 
that AD patients have elevated concentrations of aluminium (9.0-11.0 µg/g dry weight) in 
some regions (cortex, mesial temporal and temporal cortex) of their brains compared to 
controls (Crapper et al., 1973; Solomon et al., 2001; Andrasi et al., 2005; Gupta et al., 
2005).  Aluminium tends to accumulate more in the cortex and hippocampus, both in 
normal and AD brains (McDermott et al., 1979).  Aluminium deposition is progressive, 
being higher in severe AD than in moderate AD and relatively low in normal brain 
(Jagannatha et al., 1999).  Even though, the increased content of aluminium in NFT has 
been established (Perl and Brody, 1980; Lovell et al., 1993; Shin et al., 1994; McLachlan, 
1995; Tokutake et al., 1995), the presence of aluminium and silicon in the central region of 
Neurofibrillary tangles Senile plaques 
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senile plaque cores in the cortex of AD patients is a controversial issue.  Landsberg et al., 
(1992) stated that they could not find aluminium in senile plaques from autopsy AD brain 
material, and hypothesized that the occurrence of aluminium found previously in plaques 
by Candy and colleagues (1986) had been caused by contamination from dyes used to stain 
the plaques.  However, Good and Perl (1993) stated that the Landsberg and co-workers 
(1992) study did not contradict the aluminium hypothesis, since it was clear from the 
literature that aluminium was more often associated with the NFT than with the plaques 
(Zatta, 1993).  Indeed, Tokutake and co-workers (1995) found aluminium contained in 
lipofuscin granules with silicon, probably as aluminosilicate, in senile plaques of brain 
with AD.  Moreover, Exley (2005) reported the detection of aluminium associated with 
Abeta in AD brains.  Overall, whether the presence of aluminium in the brain of AD 
patients is a cause or a result of the condition remains unknown. 
 Moore and co-workers (2000) showed that under normal physiological conditions, 
the ability of the gastrointestinal tract to exclude aluminium is reduced in AD, possibly 
leading to greater systemic exposure to aluminium.  Additionally, a higher frequency of a 
genetic variant of transferrin, TfC2, has been found in AD patients compared with non-
demented controls, suggesting that this factor may be involved in an aberrant transport of 
aluminium in these patients (Van Rensburg et al., 1995; Zambenedetti et al., 2003).  
Moreover, ferritin, the iron storage protein, isolated from the brains of AD subjects, has 6-
fold higher aluminium content than normal age-matched controls (Fleming and Joshi, 
1987).  Indeed, aluminium has been shown to accumulate in rat brain ferritin (Sakamoto et 
al., 2004), which has been reported to be a component of the senile plaques in AD 
(Grundke-Iqbal et al., 1990).  From this evidence we may conclude that the aluminium 
absorption, uptake and accumulation are augmented in patients with AD.  On the other 
hand, the incidence of AD is increased in regions where people are more exposed to 
aluminium.  Although, drinking water contributes only with a minor portion of the total 
daily oral intake of aluminium, it was found that a significant relationship exists between 
the number of AD cases and the levels of aluminium present in drinking water (McLachlan 
et al., 1996; Gauthier et al., 2000; Flaten, 2001).  Additionally, two metal chelation 
therapies have been proposed for AD patients, one using Feralex-G, and another using 
desferrioxamine (Shin et al., 2003; House et al., 2004)  A “molecular shuttle chelation” 
using both desferrioxamine and Feralex-G in combination with ascorbate was also 
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proposed as a therapy for aluminium overload diseases that may include AD patients 
(Kruck et al., 2004). 
 The aluminium hypothesis has also been disputed based on the following features: 
(i) not all patients with AD have high brain levels of aluminium and the senile plaques that 
are common in AD are not seen in experimental aluminium toxicity (Wisniewski et al., 
1980; Bjertness et al., 1996); (ii) the incidence of cognitive impairment and AD symptoms 
is not increased, but only dialysis dementia in renal patients is observed with increased 
aluminium levels (Alfrey, 1986b); (iii) it has been shown that NFT in AD, which are 
composed primarily of paired helical filaments (PHF) are made up mainly of 
hyperphosphorylated tau (a microtubule associated protein), in contrast to aluminium-
induced neurofibrillary degeneration (NFD), which consists of aggregated 
hyperphosphorylated neurofilament (an intermediate filament of the neuronal cytoskeleton) 
(Munoz-Garcia et al., 1986; Erasmus et al., 1993).  However, abnormally phosphorylated 
tau has been found in aluminium-induced neurofilamentous aggregates, together with 
abnormally phosphorylated neurofilament protein (Singer et al., 1997; Huang et al., 1997).  
Also, elevated levels of phosphorylated neurofilament proteins were found in cerebrospinal 
fluid of AD patients (Hu et al., 2002).  In addition, immunoreactivity to phosphorylated 
epitopes of neurofilaments was observed in AD tangles (Sternberger et al., 1985).  
Nevertheless, the neurotoxic effects of aluminium are beyond any doubt, and aluminium as 
a factor in AD cannot be discarded, especially concerning the most elderly (over 75), or 
until the uncertainty about the neuropathological evidence is resolved (Gupta et al., 2005).  
Consequently, as a result of continued concern about the neurotoxicity of aluminium, the 
U.S. Environmental Protection Agency has put aluminium on its contaminant candidate list 
(U.S. Environm. Prot. Agency, 2002), the U.S. Food and Drug Administration 
implemented labelling requirements for aluminium in large and small volume parenterals 
(US Food and Drug Adm., 2002) and Canada established operational guidance limits for 
drinking water aluminium on the basis of the precautionary principle (Health Canada, 
2002). 
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I.1.4. Effects of aluminium on nervous system 
 
 The mechanisms by which aluminium induces neurotoxicity still remain to be 
elucidated.  However, a wide range of aluminium effects have been reported in relation to 
the neuronal response to aluminium exposure.  Intraneuronal neurofilamentous aggregates 
formed due to aluminium have been observed, mainly in rabbits.  In rodents a number of 
neurochemical and neurophysiological alterations following in vivo or in vitro exposure to 
aluminium have been observed.  Aluminium has been shown to affect behaviour, 
cholinergic activity, lipid peroxidation, glucose metabolism and signal transduction. 
 
I.1.4.1. Cytoskeletal protein aggregates 
 
 Intracisternal inoculation of aluminium into rabbit brain induces intraneuronal 
neurofilamentous aggregates (Klatzo et al., 1965; Savory et al., 1999; He and Strong, 
2000).  Injected rabbits had neurological symptoms with paralysis of their skeletal muscles 
and died with tetanic spasm just over 10 days after the administration of aluminium 
(Gotow, 2000).  Aluminium-induced neurofilamentous aggregates are characterized by 
argentophilic masses in neuronal perikarya (area surrounding the nucleus), proximal 
axonal enlargements and proximal dendrites, which are aggregates of abnormally 
phosphorylated neurofilament proteins (Troncoso et al., 1986; Gotow et al., 1995; Gotow, 
2000).  It was suggested that there is a relationship between the phosphorylation state and 
the structural organization of those neurofilaments (Gotow et al., 1995).  Abnormally 
phosphorylated tau has also been found in aluminium-induced neurofilamentous 
aggregates in rabbits (Savory et al., 1996; Singer et al., 1997; Huang et al., 1997).  Savory 
and co-workers (1996) studied the time course of cytoskeleton protein phosphorylation in 
aluminium injected animals and found that the argyrophilic bodies appeared 24 h after 
aluminium maltolate administration, with a predominance of neurofilament proteins.  Non-
phosphorylated, phosphorylation independent epitopes appeared first, followed at about 72 
h by phosphorylated forms.  Tau was also detected at the 72 h mark, although the 
characteristic epitopes of AD become most distinct at 6-7 days following aluminium 
injection (Savory et al., 1996).  In addition, aluminium-intoxicated rabbits also exhibit 
dendritic degeneration in motor neurons (Wakayama et al., 1993b). 
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 The direct injection of aluminium compounds into the rabbit central nervous system 
mimics abnormalities found in human neurodegenerative diseases.  The rabbit/aluminium 
model system provides a means of elucidating mechanisms of neurodegeneration (Bharathi 
et al., 2006), particularly those involving apoptosis and abnormal cytoskeletal proteins 
(Savory et al., 1999, 2003; He and Strong, 2000; Ghribi et al., 2001a).  Rabbits inoculated 
intracisternally with aluminium exhibited many of the clinical, histological and 
ultrastructural characteristics of ALS including argentophilic perikaryal inclusions and 
neurofibrillary tangle-like morphologies (Wakayama et al., 1996).  The altered conditions 
observed in aluminium injected rabbits also mimic a number of neuropathological and 
biochemical changes present in AD and related human neurodegenerative disorders, like 
amyloid precursor protein, Abeta, alpha 1-antichymotrypsin and ubiquitin-like 
immunoreactivities in neurofibrillary degeneration-bearing neurons (Huang et al., 1997).  
It has been proposed that phosphorylation of cytoskeletal proteins induces the formation of 
neurofilamentous aggregates, particularly in human neurodegenerative disorders.  Given 
that these aggregates are hyperphosphorylated, phosphorylation alone would make these 
protein accumulations unstable because of the predominance of negative charges on the 
phosphate groups.  Therefore it can be postulated that a positively-charged species would 
represent an inherent factor for both the formation and stabilization of the neurofibrillary 
aggregates, in AD as well as in experimental aluminium-induced neurofibrillary 
degeneration; aluminium is a strong candidate for this role in the latter (Savory et al., 
2001). 
 
I.1.4.2. Behavioural abnormalities 
 
 Animals exposed to aluminium exhibit behavioural abnormalities like spatial 
disorientation, lower activity and higher emotionality (Miu et al., 2003; Roig et al., 2006).  
Deficits in cognitive and motor function (Oteiza et al., 1993), as well as changes in 
learning and memory (Julka et al., 1995; Kaneko et al., 2006), have also been noted.  In a 
study using young and old rats exposed to aluminium, while no significant effects of 
aluminium exposure between groups could be detected on behaviour, the total number of 
synapses in the CA1 fields of hippocampal decreased with age and aluminium exposure 
(Colomina et al., 2002).  Platt and co-workers (2001), using histochemical and 
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immunocytochemical studies, suggest that the enhancement of inflammation and the 
interference with cholinergic projections may be the mode of action through which 
aluminium causes learning and memory deficits.  Additionally, an aluminium impairment 
of hippocampal long-term potentiation, a model for synaptic plasticity underlying some 
forms of learning and memory, has been reported in rats both in vivo and in vitro (Platt et 
al., 1995). 
 
I.1.4.3. Cholinergic and other neurotransmission systems 
 
 The cholinergic system is an important component of the neuronal circuitry of 
learning and memory mechanisms (Alkon et al., 1991; Cain, 1998).  Aluminium alters the 
cholinergic transmission, which is reflected in neurobehavioral deficits (Julka et al., 1995).  
Significant decrease in choline acetyltransferase (ChAT) activity after chronic aluminium 
treatment has been observed in the parietal cortex, hippocampus and striatum of rat brain 
(Gulya et al., 1990).  Following aluminium exposure the inhibition of ChAT, the reduction 
of acetylcholine levels and a significant decrease in high-affinity choline uptake were 
observed (Julka et al., 1995).  It was also reported that under oxidizing conditions 
aluminium potentiated the inhibition of the high-affinity choline uptake observed following 
lipid peroxidation (induced by ascorbate/iron) (Amador et al., 2001).  The effect of 
aluminium on the acetylcholinesterase (AChE) activity is a controversial issue.  An 
activation of AChE by aluminium in vivo and to a lesser extent in vitro was reported by 
Zatta et al. (2002).  However, an inactivation of the same enzyme was reported by Julka 
and co-workers (1995).  It was suggested that the difference in activity indicates that 
aluminium speciation may play a relevant role in producing toxicological effects (Zatta et 
al., 2003).  Indeed, prolonged treatment with aluminium chloride resulted in inhibition of 
AChE in rat brain (Dave et al., 2002).  However, Kaizer and co-workers (2005) verified an 
activation of AChE in different mouse brain regions after exposure to aluminium and 
citrate.  Still, the AChE activity in mice exposed only to aluminium was verified inhibited 
in the hypothalamus and enhanced in the striatum. 
 Various authors reported the interference of aluminium with other 
neurotransmission systems namely: glutamatergic (Platt et al., 1994; Nayak and Chatterjee, 
2001; Yang et al., 2003), GABAergic (Trombley, 1998; El-Rahman, 2003), serotonergic 
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(Kumar, 2002) and dopaminergic systems (Tsunoda and Sharma, 1999; Milanese et al., 
2001). 
 
I.1.4.4. Oxidative damage 
 
 Aluminium, a metal without redox capacity in biological systems, has been shown 
to exacerbate oxidative damage initiated by reactive oxygen species (ROS) generating 
systems.  Aluminium has been shown to promote iron-induced lipid peroxidation 
(Gutteridge et al., 1985) and to potentiate lipid peroxidation induced by ascorbate/iron 
inducing system (Amador et al., 2001).  Aluminium promotion of melanin-initiated 
oxidative damage was also demonstrated (Meglio and Oteiza, 1999), as well as the lipid 
peroxidation initiated by xanthine/xanthine oxidase system, another ROS generating 
system (Golub et al., 2002).  Mundy and co-workers (1997) reported that aluminium pre-
treatment potentiates the ROS production induced by iron in primary neuronal cultures.  
Moreover, the concentration of lipid peroxidation products was found to increase in rat 
brain following aluminium lactate injections (Ogasawara et al., 2003).  Rats treated 
similarly exhibited changes on oxidative stress markers (glutathione transferase, 
glutathione reductase and peroxidase, reduced and oxidized glutathione, superoxide 
dismutase, catalase and thiobarbituric acid reactive substances) in different neural areas, 
indicating that aluminium acts as pro-oxidant (Esparza et al., 2003).  Orally administered 
aluminium-maltolate complex was shown to enhance oxidative stress in the organs of mice 
(Kaneko et al., 2004).  More recently, chronic aluminium exposure in drinking water was 
observed to specifically enhance oxidative, as well as inflammatory events in the mouse 
brain (Becaria et al., 2006).  Enhanced lipid peroxidation after long-term exposure to low 
levels of aluminium on different mouse brain regions was also reported (Kaizer et al., 
2005).  Increased aluminium in plasma and erythrocytes, and increased superoxide 
dismutase activity in erythrocytes of rat exposed to aluminium was also described (Guo et 
al., 2004).  The mechanisms proposed for aluminium promotion of lipid peroxidation 
involve alterations in lipid substrates that enhance their susceptibility to oxidative damage, 
and changes in the physical properties of membranes (Oteiza, 1994; Van Rensburg et al., 
1995).  The mechanism is based on aluminium binding to phospholipid headgroups within 
the cell membrane and promotion of changes in the arrangement of membrane lipids, 
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including packing of fatty acids which facilitate the propagation of lipid peroxidation 
(Oteiza, 1994).  The aluminium-induced changes in the membrane physical properties 
include alterations of membrane fluidity and lipid rearrangement through lateral phase 
separation (Verstraeten et al., 2002).  Indeed, lipid peroxidation was shown to facilitate 
aluminium accumulation in rat nerve terminals (Amador et al., 1999).  The alteration of the 
structure and function of cell membranes induced by aluminium was also reported in 
human erythrocytes, leading to alterations of its shape (Suwalsky et al., 2004). 
 
I.1.4.5. Energy metabolism 
 
 Due to its high reactivity, aluminium is able to interfere with several biological 
functions, including enzymatic activities in key metabolic pathways.  Thus, aluminium 
may compromise energy production via the Krebs cycle by activating α-ketoglutarate 
dehydrogenase and succinate dehydrogenase, while inhibiting aconitase (Zatta et al., 
2000).  Glucose metabolism is also impaired by aluminium which is a strong inhibitor of 
some enzymes of the glycolysis pathway.  Aluminium inhibits the activities of hexokinase 
and glucose-6-phosphate dehydrogenase (Cho and Joshi, 1989; Exley et al., 1994).  
Moreover, a reduction in glucose metabolism in rat brain following chronic aluminium 
exposure was observed (Clauberg et al., 1994).  However, recently Kaur and Gill (2006) 
reported that chronic aluminium exposure enhanced the activity of glucose-6-phosphate 
dehydrogenase. 
 
I.1.4.6. Signal transduction pathways (second messengers) 
 
 Signal transduction pathways, including inositol 1, 4, 5-triphosphate (IP3) and 
cAMP-mediated signalling, appear to be targets of aluminium action both in vivo and in 
vitro.  These signalling pathways regulate important functions such as cell differentiation 
and proliferation, neurotransmitter release and synaptic plasticity.  Moreover, IP3 is also 
involved in long-term potentiation, i.e. a mechanism underlying memory formation 
(Berridge, 1986).  The IP3 signalling system starts with the binding of a neurotransmitter or 
other ligand to a receptor with the consequent activation of the enzyme 
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phosphatidylinositol-4, 5-diphosphate (PIP2)-specific phospholipase C (PLC), mediated by 
a guanine nucleotide-binding protein (G-protein).  Activated PIP2-PLC catalyses the 
hydrolysis of PIP2 into the second messengers diacylglycerol and IP3.  Aluminium was 
found to inhibit receptor-stimulated IP3 production in neuroblastoma cells, in a 
concentration-dependent manner (Shi and Haug, 1992; Shi et al., 1993).  Although, it was 
suggested that receptor, G-protein, or receptor-G-protein interactions are not affected by 
aluminium (Shafer et al., 1993), the competitive inhibition of PIP2-PLC by aluminium 
(100 µM AlCl3 or aluminium lactate) was verified in different rat brain regions (Nostrandt 
et al., 1996).  Indeed, aluminium at 500 µM was reported to inhibit the PIP2-PLC activity 
by approximately 80% (Shafer et al., 1994).  The aluminium inhibition of PLC and 
consequent decrease on IP3 accumulation is not age-dependent, as verified by the similar 
response obtained from cortical homogenates of 7 day old and adult rats (Mundy et al., 
1995).  Haug and co-workers (1994) proposed that following interiorization of aluminium 
by the cell, metal interactions decrease the accumulation of inositol phosphates, especially 
IP3 and derangements of intracellular calcium homeostasis.  Moreover, the same authors 
referred that if present as a phosphate-like fluoro-aluminate, a stimulatory role of 
aluminium ions is displayed in G protein-coupled transmembrane signalling.  Indeed, 
direct stimulation of G proteins by aluminium tetrafluoride was reported to induce an 
increase in inositol phosphates formation and 45Ca2+ efflux (Lo Russo et al., 1997).  
Furthermore, aluminium at low concentrations (1.25 µM) was found to have a stimulating 
effect on oligodendrocyte cell cultures by enhancing the production of IP3, stimulating G 
protein-linked signal transduction and increasing protein synthesis (Golub et al., 2002).  
These aluminium activating properties were proposed to be attributable to the aluminium 
ion acting extracellularly. 
 Aluminium is also known to interfere with intracellular calcium homeostasis (Shi 
and Haug, 1992; Haug et al., 1994; Kaur and Gill, 2005).  Gandolfi and co-workers (1998) 
reported that aluminium modifies calcium uptake by the endoplasmic reticulum, 
accelerates calcium release from mitochondria and strongly inhibits Ca-ATPase activity, 
with a consequent high-level calcium accumulation inside the cell.  In addition, a study on 
the calcium homeostatic mechanisms in the rat central nervous system revealed that 
aluminium inhibits Ca-ATPase activity both in vitro and in vivo, inhibits calcium uptake 
and affects the biological activity of calcium regulatory proteins, calmodulin and protein 
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kinase C (Julka and Gill, 1996).  These authors suggested that aluminium disrupts calcium 
homeostasis by interacting with calcium binding sites.  It was reported that aluminium ions 
bind to calmodulin in the presence of calcium ions, leading to an inactive, reversible 
conformation, instead of its physiological active form.  Structural changes of calmodulin, 
which occur upon aluminium binding, lead to the impairment of protein flexibility and to 
the loss of its ability to interact with several other proteins, which may decrease or inhibit 
the regulatory character of calmodulin (Levi et al., 1998).  Disruption of neuronal calcium 
homeostasis was also found after chronic aluminium toxicity in rats (Kaur and Gill, 2005).  
These authors reported that chronic aluminium administration caused a significant rise in 
intrasynaptosomal calcium levels, decreased Ca-ATPase activity and increased calcium 
uptake via voltage-operated calcium channels.  An inhibitory effect on calcium uptake and 
on Ca-ATPase activity was also described in monkey brain, after chronic aluminium 
exposure (Sarin et al., 1997).  Additionally, in primary neuronal cultures, aluminium was 
found to potentiate glutamate-induced calcium accumulation (Mundy et al., 1997).  The 
aluminium-induced impairment of calcium homeostasis may conduct the cell towards 
pathways that are detrimental to its survival, such as apoptosis. 
 
I.1.5. Aluminium-induced neuronal apoptosis 
 
 Apoptosis, or programmed cell death, is a normal feature in the development of the 
nervous system and may also play a role in neurodegenerative diseases and aging (Sastry 
and Rao, 2000).  Apoptosis has been suggested to be responsible for the neuronal cell loss 
observed in many pathological disorders.  Mitochondrial changes following cytotoxic 
stimuli, including the opening of the mitochondrial permeability transition pore (MTP), 
represent a primary event in apoptotic cell death.  The apoptogenic factor, cytochrome c, is 
released, probably due to the MTP opening, from mitochondria into the cytoplasm where it 
binds to another cytoplasmic factor, Apaf-1, and the complex activates the initiator 
caspase-9 that in turn activates the effector caspase, caspase-3 (Li et al., 1997).  Other 
regulating proteins, such as the anti-apoptotic Bcl-2 and Bcl-XL, and the proapoptotic Bax 
are also involved in controlling and initiating apoptosis (Adams and Cory, 2001).  
Although, mitochondrial dysfunction has been implicated in neuronal cell death, it seems 
that the endoplasmic reticulum also has an active role in regulating apoptosis (Savory et 
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al., 2003).  In contrast to necrosis, apoptosis is an ordered operation, with characteristic 
apoptotic morphological changes that include nuclear condensation and fragmentation, 
DNA damage, cell shrinkage, membrane blebbing, and the formation of membrane-bound 
apoptotic bodies (Huppertz et al., 1999). 
 Apoptosis is an active process controlled by genes which can be activated by a 
variety of stimuli, including oxidative stress and exposure to hormones, toxins and drugs.  
Indeed, intracisternal injection of aluminium into rabbit brain leads to biochemical changes 
suggestive of apoptosis (Savory et al., 1999).  Apoptotic neuronal loss was observed after 
intracisternal administration of aluminium complexes to the rabbit brain (Ghribi et al., 
2001a).  They also revealed that glial cell-derived neurotrophic factor (GDNF) markedly 
prevents aluminium-induced apoptosis.  Aluminium was found to induce stress in both 
mitochondrial and endoplasmic reticulum, eventually culminating in the activation of 
caspases and apoptosis (Savory et al., 2003).  Cytochrome c release from mitochondria and 
binding to Apaf-1 seems to be the trigger that initiates the aluminium-induced apoptosis 
cascade (Savory et al., 2003).  Ghribi and co-workers (2001a) observed cytochrome c 
release from mitochondria, Bcl-2 down-regulation in both mitochondria and endoplasmic 
reticulum, Bax translocation into mitochondria, caspase-3 activation and DNA 
fragmentation, following intracisternal aluminium administration in rabbit brain.  In 
addition, whereas pro-caspase-3 is known to be distributed mainly in the cytoplasm, active 
caspase-3 was found to be localized mainly in the endoplasmic reticulum following 
aluminium-induced neurotoxicity in rabbit hippocampus (Ghribi et al., 2002).  Aluminium 
also induced stress in the endoplasmic reticulum in rabbit hippocampus, involving nuclear 
translocation of gadd 153, a transcription factor important in growth arrest and DNA 
damage induction, and NF-KB which initiates apoptosis (Ghribi et al., 2001b). 
 The intracisternal injection of aluminium in rat brain also induced apoptosis as 
assessed by DNA fragmentation and activation of caspase-3 and caspase-12 (Yang et al., 
2004).  Aluminium-induced apoptosis was also reported in cultured cortical neurons and 
SAPK/JNK signalling pathways appear to play an important role in the apoptosis induced 
by aluminium (Fu et al., 2003).  Aluminium maltolate was found to cause death of primary 
cultured rat hippocampal neurons in a time- and dose-dependent manner, and synapse loss 
was observed (Kawahara et al., 2003).  Aluminium-induced apoptosis was also reported in 
cultured astrocytes which exhibited altered calcium homeostasis (Guo and Liang, 2001).  
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Moreover, primary cultured astrocytes accumulate aluminium which induces apoptotic 
features, such as chromatin condensation and fragmentation (Aremu and Meshitsuka, 
2005).  Apoptosis, including the release of cytochrome c, was also verified in the human 
cell line NT2 after aluminium maltolate treatment, and it appears that the cytochrome c 
release results from an opening of the MTP (Griffioen et al., 2004).  In addition, 
aluminium maltolate induced apoptosis in Neuro-2a cells, a neuroblastoma cell line.  
Besides apoptotic features such as caspase-3 activation, Bcl-2 down-regulation, Bax up-
regulation, and nuclear condensation and fragmentation, the detection of aluminium 
induced p53 up-regulation was indicative of an important role for p53 signalling in 
apoptosis induced by aluminium (Johnson et al., 2005). 
 
 
 
 
I.2. PROTEIN PHOSPHORYLATION 
 
I.2.1. Protein phosphorylation as a dynamic process 
 
 In eukaryotes, protein phosphorylation is probably the most important regulatory 
event.  Structural and regulatory proteins, namely many enzymes and receptors are 
switched “on” or “off” (activated or not) by phosphorylation and dephosphorylation.  This 
is a dynamic and reversible process controlled by phosphatases and kinases.  Protein 
phosphatases (PP) are enzymes that catalyze the cleavage of phosphate from serine, 
threonine and tyrosine residues in proteins; they dephosphorylate proteins, changing their 
shapes and activities.  On the other hand, protein kinases phosphorylate proteins by 
transferring phosphate from ATP to the protein (Figure I.3).  Thus, proper regulation of 
protein phosphorylation requires the coordinated efforts of both protein phosphatases and 
kinases.  The balance between phosphatase and kinase activities regulates different events 
such as cell proliferation and metabolism, learning and memory, receptor modulation, 
neurotransmission, muscle contraction or even gene expression (Walaas and Greengard, 
1991; Tapia et al., 1999; Genoux et al., 2002). 
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Figure I.3 - Reversible protein 
phosphorylation. The substrate protein 
is dephosphorylated by a protein 
phosphatase and phosphorylated by a 
protein kinase. 
 
 
 Protein phosphatases and protein kinases are key players in many signal 
transduction cascades; they are also regulated by a myriad of extracellular and intracellular 
signals.  The human genome encodes a far greater number of serine/threonine protein 
kinases than of phosphatases.  Although, all protein kinases belong to a single family, 
protein phosphatases are divided into several distinct and unrelated protein/gene families.  
The serine/threonine-specific protein phosphatases comprise three distinct families.  The 
tyrosine-specific phosphatase family includes the tyrosine-specific phosphatases and the 
so-called dual specificity phosphatases (capable of dephosphorylating serine, threonine and 
tyrosine residues).  Besides these intracellular phosphatases involved in signal 
transduction, there are also unrelated non-specific alkaline and acid phosphatases that are 
usually found either in specialized intracellular compartments or in the extracellular milieu. 
 
I.2.2. Serine/threonine protein phosphatases 
 
 Serine/threonine protein phosphatases were initially classified into four classes 
denominated 1, 2A, 2B and 2C, according to their biochemical characteristics, sensitivity 
to endogenous inhibitor proteins, dependence upon metal ions and substrate specificity 
(Ingebritsen and Cohen, 1983).  Type-1 phosphatases (PP1) preferentially dephosphorylate 
the β-subunit of phosphorylase kinase and are inhibited by thermostable protein inhibitor-1 
and inhibitor-2 (Cohen, 1989), while type-2 phosphatases (PP2) preferentially 
dephosphorylate the α-subunit of phosphorylase kinase and are unaffected by inhibitor-1 or 
inhibitor-2 (Ingebritsen and Cohen, 1983).  Type-2 phosphatases are further subdivided 
into PP2A, PP2B (calcineurin) and PP2C, on the basis of their requirement for divalent 
+ 
Kinases 
Phosphatases 
PO4 
PO4 
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cations.  PP2A is active in the absence of divalent cations, while PP2B is dependent upon 
calcium and stimulated by calmodulin, and PP2C requires magnesium and is okadaic acid-
insensitive (Ingebritsen and Cohen, 1983; da Cruz e Silva et al., 1987; Cohen, 1989; 
Cohen, 1997; Klee et al., 1998).  More recently, recombinant DNA and molecular cloning 
techniques revealed that serine/threonine protein phosphatases are encoded by three gene 
families, PPP (phosphoprotein phosphatase), PPM (Mg2+-dependent protein phosphatase) 
and the FCP family; they are defined by distinct amino acid sequences and crystal 
structures.  The PPP family includes the okadaic acid-sensitive phosphatases PP1 and 
PP2A, and the okadaic acid-insensitive PP2B (Figure I.4), while the PPM family 
comprises the okadaic acid-insensitive Mg2+-dependent protein phosphatases, including 
PP2C and pyruvate dehydrogenase phosphatase.  The FCP family was more recently 
recognised through its founding member FCP1 which dephosphorylates the carboxy-
terminal domain of RNA polymerase II (Cohen, 2004).  This FCP family is also Mg2+-
dependent.  Another distinct gene family encodes protein tyrosine phosphatases (PTP), 
which dephosphorylate phosphotyrosine amino acids. 
 
 
Figure I.4 – Schematic representation of the PPP gene family.  These phosphatases contain a common 
catalytic core domain that is conserved among species.  PP1 and PP2A are highly homologous enzymes, 
differing primarily in their N- and C-terminal domains.  PP2B differs in that it contains a Ca2+-calmodulin 
(CaM) binding site. PP2B contains inserts in the catalytic core that alters the okadaic acid/microcystin toxin 
binding sites contained in PP1 and PP2A (adapted from da Cruz e Silva, 1998). 
 
 Molecular cloning contributed to the protein phosphatases classification in a 
phylogenetic way, for instance, revealed that PP2A was much more related to PP1 than to 
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PP2C (Berndt et al., 1987; da Cruz e Silva et al., 1987).  PP1, PP2A and PP2B are 
structurally related to each other, whereas PP2C appears to have a distinct evolutionary 
background.  Furthermore, a group of novel protein phosphatases was discovered, which 
are more closely related to PP1 and PP2A and include PP4, PP5, PP6 and PP7 (Figure I.5) 
(Cohen, 1997; Honkanen and Golden, 2002).  PP7 is dependent on magnesium but not 
calmodulin and is activated by calcium.  These new protein phosphatases are okadaic acid-
sensitive (except PP7) and are expressed in relatively low abundance (Barford et al., 1998), 
while PP1 and PP2A together have been reported to account for more than 90% of all 
serine/threonine phosphatase activity in the mammalian cell (Cohen and Cohen, 1989). 
 
 
Figure I.5 – Serine/threonine protein phosphatase phylogenic tree.  A tree illustrating the similarity 
between the known PPases based on their primary amino acid sequence.  PP1-PP7 belong to a single gene 
family (PPP) that is structurally distinct from the PP2C family (PPM).  The phosphatases above the dashed 
line are highly sensitive to inhibition by the naturally occurring toxins, okadaic acid, mycrocistin and 
calyculin A (adapted from Honkanen and Golden, 2002). 
 
I.2.2.1. Protein phosphatase 1 
 
 Protein phosphatase 1 (PP1) is one of four major types of serine/threonine 
phosphatases mediating signalling pathways.  PP1 is ubiquitously distributed and has been 
implicated in the regulation of such diverse biological processes as synaptic plasticity, cell-
PP5 
PP1 
PP2A 
PP4 
PP6 
PP2B 
PP7 
PP2C 
(PPP) 
(PPM) 
Toxin 
sensitive 
Toxin 
insensitive 
α 
β 
γ 
α 
β 
α 
β 
γ 
Aluminium neurotoxicity and neuronal phosphorylation systems 
40 
 
cycle progression, protein synthesis, muscle contraction, gene transcription, and glycogen 
metabolism (Bollen, 2001; Cohen, 2002). 
 PP1 is highly conserved among species.  The identity between human PP1 and 
yeast reaches approximately 80%, which represents one of the most conserved among all 
enzymes of these two organisms (Lin et al., 1999).  Human PP1 has a molecular mass of 
37 kDa (Tung and Cohen, 1984).  Three genes are known to encode mammalian type 1 
phosphatase catalytic subunits, termed PP1α, PP1β (also called PP1δ) and PP1γ, which 
demonstrate >90 % homology with each other (Faver et al., 1997).  Protein sequence 
variations among these isoforms are mainly confined to the carboxyl terminus (Sasaki et 
al., 1990), thought to play a regulatory role in the catalytic activity, such as proteolysis and 
phosphorylation (Eto et al., 1995).  The gene for PP1γ produces two isoforms by 
alternative splicing, differing only in the extreme carboxyl terminus: PP1γ1 is widely 
expressed in mammalian tissues and PP1γ2 is predominantly expressed in testis (da Cruz e 
Silva et al., 1995b). 
 The sequence of the catalytic core of PP1 (residues 41-269 of the mammalian α 
isoform) is nearly identical for all isoforms, and shows a high degree of similarity with the 
corresponding fragment of the catalytic subunits of PP2A and PP2B (Egloff et al., 1995; 
Goldberg et al., 1995).  This core enzyme (228 residues) has broader substrate specificity 
than does intact PP1 catalytic subunit (330 residues) and has a severely reduced sensitivity 
to inhibitory toxins and protein regulators (Connor et al., 1999).  The extremities of the 
catalytic subunit therefore appear to restrict the substrate specificity of the enzyme and are 
essential for the binding of regulators.  Residues 270-296 seems to contribute to the 
creation of at least two binding sites for regulators (Connor et al., 1999).  Yet, intact PP1 
catalytic subunit has a rather broad substrate specificity and can dephosphorylate numerous 
proteins in vitro (Bollen and Stalmans, 1992).  However, in the cell, the catalytic region 
interacts with a number of regulatory subunits (Cohen, 1989; Cohen, 1997).  The three-
dimensional structures of mammalian PP1 catalytic subunits have been defined by 
crystallography studies (Egloff et al., 1995; Goldberg et al., 1995).  The core region of PP1 
forms a compact ellipsoidal structure, consisting of a central distorted β-sandwich of 11 β-
strands surrounded by 7 α-helices on one side and a subdomain composed of 3 α-helices 
and a 3-strand β-sheet on the other side.  In the central region of the distorted β-sandwich, 
3 β-strands connected by 2 α-helices form a β-α-β-α-β motif.  This motif is proposed as the 
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active site of the enzyme where two metal ions bind.  The presence of metal ions at the 
active site suggests that PP1 dephosphorylates its substrates through metal ion-mediated 
hydrolysis (Egloff et al., 1995; Goldberg et al., 1995). 
 In contrast to protein serine/threonine kinases whose substrate specificity is in part 
determined by the presence of sequence motifs flanking the target amino acid, protein 
phosphatases appear to lack any obvious sequence specificity (Tung et al., 1985).  A 
number of distinct proteins (regulatory subunits) bind the catalytic subunit of PP1 and 
serve to direct the enzyme toward distinct subcellular locations and/or modify the activity 
towards specific substrates.  Despite the lack of primary structure homology between these 
regulatory proteins, a PP1 binding motif, RVxF, has been found in the majority of these, 
including inhibitor-1, DARPP-32 and NIPP1, suggesting that the same domain is required 
for regulatory binding (Egloff et al., 1997; Zhao and Lee, 1997).  Regulatory subunits also 
modulate the substrate specificity of PP1, thus allowing its activity to be modulated by 
extracellular signals such as hormones and growth factors (Hubbard and Cohen, 1993).  
PP1 can dephosphorylate multiple substrates, both in vitro and in cell-free assays, with no 
obvious sequence specificity; this appears to be a consequence of the action of more than 
thirty regulatory subunits that possess the ability to target the catalytic subunit to specific 
intracellular locations (Aggen et al., 2000; Bollen, 2001; Gallego and Virshup, 2005; 
Terrak et al., 2004).  Indeed, subcellular targeting gains importance as a crucial regulator 
of protein phosphatase action (Strack et al., 1997). 
 A variety of proteins are known to interact with PP1 including its intracellular 
inhibitor proteins such as inhibitor-1 (I-1), inhibitor-2 (I-2) and DARPP-32.  Both I-1 and 
I-2 are heat stable and are not precipitated by 1% trichloroacetic acid, in contrast to most 
other proteins.  I-1 binds to and inhibits PP1 only after being phosphorylated on Thr-35 by 
cAMP-dependent protein kinase or cGMP-dependent protein kinase (Hemmings et al., 
1984b).  Amino acids 9-12 KIQF seem to be crucial for binding and inhibition of PP1 
(Egloff et al., 1997).  On the other hand, I-2 binds and inhibits PP1 regardless of 
phosphorylation.  I-2 inhibits PP1 via interaction with amino acid Tyr-272 (Zhang et al., 
1996).  All four PP1 isoforms (α, γ1, γ2 and β) are inhibited by proteins I-1 and I-2 (Depaoli 
Roach et al., 1994; Wera and Hemmings, 1995).  DARPP-32 is similar to I-1 in function 
but derived from a different gene, and is mainly expressed in the brain (Hemmings et al., 
1984a).  Among several other proteins, neurofilament L (Terry-Lorenzo et al., 2000) and 
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tau (Liao et al., 1998) where also found to interact with PP1.  Liao and co-workers (1998) 
reported that PP1 is targeted to microtubules by microtubule-associated protein tau and 
thus is involved in the maintenance of microtubule stability.  Moreover, in normal brain, it 
was shown that PP2A, PP2B and to a lesser extent PP1, are involved in the 
dephosphorylation of tau (Gong et al., 1995). 
 The tissue expression and cellular or subcellular distribution of PP1 catalytic 
subunits are not uniform.  For instance, in rat salivary glands, only some cell types were 
reported to react with antibodies specific for PP1γ1 (Shirakawa et al., 1996).  In the heart, 
where PP1α, PP1β, and PP1γ1 have been immunologically detected in whole tissue 
homogenates, the myofibrillar fractions contained mainly PP1α (Chu et al., 1994).  In the 
brain the mRNAs for PP1α, PP1β and PP1γ1 were found to be particularly abundant in 
hippocampus and cerebellum (da Cruz e Silva et al., 1995b).  At the protein level PP1α and 
PP1γ1 were found to be more highly expressed in brain than in peripheral tissues, with the 
highest levels being measured in the striatum, where they were shown to be relatively 
enriched in the medium-sized spiny neurons (da Cruz e Silva et al., 1995b).  At the 
electron microscopic level, PP1 immunoreactivity was demonstrated in dendritic spine 
heads and spine necks and possibly also in postsynaptic density (Ouimet et al., 1995).  
These authors also observed that most neuronal nuclei were not immunoreactive for PP1γ1 
but were usually strongly immunoreactive for PP1α (Ouimet et al., 1995).  Although, 
PP1γ1 is known to be widely expressed in mammalian tissues, PP1γ2 is predominantly 
expressed in testis (da Cruz e Silva et al., 1995b).  Moreover, as well as PP1, the other 
phosphatases (PP2A, PP2B and PP2C) were also found to be highly expressed in neurons 
of human brain (Pei et al., 1998). 
 
I.2.2.2. Protein phosphatase 2A 
 
 PP2A is a major protein phosphatase in all eukaryotic cells and has a wide range of 
biological functions.  These include the control of cell cycle, organization of cytoskeleton, 
transcription of immediate early genes, cholesterol and protein biosynthesis.  PP2A is a 
heterotrimeric enzyme composed of a catalytic C subunit, a structural A subunit and a 
regulatory B subunit.  cDNAs encoding two C subunits, two A subunits and over twenty B 
subunits, belonging to four gene families (B, B’, B’’, B’’’), have been identified.  There is 
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a total lack of sequence similarity between these four gene families, even though the gene 
products recognize the same or overlapping sites on the A subunit (Ruediger et al., 1992, 
1994; Janssens and Goris, 2001).  Each B subunit associates with A and C subunits in a 
mutually exclusive fashion (Kremmer et al., 1997).  There are two isoforms of mammalian 
PP2A C subunits (PP2Aα and PP2Aβ), which share 97% amino acid sequence identity, 
with the α isoform being approximately ten-fold more abundant than the β isoform (da 
Cruz e Silva and Cohen, 1987; Stone et al., 1987).  Both isoforms are highly conserved in 
nature, with human and yeast PP2A sharing ~80% identity at the level of their primary 
amino acid sequences.  The structural A subunit also consist of α and β isoforms that are 
ubiquitously expressed and share 86% sequence identity.  The A subunits function as 
scaffolds that link the C subunit to the different regulatory B subunits (Hemmings et al., 
1990; Hendrix et al., 1993).  The existence of two C, two A, four B, at least eight B’, four 
B’’ and two B’’’ isoforms, suggests the existence of numerous different PP2A complexes 
establishing vast possibilities for activation, substrate specificity and sub-cellular 
localization (Janssens and Goris, 2001).  Moreover, it is becoming clear that a major 
function of the regulatory subunits is to target the PP2A holoenzyme to distinct 
intracellular locations, signalling complexes and substrates. 
 PP2A catalytic subunit is regulated by molecular mechanisms that include 
phosphorylation, carboxylation and stimulation by ceramide.  The C subunit can be 
phosphorylated in vitro by tyrosine kinases p60v-src, p56lck, epidermal growth factor 
receptor and insulin receptor (Chen et al., 1992).  Phosphorylation occurs on Tyr-307 at 
the extreme C-terminus of the protein and leads to 90% loss of activity.  
Dephosphorylation reactivates the phosphatase.  The methylation of the α-carboxyl group 
of the C-terminal Leu-309 of PP2A in vitro has only moderate stimulatory effects on 
phosphatase activity and impairs binding of peptide-specific antibodies to the C-terminus 
of the PP2A C subunit (Favre et al., 1994).  In vitro, ceramide activates the trimeric forms 
of PP2A that contain either the PR55a (a B subunit) or the 54 kDa protein (a B’ subunit).  
In contrast, PP2A dimeric form and the isolated C subunit are insensitive to ceramide 
(Dobrowsky et al., 1993).  The intracellular PP2A activity is also inhibited by two inhibitor 
proteins called PP2A I-1 and PP2A I-2 in mammalian tissues (Li et al., 1995; Li et al., 
1996).  Both are thermostable and not inactivated by 1% trichloroacetic acid.  They inhibit 
PP2A in a noncompetitive manner with the substrate and exhibit apparent inhibition 
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constant (Ki) values in the nanomolar range (Li et al., 1995).  PP2A I-1 appears to inhibit 
the catalytic subunit directly (Li et al., 1996).  PP2A, by dephosphorylating PP1 inhibitors 
I-1 and DARPP-32, regulates the activity of PP1.  Additionally, PP2A I-1 and PP2A I-2 
regulate the activity of PP1 by associating with and modifying the substrate specificity of 
PP1C in the presence of physiological concentrations of Mn2+ (Katayose et al., 2000). 
 Concerning subcellular distribution, PP2A seems to be mainly cytosolic.  However, 
some PP2A was also detectable in the nucleus (Turowski et al., 1995).  Both PP2A 
catalytic subunit isoforms α and β are ubiquitously expressed, and high levels are found in 
brain and heart.  However, PP2Aα is about 10 times more abundant than PP2Aβ (Khew-
Goodall and Hemmings, 1988).  Among all tissues tested, PP2A activity was highest in 
brain extracts (Ingebritsen and Cohen, 1983).  The catalytic subunit was found to have a 
wide regional distribution in brain, with the highest immunoreactivity being present in 
neurons and particularly enriched in the cytosolic and synaptosolic subcellular fractions 
(Saitoh et al., 1989). 
 
I.2.2.3. Protein phosphatase 2B 
 
 PP2B, also termed calcineurin, is a calcium/calmodulin-activated protein 
serine/threonine phosphatase.  The enzyme consists of two subunits, the catalytic A subunit 
of 60 kDa (PP2B A) and the regulatory or calcium-binding B subunit of 19 kDa (PP2B B), 
which makes this the only phosphatase directly regulated by a second messenger (Klee et 
al., 1988; Cohen, 1989).  PP2B is present in nearly all mammalian cells studied.  However, 
it is most highly expressed in the brain.  Originally, the term calcineurin referred to the 
neuronal form of PP2B but, more recently, calcineurin refers to both neuronal and non-
neuronal PP2B.  The amino acid sequence of PP2B is highly conserved from humans to 
yeast with over 50% sequence identity (da Cruz e Silva and Cohen, 1989; da Cruz e Silva 
et al., 1991).  Cloning from rat brain indicated an A subunit of 521 amino acids.  PP2B 
catalytic A subunit comprises three isoforms (PP2B Aα, PP2B Aβ and PP2B Aγ) that share 
>80% identity at the level of their primary amino acid sequence (da Cruz e Silva et al., 
1991).  Both, Aα and Aβ isoforms are highly expressed in brain, whereas Aγ is testis 
specific (Ueki et al., 1992).  Differential splicing of PP2B Aα generates two transcripts (α1 
and α2), whereas PP2B Aβ gene is alternatively spliced to give three transcripts β1, β2 and 
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β3.  The PP2B A subunit shows autoinhibition that is relieved by interaction with the B 
subunit.  In contrast to PP1 and PP2A, PP2B is the only PP directly regulated by calcium.  
The inhibition of B on A is relieved if B binds calcium.  This explains why the enzyme is 
dependent on calcium for activity.  Using proteolysis of the autoinhibitory carboxyl 
terminus of the A subunits generates a calcium-independent form of the enzyme.  The B 
subunit was sequenced at the protein level and found to comprise 168 amino acids, 
exhibiting a high degree of similarity to calmodulin.  Two different B subunit genes are 
known, the PP2B Bα and the PP2B Bβ.  PP2B Bα gives rise to one isoform expressed in 
many tissues termed PP2B Bα1 (170 amino acids) and, by means of a different promoter, 
leads to another testis-specific isoform termed PP2B Bα2 (216 amino acids).  PP2B Bβ 
(179 amino acids) is only expressed in the testis (Ueki et al., 1992; Chang et al., 1994). 
 PP2B has much narrower in vitro substrate specificity than either PP1 or PP2A.  
This is consistent with its specialized functions in the nervous system, T lymphocytes and 
other cells.  The PP1 inhibitors I-1 and DARPP-32 are excellent in vitro and in vivo 
substrates for PP2B, therefore, PP2B can control PP1 activity (Mulkey et al., 1994).  PP2B 
is the target of two clinically important immunosuppressive drugs, cyclosporine and 
FK506.  The complex of each drug with its cognate intracellular receptor, known as an 
immunophilin, binds to and inhibits the PP2B heterodimer (Liu et al., 1991).  A protein 
called cain, due to its calcineurin inhibitor activity, is highly expressed at the RNA and 
protein levels in brain, kidney and testis.  It is mainly cytosolic.  It was speculated that cain 
may target inactivated PP2B to specific intracellular regions where its release would 
provide calcium-regulated phosphatase activity to specific signalling pathways (Lai et al., 
1998). 
 
I.2.2.4. Protein phosphatase 2C 
 
 PP2C is monomeric. In mammalian cells, two PP2C isoforms were known: PP2Cα 
and PP2Cβ (Tamura et al., 1989; Wenk et al., 1992).  PP2Cα is comprised of 382 amino 
acids.  Several isoforms of PP2Cα, namely, PP2Cα1, PP2Cα2 and PP2Cα3, have been 
reported (Mann et al., 1992), with PP2Cα1 being the most abundant isoform.  Alternative 
splicing seems to generate the isoforms PP2Cβ1 and PP2Cβ2.  They were cloned from a 
mouse library and show differences in carboxyl termini and the 3’-untranslated region.  
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PP2Cβ1 is expressed in all mouse tissues studied, whereas PP2Cβ2 is confined to heart and 
brain where they might subserve special functions (Terasawa et al., 1993).  PP2Cβ1 and 
PP2Cβ2 code for 390 and 389 amino acids, respectively.  PP2C was originally assumed to 
be exclusively cytosolic (Shenolikar and Nairn, 1991), but more recent work identified 
PP2C also in the nucleus of mammalian cells (Das et al., 1996). 
 
I.2.2.5. New protein phosphatases: PP4, PP5, PP6 and PP7 
 
 PP4, also called PPX (da Cruz e Silva et al., 1988, Brewis et al., 1993), is 
expressed highly in testis, however, it was also detected in other tissues.  Its structure, like 
that of PP6, is reminiscent of PP2A.  PP4 is comprised of 307 amino acids (rabbit) and is 
mainly localized in the nucleus, although smaller amounts are also present in the cytosol 
(Brewis et al., 1993). 
 PP5 is ubiquitously expressed in human tissues.  The calculated molecular mass of 
the protein is 58 kDa (Chen et al., 1994).  PP5 contains an autoinhibitory domain.  
Polyunsaturated fatty acids can relieve this inhibition (Chen and Cohen, 1997).  PP5 was 
detectable mainly in the nucleus, although some immunoreactivity was also present in the 
cytosol (Chen et al., 1994). 
 PP6 is also structurally related to PP2A.  PP6 has been identified in all mammalian 
tissues examined (Mann et al., 1993). 
 PP7 is comprised of 653 amino acids.  PP7 was only detectable in the retina by 
analysis of RNA from various human tissues (Huang and Honkanen, 1998). 
 
I.2.3. Protein phosphatase inhibitors 
 
 Several natural compounds, such as okadaic acid (Tachibana et al., 1981; Takai et 
al., 1987; Bialojan and Takai, 1988), microcystin (Carmichael et al., 1988; Honkanen et 
al., 1990), nodularin (Honkanen et al., 1991), tautomycin (Cheng et al., 1987; Takai et al., 
2000), fostriecin (Hastie and Cohen, 1998; Walsh et al., 1997), cantharidin (Hastie and 
Cohen, 1998; Li and Casida, 1992) and calyculin A (Sheppeck et al., 1997; Matsunaga et 
al., 1997), have been found to inhibit the activity of the PP1-PP6 family of protein 
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phosphatases.  Most of these compounds were originally derived from extracts of natural 
products and many were initially identified as eukaryotic cell toxins.  The organisms that 
make these inhibitors are biologically diverse, with potent inhibitors produced by 
dinoflagellates (i.e. okadaic acid), cyanobacteria (i.e. microcystin and nodularin), 
Streptomyces (i.e. tautomycin and fostriecin), insects (i.e. cantharidin), and calyculin A 
was identified from a marine sponge extract (Honkanen and Golden, 2002).  Table I.1 
summarizes the IC50 of each compound for each protein phosphatase.  As a specific PP1 
and PP2A inhibitor, okadaic acid is an excellent tool to evaluate the contribution of those 
phosphatases in a wide range of systems (e.g. Boudreau and Hoskin, 2005). 
 
Table I.1 - Natural serine/threonine protein phosphatases inhibitors 
 
Inhibition of Ser/Thr protein phosphatase activity (IC50, nM) 
Compound PP1 PP2A PP2B PP4 PP5 PP7 
Okadaic acid 20-50 0.1-0.3 ~4 µM 0.1 3.5 >1 µM 
Microcystin 0.3-1 <0.1-1 ~1 µM 0.15 1 >1 µM 
Nodularin 2.4 0.3 >1 µM ND ND >1 µM 
Calyculin A 0.4 0.25 >1 µM 0.4 3 >1 µM 
Tautomycin 1 10 >1 µM 0.2 10 ND 
Cantharidin 450 50 >10 µM 50 3.5 µM ND 
Fostriecin 45-58 µM 1.5-5.5 >100 µM 3 70 µM ND 
(Adapted from Honkanen and Golden, 2002) 
 
 Besides natural toxins, the serine/threonine protein phosphatases also have 
endogenous protein inhibitors.  PP1 specific inhibitors include inhibitor 1 (I-1) and 
inhibitor 2 (I-2) (Huang and Glinsmann, 1976), both are cytosolic heat-stable proteins with 
molecular mass of 18.7 kDa and 22.9 kDa, respectively.  I-1 and I-2 inhibit PP1 activity 
with inhibition constants (Ki) of 1.6 nM and 3.1 nM, respectively.  Other protein inhibitors 
of PP1 are dopamine-and-cAMP-regulated phosphoprotein of Mr 32,000 Da (DARPP-32) 
(Walaas et al., 1983), nuclear inhibitor of PP1 (NIPP-1) (Beullens et al., 1992), C-kinase 
activated phosphatase inhibitor of Mr 17,000 Da (CPI17) (Eto et al., 1995) and ribosomal 
inhibitor of PP1 (RIPP-1) (Beullens et al., 1996).  I-1 and DARPP-32 need to be 
phosphorylated to inhibit PP1.  However, I-2 and NIPP-1 are more potent phosphatase 
inhibitors in their dephosphorylated state.  PP2A specific protein inhibitors include 
inhibitor 1 of PP2A and inhibitor 2 of PP2A.  Both are thermostable endogenous proteins 
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of 30 kDa and 39 kDa, which specifically inhibit PP2A with Ki of 30 nM and 2 nM, 
respectively (Li et al., 1995; Li et al., 1996).  As described above PP2B also has an 
endogenous inhibitor identified as cain (Lai et al., 1998) with 240 kDa that inhibits PP2B 
with a Ki = 0.44 µM (Oliver and Shenolikar, 1998).  The specificity of these inhibitors for a 
given phosphatase makes them key tools in the study of phosphorylation dependent 
processes. 
 
I.2.4. Abnormal phosphorylation of proteins 
 
 Abnormal protein phosphorylation has been associated with various disorders, 
including cancer, diabetes, and several neurodegenerative disorders such as ALS, 
Parkinson’s disease, Huntington’s disease and AD (Grundke-Iqbal et al., 1986b; Goedert et 
al., 1997; Sridhar et al., 2000).  Hyperphosphorylated neurofilaments and tau proteins are 
known to be associated with various neurodegenerative diseases (Wang et al., 2001; 
Wakayama et al., 1993a; Grundke-Iqbal et al., 1986b). 
 
I.2.4.1. Neurofilaments 
 
 Neurofilaments (NF), the neuron-specific intermediate filaments, are a major 
cytoskeletal component in neurons.  In combination with other cytoskeletal proteins, NF of 
~10 nm diameter cross-link with one another and form a three-dimensional network in the 
axon, defining the calibre and shape of the axon and providing an anchor for other 
constituents of the cytoplasm.  NF are composed structurally of two unique portions: a 
central shaft 10-12 nm in diameter, called core filament, and peripheral strands 4-5 nm in 
diameter deriving from the core filament, called projections.  Those projections may be 
connected with projections from other filaments forming cross-bridges.  NF are co-
assembled from three subunits in mammals, referred to as NF high (NF-H), medium (NF-
M) and low (NF-L) molecular weight subunit, with apparent molecular masses of 
approximately 180-200 kDa, 140-160 kDa and 68-70 kDa, respectively (Lee and 
Cleveland, 1996) (Figure I.6).  The three NF subunits share a characteristic ~310-amino-
acid α-helical central domain containing a hydrophobic heptad repeat essential for 
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assembly.  Flanking this central rod are globular head and tail segments, which are 
markedly divergent in length and sequence among the three subunits.  Although the head 
domains of NF subunits do not share obvious amino acid sequence homologies, they are 
rich in serine and threonine residues.  Phosphorylation and O-glycosylation of these 
residues are believed to be important for in vivo regulation of NF assembly.  The most 
distinct features of the NF subunits are the carboxy-terminal (C-terminal) tail domains.  
For NF-L, this region is highly acidic, with many glutamic acid residues comprising a 
segment sometimes referred to as the segment E.  NF-M has a longer tail domain, also 
contains E segments as well as segments rich in glutamic acid and lysines.  The NF-H tail 
is unique since it possesses multiple repeats of lysine-serine-proline (KSP).  Although the 
number and the distribution of repeats differ among vertebrates, the serines in the KSP 
domains are extensively phosphorylated in axons (Lee and Cleveland, 1996; Gotow, 2000).  
NF-M also contains a few KSP motifs.  Their number and position are not conserved, but 
they are phosphorylated in axons (Xu et al., 1992b).  The two major types of KSP motifs in 
the NF-H tail domain are KSPXKX and KSPXXX (Chin and Liem, 1990).  NF-L is less 
phosphorylated and the phosphorylation sites are in the amino-terminal (N-terminal) of the 
protein (Hashimoto et al., 2000) (Figure I.6).  Phosphorylation of the head domain of NF-L 
may play an important role in NF dynamics (Nixon, 1993; Hashimoto et al., 2000). 
 
 
Figure I.6 – Schematic diagram of mammalian NF-L, NF-M and NF-H neurofilament subunits.  The 
numbers below correspond to amino acids from the murine neurofilament subunits.  Variable head and tail 
domains flank the conserved α-helical rod domains.  Known or predicted glycosylation sites are indicated, as 
well as known sites of phosphorylation (adapted from Lee and Cleveland, 1996). 
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 All three NF subunits are integral components of NF.  The NF assembly requires 
the heteropolymerization of NF-L with either NF-M or NF-H in rodents (Lee et al., 1993; 
Jacomy et al., 1999), although, human NF-L alone can form homopolymers when 
expressed in a mammalian cell (Carter et al., 1998).  The core filaments are built up by 
both N-terminal head and central conserved helical domains of all three NF subunit 
proteins, whereas the projections are formed from C-terminal tail domains of both NF-M 
and NF-H (Gotow et al., 1992).  Following synthesis, NF are assembled in the cell body 
and, it seems that for efficient NF protein transport in vivo, the formation of hetero-
oligomers is required (Yuan et al., 2003).  Assembled NF move into and through axons via 
slow axonal transport, the rate for which varies between 0.1-1 mm/day.  The velocity 
depends on: the group of neurons, the age of the animal, and the location along the nerve 
(Lee and Cleveland, 1996).  However, it has been reported that NF polymers move along 
the axon in a rapid, intermittent, bidirectional and highly asynchronous manner (Brown, 
2000; Wang et al., 2000).  The NF moved at peak rates of up to 3 µm/s, or did not move at 
all during the observation period.  Thus, the peak rate of movement in slow axonal 
transport may be fast, but the overall rate is slow because the rapid movements are 
interrupted by prolonged pauses (Wang and Brown, 2001; Ackerley et al., 2003; Brown et 
al., 2005).  During axonal transport NF are extensively phosphorylated on the C-terminal 
tail of NF-H and NF-M (Nixon, 1993; Nixon et al., 1994).  The extent of phosphorylation 
of the KSP repeat domain promotes the slowing of NF transport rate (Nixon et al., 1994; 
Shea et al., 2003), apparently this is due to increased pausing in NF movement (Ackerley 
et al., 2003).  Indeed, hypophosphorylated NF are transported more quickly than 
extensively phosphorylated ones (Jung et al., 2000).  Additionally, using knockout mice 
for the NF-M and NF-H genes, the absence of the NF-M protein resulted in an accelerated 
rate of slow axonal transport of NF in sciatic nerves (Jacomy et al., 1999).  However, a 
controversy arose when Rao et al. (2002) reported, and Yuan et al. (2006) confirmed, that 
NF transport rate in vivo is not altered by deleting the extensively phosphorylated NF-H 
tail domain.  Shea et al. (2003) proposed that deletion of the NF-H C-terminal region 
accelerates the transport of a subpopulation of NF, using the same NF-H tail-depleted 
mutant mice used by Rao and Yuan and co-workers.  In fact, it was reported that cdk5, a 
kinase responsible for the NF C-terminus phosphorylation, regulates axonal transport and 
phosphorylates NF in cultured neurons (Shea et al., 2004).  The authors demonstrated that 
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overexpression of cdk5 increases NF phosphorylation and inhibits NF axonal transport; 
consequently phosphorylated-NF “bundles” were found in perikarya.  NF transport into 
and along axons requires microtubules (Helfand et al., 2004; Francis et al., 2005) and 
microtubule-associated motor proteins, such as kinesin and cytoplasmic dynein, which 
mediate the translocation of NF along microtubules (Yabe et al., 1999; Shah et al., 2000; 
Wagner et al., 2004; He et al., 2005).  Kinesin mediates anterograde (from cell body to 
axon tip) NF axonal transport (Yabe et al., 1999).  Both NF-H and NF-M regulate the 
association of NF with kinesin and the phosphorylation of NF-H dissociates NF from 
kinesin contributing to the slowing of NF axonal transport (Jung et al., 2005).  On the other 
hand, dynein mediates retrograde NF transport within axons (Shah et al., 2000; Wagner et 
al., 2004; He et al., 2005).  Dynein also mediates anterograde delivery of NF from 
perikarya into axons, and C-terminal NF phosphorylation promotes motor association 
(Motil et al., 2006).  NF transport also appears to depend on actin and myosin (Helfand et 
al., 2004; Jung et al., 2004).  NF are intrinsic determinants of radial growth of axons and 
phosphorylation of NF-H and NF-M are likely to play a critical role in organizing NF and 
in their ability to mediate control of caliber (Lee and Cleveland, 1996).  Indeed, it was 
reported that the C-terminal domain of NF-M is essential for the radial growth and 
cytoskeletal architecture of axons (Rao et al., 2003).  Still, the deletion of the tail domain 
of NF-H seems not to alter the axonal caliber (Rao et al., 2002).  Moreover, it was reported 
that the absence of the NF-M subunit resulted in a two- to threefold reduction in the caliber 
of large myelinated axons, whereas the lack of NF-H subunits had little effect on the radial 
growth of motor axons (Jacomy et al., 1999).  Another posttranslational modification of 
the NF subunits concerns the addition of O-linked N-acetylglucosamine (O-GlcNAc) 
moieties (Dong et al., 1993; Dong et al., 1996).  Finally, NF are degraded by proteases 
upon arrival at the nerve terminals.  NF can be degraded by a variety of proteases, 
particularly those activated by calcium (Greenwood et al., 1993).  Phosphorylation seems 
to protect NF against proteolysis (Goldstein et al., 1987).  Thus, C-terminal tail domain 
phosphorylation regulates NF axonal transport, dynamics and proteolysis (Nixon, 1998; 
Jung and Shea, 1999; Ackerley et al., 2003).  Additionally, tail domain phosphorylation 
may control inter-filament distance and, indirectly, axon diameter through electrostatic 
repulsion between the side arms of adjacent NF (Nixon et al., 1994; Lee and Cleveland, 
1996; Rao et al., 2003).  In contrast, phosphorylation of the N-terminal head domain 
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appears to prevent premature polymerization of NF subunits in the cell body (Sihag and 
Nixon, 1990; Sihag and Nixon, 1991). 
 Under normal conditions the phosphorylation states of the two larger NF protein 
subunits, specially NF-H, are different between the axonal and somatodendritic 
compartments.  That is, phosphorylated NF appear to be localized mainly in the axon and 
absent from the cell body, whereas the nonphosphorylated forms are found in the perikarya 
and dendrites (Sternberger and Sternberger, 1983; Gotow et al., 1995), suggesting the 
importance of NF phosphorylation in its transport and interaction with other cytoskeletal 
proteins.  Corresponding to the difference in phosphorylation level between these two 
compartments of the neuron, there is a morphological difference in NF organization, i.e., 
NF are much denser and arranged into parallel bundles through well-developed cross-
bridges in the axons, whereas they are sparse and aligned irregularly with less-developed 
cross-bridges in the perikarya and dendrites.  This features indicates that phosphorylation 
of NF-H is necessary for the interaction of projections with other projections to form 
regular cross-bridges, while dephosphorylation is necessary for the interaction of 
projection with other structures such as microtubules or membrane-bound organelles 
(Hisanaga et al., 1991; Gotow et al., 1995).  Indeed, the interaction of NF-H with 
microtubules was reported to be accelerated when NF-H was dephosphorylated in vitro 
(Hisanaga et al., 1991). 
 Since, NF are confined to the nervous system, they might be one of the best 
markers reflecting neuronal pathogenic changes seen in some neurological disorders.  In 
fact, neuronal accumulation of abnormally phosphorylated NF has been seen in several 
neurodegenerative diseases, namely: in motor neurons in ALS, in NFT in AD, and in 
aluminium-induced encephalopathies.  The NF accumulate in the neuronal perikaryal 
compartment and their NF-H tends to be hyperphosphorylated.  The accumulation of 
hyperphosphorylated NF in perikarya might be associated with axonal dysfunction or 
degeneration, resulting in neuronal death (Gotow, 2000).  The accumulation of 
phosphorylated NF also reflects an anomaly of NF processing, inefficient degradation by 
proteases, enhanced and aberrant phosphorylation and protein misfolding.  All of these 
features are also noted in the normal aging brain, without manifestation of dementia.  
Insidious accumulation of these aberrant misfolded proteins in large quantities interferes 
with synaptic transmission in critical topographic brain areas and may manifest as motor 
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neuron disease or AD-type dementia (Gupta et al., 2005).  In AD brain, NF in addition to 
tau are hyperphosphorylated and accumulated.  In fact, the levels of all three NF subunits 
have been found to be markedly increased and at least NF-H and NF-M appear to be 
significantly hyperphosphorylated at several sites (Wang et al., 2001; Hu et al., 2002). 
 Several evidence points to the involvement of protein phosphatases in the 
regulation of the phosphorylation of neurofilaments.  Veerana et al. (1995) suggested the 
involvement of PP2A in the regulation of the phosphorylation state of KSPXKX motifs in 
NF-H.  PP2A as well as PP1 were found to be associated with and dephosphorylate all 
three NF subunits in vitro (Strack et al., 1997).  Wang et al. (2001) also reported that 
treatment of human neuroblastoma SY5Y cells with okadaic acid, an inhibitor of PP2A and 
PP1, also results in the phosphorylation and accumulation of NF-H and NF-M subunits, as 
seen in AD.  Similarly, Gong et al. (2003) reported that inhibition of PP2A induces an 
increase in the phosphorylation of NF-H and NF-M subunits and a general accumulation of 
NF throughout the whole neuron, using metabolically active rat brain slices.  In addition, 
NF-L was reported to be a PP1 binding protein (Terry-Lorenzo et al., 2000).  Moreover, it 
was reported that a form of PP2A associates with NF and dephosphorylates NF-L 
phosphorylated by exogenous protein kinase A, a kinase which phosphorylates the N-
terminal (Saito et al., 1995).  On the other hand, the cyclin-dependent kinase-5 (cdk5) 
family could be responsible for the phosphorylation of KSP sequences in the NF-H and 
NF-M tail domain (Shetty et al., 1993; Veerana et al., 1995; Ackerley et al., 2003).  It was 
also reported that the stress activated protein kinase-1b phosphorylates NF-H tail 
(Brownlees et al., 2000).  Protein kinase A, protein kinase C and CaM kinase II have all 
been reported to be responsible for the phosphorylation of specific sites in the N-terminal 
head domain of NF-L and NF-M (Sihag and Nixon, 1990; Sihag and Nixon, 1991; Carter 
et al., 1996; Sihag et al., 1999). 
 
I.2.4.2. Tau protein 
 
 Microtubule-associated protein τ (tau) is essential in maintaining the microtubular 
integrity of the cell by promoting the assembly and stabilizing the microtubules in neurons.  
The state of phosphorylation of tau interferes with its normal function to bind with 
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microtubules. Non-phosphorylated tau associates with microtubules and 
hyperphosphorylated tau dissociates from microtubules (Drechsel et al., 1992). 
 In AD and other tauopathies, tau protein, the major component of neurofibrillary 
tangles (NFT), is abnormally hyperphosphorylated at several serine/threonine sites, 
aggregated into paired helical filaments (PHF) in affected neurons, and does not bind to 
microtubules or stimulate microtubule assembly (Figure I.7). 
 
 
 
 
 
Figure I.7 – Paired helical filament (PHF) 
formation scheme.  Tau protein in its normal 
state helps microtubule to assemble, however 
when it is hyperphosphorylated, it aggregates 
into PHF (adapted from 
www.abpi.org.uk/publications/publication_det
ails/targetAlzheimers/industry_d.asp). 
 
 
 
 Abnormal hyperphosphorylation of tau is believed to lead to the neurofibrillary 
degeneration observed in those diseases.  Tau associated with PHF is insoluble, displays 
retarded mobility on SDS-PAGE, besides being abnormally hyperphosphorylated 
(Grundke-Iqbal et al., 1986b; Lee et al., 1991).  The abnormal phosphorylation of tau is 
essential for the self-assembly of tau into tangles of PHF, since this assembly is abolished 
by its dephosphorylation (Alonso et al., 2001).  Moreover, the switch of tau protein to an 
AD-like state includes the phosphorylation of two serine-proline motifs (Ser 199/202) 
upstream of the microtubule binding region (Biernat et al., 1992). 
 The molecular mechanism leading to the abnormal hyperphosphorylation of tau in 
AD is still not well understood.  Tau phosphorylation is catalysed by tau protein kinases 
and reversed by tau protein phosphatases.  Among the protein kinases that have been 
implicated in the abnormal phosphorylation of tau associated with the formation of PHF 
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are glycogen synthase kinase-3 (Ishiguro et al., 1993), neuronal proline-directed protein 
kinase (Paudel et al., 1993), mitogen-activated protein kinase (Drewes et al., 1992), 
calcium/calmodulin-dependent protein kinase II (Steiner et al., 1990), casein kinase I 
(Singh et al., 1995), cAMP-dependent protein kinase (Jicha et al., 1999) and cyclin-
dependent protein kinase-5 (Noble et al., 2003). 
 More than 30 phosphorylation sites have been identified in the 
hyperphosphorylated tau isolated from AD brain and all are either on serine or threonine 
residues.  Thus, serine/threonine protein phosphatases (PP) are expected to be involved in 
the regulation of the phosphorylation of tau in the AD brain.  In normal brain, it was shown 
that PP2A, PP2B and, to a lesser extent, PP1 are involved in the dephosphorylation of tau 
(Gong et al., 1995).  On the other hand, by using the abnormally hyperphosphorylated tau 
protein isolated from AD brain as a substrate, it was found that PP2A, PP2B, and to a 
lesser extent PP1, but not PP2C, can efficiently dephosphorylate tau in vitro (Wang et al., 
1995; Gong et al., 1994a, b ,c; Rahman et al., 2006).  PP2A has been reported to regulate 
tau phosphorylation in vivo (Gong et al., 2000).  PP2B isolated from human brain was 
found to dephosphorylate serine residues of the Alzheimer disease abnormally 
hyperphosphorylated tau (Rahman et al., 2006).  In addition, PP5 was also reported to be 
responsible for the dephosphorylation of tau protein (Liu et al., 2005a).  PP1, PP2A, PP2B 
and PP5 all dephosphorylate tau at serine or threonine sites, but each protein phosphatase 
catalyses the dephosphorylation of tau at different sites with different efficiencies.  The 
relative contributions of PP2A, PP1, PP5 and PP2B to the regulation of tau 
phosphorylation have been estimated to be ~71%, ~11%, ~10% and ~7%, respectively (Liu 
et al., 2005b).  Moreover, it has been reported that the expression and/or activities of PP1, 
PP2A, PP2B and PP5 are decreased ~20-30% in the affected areas of AD brain (Gong et 
al., 1993, 1995; Lian et al., 2001; Liu et al., 2005a).  Thus, the abnormal phosphorylation 
of tau in AD has been suggested to be the result of a deficiency of the protein phosphatase 
system (Trojanowski and Lee, 1995).  Namely, a down-regulation of tau phosphatases in 
AD brain might underlie the abnormal hyperphosphorylation of tau (Liu et al., 2005b). 
 PP2A is thought to be the major tau phosphatase that regulates its phosphorylation 
at multiple sites in human brain.  The abnormal hyperphosphorylation of tau may be 
partially due to a down-regulation of PP2A activity in AD brain.  Indeed, the inhibition of 
PP2A by okadaic acid induced hyperphosphorylation and accumulation of tau (Gong et al., 
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2000).  Also, in vivo studies using rats injected with PP1 and PP2A inhibitors, tau 
phosphorylation was achieved (Janke et al., 1998).  Moreover, Tanimukai and co-workers 
found a significant increase in the neocortical levels of I1 and I2, endogenous inhibitors of 
PP2A, in AD, as compared to control cases, suggesting the possible contribution or 
involvement of I1 and I2 in the abnormal hyperphosphorylation of tau in AD (Tanimukai 
et al., 2005).  Furthermore, a reduction of PP2A activity in AD brains might keep the PP1 
inhibitors, I1 and DARPP32, up-regulated and thereby result in decreased PP1 activity 
(Iqbal et al., 2005).  Using metabolically active rat forebrain slices, it was reported that a 
decrease in PP2A activity leads to abnormal hyperphosphorylation of tau at Ser 
198/199/202, Ser 396/404 and Ser 422, and PP1 up regulates the phosphorylation of tau at 
those residues (Bennecib et al., 2000).  PP2A also regulates the activities of several tau 
kinases in brain.  Additionally, the decrease in the PP2A and PP1 activities in the brain 
leads to hyperphosphorylation of tau at Ser 262/356, not only by inhibition of its 
dephosphorylation but also by promoting the calcium/calmodulin-dependent protein kinase 
II activity in rat forebrain cytosol (Bennecib et al., 2001).  Pei et al. (2003) reported that 
okadaic acid-induced inhibition of PP2A produces activation of mitogen-activated protein 
kinases ERK1/2, MEK1/2 and p70 S6, through dephosphorylation of serine/threonine 
residues of those kinases, similar to that in AD, and suggested that in AD brain the 
decrease in PP2A activity could have caused the activation of ERK1/2, MEK1/2 and p70 
S6 kinase, and the abnormal phosphorylation of tau both via an increase in its 
phosphorylation and a decrease in its dephosphorylation.  Thus, the hyperphosphorylation 
of tau in AD may be due to a protein phosphorylation/dephosphorylation imbalance 
produced by a decrease in the activity of protein phosphatase and increase in the activities 
of tau kinases which are directly or indirectly regulated by protein phosphatases (Iqbal et 
al., 1998, 2002, 2005). 
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I.3. ALUMINIUM CONTRIBUTION TO ABNORMAL PROTEIN 
PHOSPHORYLATION 
 
 Aluminium has not only been implicated in several neurological and other 
disorders, but is also known to induce the hyperphosphorylation of neurofilaments and tau 
proteins (Shea et al., 1992b; Shin et al., 1994; Singer et al., 1997), and to promote the 
aggregation of proteins such as hyperphosphorylated tau (Shin et al., 1994; Savory et al., 
1998; Shin, 2001) and Abeta (Exley, 1993; Kawahara et al., 1994; Ricchelli et al., 2005). 
 
I.3.1. Aluminium and tau 
 
 Aluminium has long been a target of research concerning its role as an 
environmental risk factor in the aetiology of AD.  High levels of aluminium were found in 
AD patients brains (Kruck and McLachlan, 1988) and this metal has been correlated with 
both hallmark lesions of AD, being found co-localised with silicon in the central region of 
senile plaque cores in the cortex of AD patients (Candy et al., 1986; Tokutake et al., 1995) 
and accumulating in association with NFT in affected neurons (Perl, 1988; Shin et al., 
1995).  It has been suggested that aluminium binds selectively to PHF tau (Shin et al., 
1994; Savory and Garruto, 1998) and induces the aggregation of hyperphosphorylated tau 
(Shin et al., 1994; Singer et al., 1997; Savory et al., 1998).  Abnormally phosphorylated 
tau has been found in aluminium-induced neurofilamentous aggregates in rabbits, together 
with abnormally phosphorylated neurofilament protein (Singer et al., 1997).  It was 
observed that purified recombinant human tau protein incubated with aluminium salts 
induces noncovalent tau aggregation into NFT-like bundles and this tau coalescence can be 
reversed by addition of EDTA.  However, when incubated with a nucleotide triphosphate 
such as ATP, aluminium catalyzes a covalent linkage that results in the incorporation of 
phosphate into the tau protein via an O-linkage to the alpha-phosphate (Abdel-Ghany et 
al., 1993).  These reactions occur at aluminium concentrations similar to those found in 
AD brains suggesting a physiological significance in vivo in neurodegenerating brain 
tissue.  Aluminium-induced aggregation of hyperphosphorylated tau seems to be by 
interacting directly with the phosphorylated epitopes of tau, in AD brains (Zatta, 1995; 
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Murayama et al., 1999; Shin, 2001).  It was also reported that the binding of aluminium to 
PHF tau besides inducing its aggregation also retards its proteolysis (Shin et al., 1994).  
Moreover, aluminium is known to bind avidly to phosphate groups in proteins, and this 
binding can modify the conformation of the proteins (Martin, 1986; Birchall and Chappell, 
1988).  It was suggested that aluminium induces aggregation of brain cytoskeletal proteins 
by forming very stable bridges between phosphate groups of the hyperphosphorylated tau 
elements (Zatta, 1995).  Moreover, the accumulation of aluminium in the neurofibrillary 
lesions is attributable to the presence of PHF tau that provides binding sites for aluminium 
at its phosphorylated epitopes, including Ser 202, Ser 396, Ser 404 and Ser 422, and the 
biological consequence of the aluminium interaction involves formation of PHF tau 
aggregates that persist in the affected neurons (Shin et al., 1994; Murayama et al., 1999; 
Shin, 2001).  Iron was also shown to accumulate in neurons with NFT, and in its ferric 
form (Fe3+) has the ability, similar to that of aluminium (Al3+), to bind with tau and to 
induce its aggregation in vitro (Yamamoto et al., 2002).  Furthermore, it has been recently 
reported that a novel trivalent cation chelator dissociates binding of aluminium and iron 
associated with hyperphosphorylated tau of AD (Shin et al., 2003). 
 Besides, having been implicated in the aggregation of hyperphosphorylated tau into 
PHF leading to the formation of NFT, aluminium was also suggested to contribute to tau 
aggregation by altering its phosphorylation state.  The dephosphorylation of tau by PP2A 
was reported to be inhibited by aluminium (Yamamoto et al., 1990).  Aluminium was 
found to inhibit the phosphorylation of tau by neuronal cdc2-like kinase and 
dephosphorylation of phosphorylated tau by PP2B (Li et al., 1998).  Li and co-workers 
(1998) also observed that phosphorylated tau is more sensitive to aluminium-induced 
aggregation than nonphosphorylated tau and suggested that phosphorylation sensitizes tau 
to aluminium and phosphorylated tau transforms irreversibly into a phosphatase and 
protease resistant aggregate in the presence of this metal ion (Li et al., 1998). 
 
I.3.2. Aluminium and Abeta 
 
 Beta-amyloid (Abeta), the major component of senile plaques in AD brain, has an 
intrinsic tendency to form insoluble aggregates.  Abeta is a 39-43 amino acid long peptide 
derived from a larger transmembrane protein, the amyloid precursor protein (APP).  It has 
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been suggested that aluminium induces the aggregation, deposition and toxicity of Abeta 
(Tokutake et al., 1995; Evans and Harrington, 1998; Pratico et al., 2002).  Exley et al. 
(1993) first demonstrated by circular dichroism spectroscopy that aluminium causes 
conformational changes of Abeta (1-40).  In physiological buffers, Ca, Co, Cu, Mn, Mg, 
Na or K had no effect on the rate of Abeta aggregation.  In contrast, Al, Fe and Zn under 
the same conditions strongly promoted Abeta aggregation (Mantyh et al., 1993).  Other 
authors also reported that aluminium promotes the aggregation of Abeta (Kawahara et al., 
1994; Exley, 2005; Ricchelli et al., 2005).  Moreover, long-term exposure to aluminium 
promoted the aggregation of Abeta on cultured cortical neurons and enhanced its 
neurotoxicity (Kuroda et al., 1995).  Chronic dietary administration of aluminium was 
found to increase Abeta levels and accelerate plaque deposition in APP transgenic mice, a 
model of AD-like amyloidosis (Pratico et al., 2002), an in vivo evidence for Abeta 
accumulation induced by aluminium.  Ricchelli and co-workers (2005) studied the 
structural effects induced by aluminium on different Abeta fragments and found that 
aluminium caused peptide enrichment in beta sheet structure and formation of solvent-
exposed hydrophobic clusters.  These intermediates evolved to polymeric aggregates 
which organized in fibrillar forms in the case of the aluminium Abeta (1-42) complex.  
However, Nakagawa et al. (2005) reported that aluminium chloride does not facilitate 
deposition of human synthetic Abeta (1-42) peptide in the rat ventricular system of a short-
term infusion model.  Indeed, synthetic Abeta (1-42) aggregates with aluminium chloride 
almost disappear from the rat ventricular system by 28 days post-infusion.  However, 
Clauberg and Joshi (1993) suggested that aluminium accumulated in AD brain accelerates 
the generation of Abeta due to the faulty proteolysis of normal APP.  Therefore, aluminium 
by enhancing the processing of APP, leads to the accumulation of Abeta and plaque 
formation.  Furthermore, it was reported that aluminium increases the levels of Abeta in 
neuroblastoma but not in glioma cells (Campbell et al., 2000).  Aluminium-aggregated 
Abeta tightly binds to the surface of cultured neurons and forms fibrillar deposits, while 
zinc-aggregated Abeta was rarely observed on the surface of cultured neurons (Kawahara 
et al., 2001).  The authors suggested that aluminium-aggregated Abeta has a strong affinity 
to membrane surface and is poorly degraded by proteases. 
 The catabolism of Abeta may be important to its accumulation in the brain in both 
early and late-onset AD.  The serine protease plasmin is one of a suite of proteases 
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implicated in AD.  It is a promoter of alpha-cleavage of APP and degrades Abeta in vitro.  
Korchazhkina et al. (2002) demonstrated that the cleavage of the amyloidogenic Abeta 
(25-35) by plasmin produces the non-amyloidogenic fragment Abeta (29-35).  They also 
found that the degradation of Abeta (25-35) by the serine protease plasmin is inhibited by 
aluminium.  On the other hand, aluminium also modulates APP.  Accumulation of APP in 
damaged neuronal processes and microglia was observed following intracerebral 
administration of aluminium salts in rat brain (Shigematsu and McGeer, 1992).  
Aluminium was also found to promote aggregation of human recombinant APP in vitro, in 
a dose-dependent manner (Chong and Suh, 1995).  In addition, Sinclair and Pennington 
(1996) presented aluminium-induced changes in APP mRNA expression.  Furthermore, it 
is known that protein phosphorylation modulates APP processing (da Cruz e Silva et al., 
1993), more specifically PP1 was shown to be involved in this process (da Cruz e Silva et 
al., 1995a; da Cruz e Silva and da Cruz e Silva, 2003).  Abeta-formation in rat brains, after 
in vivo inhibition of PP1 and PP2A was also reported (Arendt et al., 1998).  The decrease 
in the phosphatase activities in AD might also be involved in the formation of Abeta by 
augmenting the amyloidogenic pathway processing of APP (Gong et al., 1993). 
 
I.3.3. Aluminium and neurofilaments 
 
 It is known that the accumulation of NF in the perikarya and dendrites of neurons 
occurs when the rabbit brain is treated with aluminium (Klatzo et al., 1965; Crapper et al., 
1973; Erasmus et al., 1993; Strong et al., 1996; Savory et al., 1999; He and Strong, 2000; 
Forbes et al., 2002).  In fact, NF began to accumulate a few hours after the intracisternal 
injection of aluminium (Bugiani and Ghetti, 1982).  Those rabbits developed neurological 
symptoms with paralysis of their skeletal muscles and died with tetanic spasm just over 10 
days after the administration of aluminium.  Perikaryal NF accumulation was observed in 
the pyramidal neurons of the cerebral cortex and hippocampus, motor neurons of spinal 
cord, ganglion cells, bipolar cells of retina, and Purkinje cells of cerebellum (Erasmus et 
al., 1993).  Compared with axonal NF, the NF accumulated in the perikarya were found to 
be densely compact, composed of less-developed cross-bridges and more irregularly 
aligned core filaments.  Additionally, in contrast to the phosphorylated NF-H localization 
under normal conditions (abundant in axons and absent in the cell body) in aluminium 
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treated rabbits the phosphorylated NF-H were detected in perikarya, although they were 
less phosphorylated than in axons (Troncoso et al., 1986; Shea et al., 1989; Gotow et al., 
1995; Gotow, 2000).  The difference in the density is probably the result of the presence of 
less developed cross-bridges.  Irregularly aligned core filaments, as well as less developed 
cross-bridges may be due to the lower phosphorylation level of NF-H.  Highly 
phosphorylated NF-H are necessary for NF to form well developed cross-bridges and the 
resultant regularly aligned core filaments, as occurs in axons.  The increase in the amount 
of less phosphorylated NF-H may induce disorganization of NF in the perikarya and 
probably also in the axons, possibly leading to axonal degeneration, muscle atrophy and 
finally death provoked by the impairment of axonal transport (Meiri et al., 1993; Gotow, 
2000).  Furthermore, with the observation of a strong degree of immunostaining for 
phosphorylated NF epitopes in both untreated and aluminium-injected animals, it was 
suggested that protein subunits that are already present in the neurons under normal 
circumstances are recruited, in the presence of aluminium, to form NF accumulation 
through the directed assembly of masses of oriented filaments (Forbes et al., 2002). 
 Perikaryal NF accumulation following aluminium exposure was also found in a 
neuroblastoma cell line (Shea et al., 1989), in PC12 cells differentiated with nerve growth 
factor, although to a less extent (Shea and Fischer, 1991), or in cultured rat dorsal root 
ganglia explants (Gilbert et al., 1992).  NF accumulation was also observed in abnormal 
neurites following intracerebral administration of aluminium to the rat brain (Shigematsu 
and McGeer, 1992).  Following chronic aluminium treatment aggregation of cytoskeletal 
proteins was found in various regions of the rat brain (Kaur et al., 2006).  Moreover, it was 
reported that aluminium can cause aggregation of purified bovine, rabbit and rat NF in 
vitro (Troncoso et al., 1990).  It was suggested that free aluminium ions, acting as bridges 
among charged residues (namely phosphate groups) on neighbouring filaments, may cause 
cross-linking and accumulation of NF in neuronal perikarya (Gilbert et al., 1992).  In fact, 
it was reported that aluminium binding to phosphorylated NF-M induces conformational 
changes that resulted in conformations containing high β–pleated-sheet contents, which 
precipitate on standing (Hollosi et al., 1992; Shen et al., 1994).  Additionally, according to 
in vitro experiments presented by Leterrier et al. (1992) aluminium alone, or in 
combination with maltol or other chelators, increases the phosphorylation of NF-M and 
NF-H subunits and induces the aggregation of NF.  These authors, using purified NF 
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incubated with aluminium, saw that the binding of aluminium to the arm-like projections 
of the NF-H and NF-M subunits caused a conformational change of the molecule 
(intrafilamentous reaction), and that it strongly stimulated the interaction between NF 
(interfilamentous reaction) (Leterrier et al., 1992). 
 Indeed, aluminium can induce neurofilamentous aggregates by a number of 
mechanisms, from the level of gene expression (altered gene expression) to terminal NF 
proteolysis.  The expression of mRNA coding for NF subunits is reduced in aluminium 
intoxicated animals (Muma et al., 1988) and also in aluminium treated cultured neuronal 
cells (Gilbert et al., 1992).  NF-H mRNA levels were found to be decreased in neurons 
containing aluminium-induced NF accumulation (Chambers and Muma, 1997).  The 
authors suggested that the NF-H gene expression may be down regulated by an inhibitory 
feedback mechanism induced by perikaryal accumulation of NF.  Moreover, Nixon and 
Sihag (1991) proposed that premature phosphorylation of C-terminal tails of NF in the cell 
body might prevent their entry into the axon.  Impairment of axonal transport of NF was 
also observed in rabbits following aluminium treatment (Troncoso et al., 1985), which may 
reflect abnormalities of NF phosphorylation and NF interactions.  Aluminium-induced 
aggregation of NF-H and NF-M subunits is dependent upon their phosphorylation state 
(Shea et al., 1992b).  Increased addition of phosphate groups to NF-H proteins was 
observed in vivo following the administration of aluminium in drinking water to rats 
(Johnson and Jope, 1988).  The aberrant state of phosphorylation appears to be due to the 
altered activity of cdk5/p35 kinase (Lew et al., 1994), a member of the cyclin-dependent 
kinase-5 (cdk5) family which appears to be predominantly responsible for the 
phosphorylation of KSP motifs in NF tail (Hisanaga et al. 1991; Shetty et al., 1993; 
Veerana et al., 1995).  Furthermore, the activity of protein kinase C, a kinase among others 
involved in the phosphorylation of NF head, was also found to increase due to aluminium 
in rat brain (Johnson et al., 1990).  On the other hand, aluminium also contributes to 
abnormal NF phosphorylation by inhibiting endogenous phosphatase activity (Shetty et al., 
1992).  In addition, it was observed that following intracisternal AlCl3 inoculation, a dose-
dependent inhibition of NF-H dephosphorylation by exogenous phosphatases was induced 
(Strong and Jakowec, 1994).  Spinal motor neuron neuroaxonal spheroids after chronic 
aluminium neurotoxicity were found to contain phosphatase-resistant NF-H (Gaytan-
Garcia et al., 1996).  Moreover, following chronic aluminium treatment the levels of 
Chapter I 
Centro de Biologia Celular                                                                                                                                63 
Universidade de Aveiro 
phosphoprotein phosphatases were found to be depleted in the cerebral cortex (Kaur et al., 
2006).  Effects on NF proteolysis were also reported.  It was demonstrated that aluminium 
caused inhibition of proteolysis of NF in cytoskeleton preparations (Nixon et al., 1990).  
Shea and co-workers (1992a) showed that in vitro aluminium induced the resistance of NF 
to calpain-mediated proteolysis.  Also, NF isolated from intact cells treated with 
aluminium were found to be resistant to in vitro degradation by endogenous calcium-
dependent proteases (Shea et al., 1995).  Therefore, an increase in the amount of NF may 
occur even when NF proteins are less expressed.  In concert with the phosphorylation 
described earlier, aluminium will thus potentially induce a pool of highly or aberrantly 
phosphorylated NF resistant to dephosphorylation and proteolysis (Strong et al., 1996). 
 
I.4. AIMS 
 
 Aluminium is the most widely distributed metal in the environment and is 
extensively used in modern life.  Aluminium enters the human body from the environment 
and from diet and medication.  However, there is no known physiological role for 
aluminium within the body and hence this metal may produce adverse physiological 
effects.  Aluminium has been related to neurodegenerative diseases, including dialysis 
encephalopathy, ALS/PD and AD.  The impact of aluminium on the nervous systems is 
broad, including abnormalities in cytoskeletal proteins, behaviour, neurotransmission 
systems, energy metabolism, second messengers, and is also known to induce oxidative 
damage and neuronal apoptosis.  Thus, the study of aluminium neurotoxicity is of major 
importance.  Altered protein phosphorylation is also correlated with neurodegenerative 
disorders.  Indeed, proteins such as neurofilaments (NF) or tau are found abnormally 
phosphorylated in AD brains.  This alteration of protein phosphorylation might be due to 
changes in protein phosphatase expression or activity.  Moreover, it has been reported that 
aluminium contributes to the abnormal phosphorylation of these proteins.  Therefore, the 
study of the relation between aluminium toxicity and alteration in protein phosphatase 1, 
and consequently on the cellular signal transduction pathways involved, was the general 
aim of this dissertation. 
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 The first approach was to evaluate the effect of aluminium on cellular viability and 
on PP1 expression and activity.  Thus, a comparative study was performed using two cell 
lines with non-neuronal or neuronal-like characteristics.  This work is presented in Chapter 
II.  Given that aluminium is known to induce neurotoxicity, the next step was to evaluate 
the aluminium effect in a neuronal system.  For that, cortical neuronal primary cultures 
were used.  In this system, the alterations observed under aluminium exposure on cellular 
viability were monitored, as well as changes on the expression of the proteins PP1, 
neurofilaments and synaptophysin.  This study is described in Chapter III.  The discovery 
of other proteins whose expression may be altered due to aluminium was another goal that 
was achieved using SELDI-TOF MS technology.  This data, obtained using in vitro and in 
vivo systems is presented in Chapter IV. 
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II. EFFECT OF ALUMINIUM ON PP1 EXPRESSION AND 
ACTIVITY IN PC12 AND COS-1 CELL LINES 
 
II.1. INTRODUCTION 
 
 Several studies have implicated aluminium with neurodegenerative diseases such as 
ALS/PD and AD.  The finding of high aluminium contents in AD brain, especially in the 
core of senile plaques and associated with neurofibrillary tangles have been responsible for 
the aluminium hypothesis in this disease.  Moreover, the neurotoxicity observed in animals 
exposed to aluminium has been shown to mimic many of the pathophysiological features 
of AD.  Abnormal phosphorylation of proteins has also been related with 
neurodegenerative diseases and associated processes.  This anomaly is a consequence of 
altered protein kinase and/or protein phosphatase (PP) expression or activity.  The 
contribution of aluminium to these processes has also been reported. 
 In this chapter we aim to evaluate aluminium involvement in the inhibition of 
protein phosphatases and neurodegeneration.  For that purpose the effect of aluminium was 
evaluated on cellular viability, on the expression of two PP1 isoforms, and on PP1 activity.  
Two cell lines were used in a comparative study: PC12 with neuronal-like properties and 
COS-1 a non-neuronal cell line. 
 It is known that aluminium binds strongly to oxygen-donor ligands such as 
phosphate, and to serum proteins such as transferrin.  Thus, all the experiments with 
aluminium were performed in phosphate-free medium.  Also, because the composition of 
serum (FBS or HS) is not fully defined and some aluminium ligands may be present, all 
the aluminium experiments were also performed with serum-free medium.  The 
experiments with serum were performed only as a control, for comparative purposes. 
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II.2. MATERIALS AND METHODS 
 
 The complete composition of all solutions and media used, as well as other relevant 
information, is presented in Appendix I.  All reagents were of cell culture grade or ultra 
pure.  Detailed methods are also described in Appendix II. 
 
II.2.1. Cell culture 
 
 In this study, two cell lines were used, a rat adrenal pheochromocytoma cell line 
(PC12), with neuronal-like properties, and a non-neuronal monkey kidney cell line (COS-
1).  PC12 cells were cultured in complete RPMI 1640 medium: RPMI 1640 (Gibco, 
Invitrogen) supplemented with 10% (v/v) heat-inactivated horse serum (HS) (Gibco, 
Invitrogen), 5% (v/v) heat-inactivated fetal bovine serum (FBS) (Gibco, Invitrogen), 1% 
(v/v) antimycotic-antibiotic solution (10000 U/ml penicillin, 10000 µg/ml streptomycin, 25 
µg/ml amphotericin B in 0.85% saline) (Gibco, Invitrogen) and 0.85 g/L NaHCO3.  COS-1 
cells were maintained in complete DMEM (Dulbecco’s modified Eagle’s medium): 
DMEM (Sigma-Aldrich) supplemented with 10% (v/v) heat-inactivated FBS, 1% (v/v) 
antibiotic-antimycotic solution and 3.7 g/L NaHCO3.  Both cell lines were grown routinely 
in 100 mm cell culture plates and maintained at 37 ºC in an atmosphere of 5% CO2.  For 
passaging, COS-1 cells were dissociated with trypsin-EDTA (Gibco, Invitrogen).  For 
experimental procedures, cells were collected, counted and seeded onto 6-well plates.  
When using PC12 cells, the plates were previously treated with 100 µg/ml poly-L-ornithine 
(Sigma-Aldrich) for 10 min and washed 3 times with sterile deionised water. 
 
II.2.2. Experimental cell treatments 
 
II.2.2.1. Exposure to aluminium 
 
 To evaluate the aluminium effects on PP1α and PP1γ1 expression in PC12 and 
COS-1 cells, both cell lines were plated onto 6-well plates and were allowed to reach 80% 
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confluency.  Cells were then washed twice with serum-free and phosphate-free medium, 
RPMI (Biosource) or DMEM (Sigma-Aldrich), depending on the cell line.  Cells were 
subsequently incubated with, respectively: phosphate-free medium with serum (10% HS 
and 5% FBS or 10% FBS), serum-free and phosphate-free medium or aluminium solution 
(10 mM AlCl3.6H2O/50 mM HEPES pH 7.4 in phosphate-free medium) at final 
concentrations of 0.1 mM, 0.5 mM or 1 mM.  Cells were incubated at 37 ºC for varying 
times (12, 24, 36 or 48 h).  A control sample, without treatment, collected at time 0 h was 
also included.  Samples were collected and immunoblotting was performed as described 
below.  Another set of cells treated as above was used to evaluate cellular viability using 
the MTT assay. 
 
II.2.2.2. Recovery study 
 
 To evaluate if the effects of aluminium on PP1 expression were reversible, a 
recovery experiment was also performed using both cell lines.  PC12 and COS-1 cells were 
incubated with aluminium at final concentrations of 0.5 and 1 mM for 24 h in serum-free 
and phosphate-free RPMI or serum-free and phosphate-free DMEM, respectively.  After 
incubation the medium with aluminium was removed from two sets (from a total of three 
sets) and replaced with fresh phosphate-free and serum-free medium (without serum) in 
one set and with fresh complete medium (with serum) in another set.  To the third set (the 
one which medium was not removed), fresh serum (10% HS and 5% FBS for PC12 or 10% 
FBS for COS-1) was added to the conditioned medium (with aluminium).  All three sets 
were further incubated for another 24 h.  A control of cells incubated with serum-free and 
phosphate-free medium (without treatment) for 48 h was also included.  Samples were 
collected and immunoblotting was performed as described below.  Cellular viability was 
also evaluated with the MTT assay using control sets of cells treated as above. 
 
II.2.3. Cellular viability 
 
 Cellular viability was evaluated by the MTT assay.  This method is based on the 
reduction of MTT, a water soluble tetrazolium salt, by mitochondrial dehydrogenase, to an 
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insoluble intracellular purple formazan.  The extent of reduction of MTT was measured 
spectrophotometrically at 570 nm, according to Mossman (1983). 
 After cell treatment, the conditioned medium was removed and 0.5 mg/ml MTT 
(Sigma-Aldrich) solution (in serum-free RPMI or serum-free DMEM) was added and 
incubated for 3 h at 37 ºC.  The resulting insoluble formazan precipitates were solubilized 
with 0.04 M HCl/Isopropanol.  The absorbance of the converted dye was measured at a 
wavelength of 570 nm in a Cary 50 spectrophotometer.  The cellular viability was 
expressed as a percentage of O.D. values from control cells, meaning that 90% of viability 
denotes a 10% decrease in viability. 
 
II.2.4. SDS-PAGE and immunoblotting 
 
II.2.4.1. Sample collection and immunodetection 
 
 After treatment, the conditioned medium was removed; cells were washed with 
PBS (Phosphate Buffered Saline, Pierce) and collected in 1 ml boiling 1% SDS solution.  
Cell lysates were then boiled for 10 min and sonicated for 30 sec.  The total protein 
concentration of each sample was determined using the BCA protein assay kit (Pierce), 
which is based on bicinchoninic acid (BCA) for the colorimetric detection and 
quantification of total protein (Smith et al., 1985), according to the supplier’s instructions 
(see Appendix II).  Normalized protein samples were electrophoretically separated by 12% 
SDS-poliacrylamide gel electrophoresis (SDS-PAGE) using a discontinuous buffer system 
(Laemmli, 1970).  Molecular weight markers (Kaleidoscope Prestained or Prestained SDS-
PAGE Standards-Broad Range, BioRad) were used.  Separated proteins were 
electrotransferred onto nitrocellulose membranes (Burnette, 1981) followed by 
immunodetection of specific proteins.  To reduce the background of non-specific binding 
sites, the immunoblots were first blocked with 5% non-fat dry milk in 1x TBS-T (Johnson 
et al., 1984) followed by the incubation with primary antibody for 2 h at room temperature 
(RT), with antibodies CBC2C (anti-PP1α), CBC3C (anti-PP1γ) or anti-β-tubulin (used as a 
control).  Both antibodies, CBC2C and CBC3C, were raised against specific C-terminal 
peptides of the PP1α and PP1γ proteins, respectively.  All primary and secondary 
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antibodies were diluted in 3% non-fat dry milk in 1x TBS-T at the dilutions specified 
(Table II.1).  Detection was carried out using horseradish peroxidase-linked secondary 
antibodies and an enhanced chemiluminescence detection system (ECL kit, Amersham 
Pharmacia Biotech) or using alkaline-phosphatase-linked secondary antibody and a 
colorimetric method (NBT/BCIP, Promega). 
 
 
Table II.1 List of antibodies used, specific dilutions and detection method employed. 
Target Protein Primary Antibody Secondary Antibody 
PP1α CBC2C 
dilution: 1:2500 
Horseradish Peroxidase conjugated Rabbit IgG 
dilution: 1:5000 
PP1γ1 CBC3C dilution: 1:2500 
Horseradish Peroxidase conjugated Rabbit IgG 
dilution: 1:5000 
Alkaline phosphatase conjugated Mouse IgG 
dilution: 1:1000 
β-Tubulin Anti-β-Tubulin 
dilution: 1 µg/ml 
Horseradish Peroxidase conjugated Mouse IgG 
dilution: 1:5000 
 
 
II.2.4.2. Quantification and data analysis 
 
 The intensity of the obtained bands (protein expression) on film, was quantified by 
densitometry using a GS-710 calibrated imaging densitometer and Quantity One software 
(BioRad).  Data are expressed as means ± SEM of triplicate determinations from at least 
three independent experiments.  Statistical significance analysis was conducted by one way 
analysis of variance (ANOVA) followed by the post test Student’s t test.  Unless otherwise 
noted, a level of statistical significance is considered * p < 0.05 versus control. 
 
 
Aluminium neurotoxicity and neuronal phosphorylation systems 
72 
 
II.2.5. Protein phosphatase activity assays 
 
II.2.5.1. Aluminium IC50 for PP1α and PP1γ1 
 
 The effect of aluminium on purified PP1 isoform activity was assessed using 32P-
phosphorylase a as substrate.  The substrate was prepared from phosphorylase b (Sigma) 
using [γ-32P]ATP (3000 Ci/mmol, Amersham Pharmacia Biotech) and phosphorylase 
kinase (Sigma) as previously described (Watanabe et al., 2003).  Aluminium stock solution 
was diluted in 50 mM Tris-HCl, pH 7.5 containing 0.1 mM EGTA, 0.03% (v/v) Brij-35 
and 0.1% (v/v) 2-mercaptoethanol (buffer B) to the final concentrations just before use.  
PP1 and PP2A catalytic subunits diluted in 50 mM Tris-HCl, pH 7.5 containing 1 mM 
MnCl2, 0.1 mM EGTA, 0.1% (v/v) 2-mercaptoethanol and 1 mg/ml BSA (buffer A) were 
incubated with aluminium for 5 min at 30 ºC.  The reaction was started with the addition of 
32P-phosphorylase a (3 mg/ml) to a final volume of 30 µl.  After 10 min, 100 µl of ice-cold 
20% (w/v) TCA were added and the mixture centrifuged at 12000 x g for 2 min at RT.  
The 32P-phosphate released into the supernatant was measured in a scintillation counter.  
The control phosphatase activity was 10-20% of total substrate radioactivity to ensure 
linearity.  The appropriate range of concentrations was used to calculate the IC50 using the 
BioDataFit 1.02 software. 
 
II.2.5.2. PC12 and COS-1 incubation with aluminium 
 
 To evaluate the effect of aluminium on PP activity, PC12 and COS-1 cells were 
plated onto 6-well plates in complete RPMI or DMEM and allowed to reach 80% 
confluence.  The medium was removed and cells were washed 2 times with serum-free and 
phosphate-free medium followed by incubation with aluminium solution in serum-free and 
phosphate-free RPMI or DMEM at final concentrations of 0.5 or 1 mM for 24 h.  After the 
incubation, cells were washed with cold 50 mM Tris/0.1 mM EDTA solution, scraped and 
collected in 1 ml Tris/EDTA solution.  The cellular suspension was centrifuged at 310 x g 
for 5 min at 4 ºC and the pellet was ressuspended in 1 ml of cold homogenization buffer 
(see Appendix I).  The total protein concentration from each sample was determined by the 
BCA protein assay. 
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II.2.5.3. Phosphatase activity assays cell extracts 
 
 The total phosphatase activity of the control and aluminium incubated cell extracts 
was determined by assaying the appropriate dilution (1/5 for PC12 and 1/3 for COS-1) in 
50 mM Tris-HCl, pH 7.5 containing 0.1 mM EGTA, 0.1% (v/v) 2-mercaptoethanol and 1 
mg/ml BSA, with the 32P-phosphorylase a.  The PP2A activity was determined by pre-
incubating the cell extracts with 200 nM I-2 (New England Biolabs) for 15 min at 30 ºC 
before adding the substrate.  The PP1 activity in the cell extracts was calculated as the total 
phosphatase activity minus the PP2A activity towards the 32P-phosphorylase a substrate. 
 
II.3. RESULTS 
 
II.3.1. Cellular viability 
 
 Cellular viability was evaluated with the MTT assay (Mossman, 1983) in PC12 and 
COS-1 cells.  The effect of serum withdrawal and the effect of increasing aluminium 
concentrations for different periods of incubation were evaluated, as well as the recovery 
after removal of aluminium. 
 
II.3.1.1. Effect of serum withdrawal on cellular viability 
 
 The cellular viability and the effect of serum withdrawal were evaluated with time 
in both cell lines.  Data is presented as % of control (the levels of cellular viability obtained 
at time 0 h, without treatment, were taken as 100%), a relation between MTT reduction and 
total protein concentration was performed to adjust the changes of viability induced by cell 
proliferation.  Statistical differences are presented in relation to the control. 
 Although, slightly significant differences were observed, the cellular viability in 
PC12 cells incubated with complete medium (medium with serum) remained almost 
unaltered during time, exhibiting values of 87% ± 2.6%, 93% ± 4%, 90% ± 2.3% and 84% 
± 1.9% after 12 h, 24 h, 36 h and 48 h of incubation, respectively (Fig. II.1).  Incubation 
with medium without serum induced a similar response, revealing also slightly significant 
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decreases of the cellular viability to 81% ± 2.8% after 12 h, to 89% ± 4% after 24 h, to 
91% ± 4.1% after 36 h, and to 91% ± 3.9% after 48 h of incubation.  In spite of the 
significant changes observed in relation to the control, for both conditions (presence or 
absence of serum in the medium), serum withdrawal (when comparing both conditions) did 
not induced significant variations on cellular viability, for all time points studied in PC12 
cells. 
 
 
Fig. II.1 – Effect of serum withdrawal on cellular viability of PC12 and COS-1 cells as a function of 
time.  PC12 and COS-1 cells were incubated with or without serum in the respective medium.  Results are 
expressed as percentage of control (time 0 h is 100%) as means ± SEM of triplicate determinations from at 
least three independent experiments.  *, **, *** Value statistically different from the control (p < 0.05, p < 
0.01, p < 0.001, respectively). 
 
 
 The cellular viability in COS-1 cells incubated with complete medium (medium 
with serum) significantly decreased for all time points by about 30%.  The cellular viability 
remained constant over time and the values were of 72% ± 1.8%, 73% ± 0.9%, 70% ± 
2.3% and 69% ± 3.3% after 12 h, 24 h, 36 h and 48 h, respectively (Fig. II.1).  A similar 
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response on cellular viability was observed in the same cells incubated in medium without 
serum, over time, showing a significant decrease of around 25% and keeping constant 
afterwards (75% ± 1.7%, 77% ± 2%, 73% ± 1.2% and 71% ± 1.5% after 12h, 24 h, 36 h 
and 48 h of incubation, respectively).  Even though a decrease was observed for both 
conditions when related to the control, the serum withdrawal did not induce any change on 
the cellular viability, as verified for PC12 cells. 
 
II.3.1.2. Effect of aluminium on cellular viability with time of exposure 
 
 The effect of AlCl3 at increasing concentrations (0.1 mM, 0.5 mM or 1 mM) was 
also evaluated during time (24 h and 48 h), in both cell lines.  Data is shown as % of 
control (the levels of cellular viability obtained for cells incubated without aluminium, at 
each time, were taken as 100%).  Statistical differences are presented in relation to the 
control. 
 Aluminium induced significant decreases of cellular viability after 24 h and 48 h 
exposure in PC12 cells.  No significant variations were observed for different aluminium 
concentrations in both periods (Fig. II.2).  A decrease of cellular viability was observed at 
24 h for all aluminium concentrations (to 79% ± 7.4% for 0.1 mM, 75% ± 2.8% for 0.5 
mM and 73% ± 3.7% for 1 mM).  After 48 h, cellular viability decreased to 57% ± 8.1% 
for 0.1 mM, to 44% ± 3.9% for 0.5 mM and to 41% ± 4.2% for 1 mM AlCl3. 
 In COS-1 cells a similar response to aluminium treatment was observed for both 
periods of incubation with the same aluminium concentrations (Fig. II.2).  No significant 
effect was observed with the exposure to 0.1 mM AlCl3 for 24 h or 48 h, whereas 
statistically significant decreases of cellular viability were observed with 0.5 mM AlCl3 
and 1 mM AlCl3, in both periods.  Cellular viability decreased to 83% ± 2% for 0.5 mM 
and to 71% ± 1.3% for 1 mM after 24 h and to 83% ± 3.4% for 0.5 mM and to 64% ± 3.6% 
for 1 mM AlCl3 after 48 h of incubation. 
 
 
 
 
Aluminium neurotoxicity and neuronal phosphorylation systems 
76 
 
 
Fig. II.2 – Aluminium effect on cellular viability in PC12 and COS-1 cells.  PC12 and COS-1 cells were 
incubated with increasing aluminium concentrations for different times.  Results are expressed as percentage 
of control (absence of aluminium at each time) as means ± SEM of triplicate determinations from at least 
three independent experiments.  *, ***, Value statistically different from the control (p < 0.05, p < 0.001, 
respectively). 
 
 
II.3.1.3. Effect of aluminium withdrawal on cellular viability 
 
 Both cell lines were allowed to recover from 24 h incubation with 0.5 mM and 1 
mM AlCl3 by replacement of experimental medium with medium without serum, medium 
with serum or by the addition of 5% FBS plus 10% HS for PC12 cells, or 10% FBS for 
COS-1 cells, directly to the experimental medium and allowing them to recover for another 
24 h.  Data is presented as % of control, i. e. 100% was defined as the level of cellular 
viability obtained for cells incubated without aluminium for 48 h.  Statistical differences 
are expressed in relation to the control. 
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 After recovery the cellular viability reached values similar to control in both cell 
lines, even rising significantly higher with the addition of FBS/HS to the PC12 cells 
incubated with 0.5 mM or 1 mM aluminium for 24 h, with values reaching 125% ± 6% and 
124% ± 6.6%, respectively (Fig. II.3).  The substitution for medium without serum in both 
cell lines incubated with 1 mM, also resulted in a significant increase in cellular viability, 
to 120% ± 6.1% for PC12 cells and 113% ± 3.4% for COS-1 cells. 
 Unaltered values, in relation to the control, were 125% ± 11.4% and 114% ± 7.3% 
for 0.5 mM “without serum” and “with serum” respectively and 120% ± 6.1% for 1 mM 
“with serum” for PC12 cells.  For COS-1 cells the values were 111% ± 4.7%, 102% ± 
2.6% and 104% ± 4.8% for 0.5 mM “without serum”, “with serum” and “with FBS” 
respectively and 102% ± 2% and 105% ± 2.8% for 1 mM “with serum” and “with FBS”. 
 
 
Fig. II.3 – Effect of recovery from aluminium on cellular viability in PC12 and COS-1 cells.  PC12 and 
COS-1 cells were incubated with 0.5 mM or 1 mM aluminium for 24 h in their respective serum-free, 
phosphate-free medium and allowed to recover for 24 h under the indicated conditions.  Results are 
expressed as percentage of control (absence of aluminium at 48 h) as mean ± SEM of triplicate 
determinations from at least three independent experiments.  *, **, Value statistically different from the 
control (p < 0.05, p < 0.01, respectively). 
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II.3.2. Protein phosphatase expression 
 
 The effect of serum withdrawal and the effect of AlCl3 (0.1 mM, 0.5 mM or 1 mM) 
on protein phosphatase (PP1α and PP1γ1) expression was evaluated by immunoblot 
analysis (using specific antibodies) in both cell lines as a function of time of exposure (12 
h, 24 h, 36 h and 48 h).  A recovery study was also performed.  The expression of β-tubulin 
was determined and used as a control, utilizing the same immunoblots previously used for 
assessing PP1 expression.  No differences were detected in β-tubulin expression under the 
conditions tested, for both cell lines (Fig. II.4-II.9). 
 
II.3.2.1. Effect of serum withdrawal on PP1α and PP1γ1 expression 
 
 The expression of PP1α and PP1γ1 and the effect of serum withdrawal were 
evaluated with time for both cell lines.  Data is presented as % of control (the levels of 
expression obtained for cells collected at time 0 h, without treatment, were taken as 100%).  
Statistical differences are expressed in relation to the control. 
 In PC12 cells the expression of PP1α was not significantly altered up to 24 h in 
complete medium (with serum), in relation to the control.  Similar results were observed 
when cells were incubated in medium without serum, although a slight statistically 
significant decrease was observed at 24 h.  Comparing both conditions, serum withdrawal 
had no apparent effect on the expression of this protein (Fig. II.4).  On the other hand, a 
small but reliable increase in the expression of PP1γ1 was observed after 12 h of incubation 
in medium with serum, decreasing afterwards with time.  The expression of PP1γ1 in cells 
grown in medium without serum practically did not change with time, only a slight 
decrease was observed at the 24 h time point.  Comparing both conditions, serum 
withdrawal led to an effective maintenance of PP1γ1 expression, an effect not observed for 
PP1α. 
 The expression of PP1α in PC12 cells incubated with complete medium was 113% 
± 6.4% and 100% ± 10% of control after 12 h and 24 h of incubation, and decreased 
significantly to 67% ± 3.8% after 36 h and to 48% ± 4.2% after 48 h of incubation.  In cells 
incubated in serum-free medium PP1α expression was 98% ± 5.8% of control after 12 h 
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and a significant reduction was observed to 88% ± 5.1% after 24 h of exposure, to 70% ± 
6.1% after 36 h and to 62% ± 8.6% after 48 h. 
 
 
Fig. II.4 – Effect of serum withdrawal on PP1α and PP1γ1 expression in PC12 cells.  Cells were 
incubated with or without serum for different periods of time.  The expression level of PP1α and PP1γ1 was 
analysed by immunobloting with specific antibodies (A).  β-Tubulin levels were also assessed as a control.  
Results obtained from at least three independent experiments were quantified and are represented graphically 
(B) as percentage of control (time 0 h).  Data are expressed as mean ± SEM (*, **, *** value statistically 
different from control; p < 0.05, p < 0.01, p < 0.001, respectively). 
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 PP1γ1 expression in PC12 cells incubated in medium with serum was observed to 
increase to 122% ± 5.2% of control after 12 h of treatment, followed by significant 
decreases to 71% ± 8.7% after 24 h, to 41% ± 8.7% after 36 h and to 18% ± 4% after 48 h 
of incubation.  Cells incubated in serum-free medium showed statistically non-significant 
decreases in PP1γ1 expression to 91% ± 9.7% of control after 12 h, to 78% ± 10.9% after 
36 h, to 66% ± 16.7% after 48 h, but a significant decrease after 24 h exposure to 82% ± 
5.8%. 
 In COS-1 cells, the expression of PP1α and PP1γ1 decreased from 24 h onwards for 
both media used (Fig. II.5).  The expression of PP1α with time in COS-1 cells was similar 
to that verified in PC12 cells.  COS-1 cells incubated with serum demonstrated a 
significant decrease in PP1α expression after 36 h (80% ± 3.9%) and 48h (67% ± 4.9%).  
At 12 h and 24 h the values were 125% ± 15.7% and 93% ± 7.6%, respectively.  COS-1 
cells incubated in medium without serum, as verified for PC12 cells, exhibited a significant 
decrease of PP1α expression from 24 h of incubation onwards.  PP1α expression was of 
103% ± 17.8% at 12 h, but decreased to 66% ± 4.8% at 24 h, to 61% ± 8.5% at 36 h and to 
52% ± 7.4% at 48 h of incubation. 
 The expression of PP1γ1 in COS-1 cells incubated with complete medium, 
remained unaltered up to 12 h (119% ± 14.4%), but significantly decreased with time to 
68% ± 8.8% (24 h), to 61% ± 6.1% (36 h) and to 42% ± 5.7% (48 h).  For cells incubated 
in medium without serum, a similar response was observed.  At 12 h no statistically 
significant change was verified (90% ± 18.9%).  Significant decreases in PP1γ1 expression 
were observed after 24 h (to 38% ± 3.8%), 36 h (to 34% ± 5.5%) and 48 h of exposure (to 
21% ± 3.7%). 
 
II.3.2.2. Effect of aluminium on PP1α and PP1γ1 expression with time 
 
 The effect of increasing concentrations of AlCl3 (0.1 mM, 0.5 mM or 1 mM) on 
PP1α and PP1γ1 expression were evaluated, with time (12 h, 24 h, 36 h and 48 h), in PC12 
and COS-1 cell lines.  Data is shown as % of control (the levels of expression obtained for 
cells incubated with serum free and phosphate free medium, and without aluminium, at 
each time, were considered as 100%).  Thus, the possible effect of serum withdrawal on 
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PP1α and PP1γ1 expression was suppressed, and only the effect of aluminium was 
evaluated.  Statistical differences are expressed in relation to the control. 
 
 
Fig. II.5 - Effect of serum withdrawal on PP1α and PP1γ1 expression in COS-1 cells.  Cells were 
incubated with or without serum for different periods of time.  The expression levels of PP1α and PP1γ1 were 
analysed by immunobloting with specific antibodies (A).  β-Tubulin levels were also assessed as a control.  
Results obtained from at least three independent experiments were quantified and are represented graphically 
(B) as percentage of control (time 0 h).  Data are expressed as mean ± SEM (**, *** value statistically 
different from control; p < 0.01, p < 0.001, respectively). 
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 The expression of PP1α in PC12 cells, in general, decreased with increasing 
aluminium concentrations and with time of exposure at each concentration (Fig. II.6). 
 
 
Fig. II.6 - Aluminium effect on PP1α and PP1γ1 expression in PC12 cells.  Cells were incubated with 
increasing aluminium concentrations for different periods of time.  The expression level of PP1α and PP1γ1 
were analysed by immunobloting with specific antibody (A).  β-Tubulin levels were also assessed as a 
control.  Results obtained from at least three independent experiments were quantified and are represented 
graphically (B) as percentage of control (absence of aluminium at each time).  Data are expressed as means ± 
SEM (*, **, *** value statistically different from the control p < 0.05, p < 0.01, p < 0.001, respectively). 
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 PC12 cells incubated with 0.1 mM AlCl3 presented a small but significant increase 
at 12 h to 109% ± 2.2% of control of PP1α expression, with a significant decrease only 
being observed after 48 h of exposure (90% ± 1.2%).  Statistically significant decreases of 
PP1α expression in PC12 cells were obtained at 36 h and 48 h of treatment with 0.5 mM 
AlCl3 (to 95% ± 1.8% and to 82% ± 4.2%, respectively).  In contrast, incubation with 1 
mM AlCl3 produced significant decreases at all time points (to 84% ± 6% at 12 h, to 79% 
± 5.4% at 24 h, to 73% ± 11.4% at 36 h and to 71% ± 6.3% at 48 h). 
 The incubation of PC12 cells with aluminium induced a similar effect on the 
pattern of expression of PP1γ1 showing a decrease with increasing aluminium 
concentrations and with time, as verified for PP1α (Fig. II.6).  Statistically, with 0.1 mM 
AlCl3 PP1γ1 expression significantly decreased only after 36 h (to 94% ± 3.7%) and 48h of 
treatment to (85% ± 6.8%).  Whereas, incubation with 0.5 mM AlCl3 yielded significant 
decreases earlier, from 24 h onwards (to 78% ± 5.3% at 24 h, to 58% ± 6.4% at 36 h and to 
52% ± 6.8% at 48 h), 1 mM AlCl3 produced significant decreases at all time points 
sampled (to 76% ± 4% at 12 h, to 67% ± 3.2% at 24 h, to 57% ± 4% at 36 h and to 43% ± 
4.6% at 48 h). 
 As verified for PC12 cells, PP1α expression in COS-1 cells exhibits a similar 
response with increasing aluminium concentration and with time (Fig. II.7).  For COS-1 
cells no significant differences on the expression were observed, during time, with the 
incubation of 0.1 mM AlCl3.  Whereas incubation with 0.5 mM AlCl3 yielded significant 
decreases evident at the earliest time point of increasing with time (to 77% ± 7.6% after 24 
h, to 68% ± 4.1% after 36 h and to 53% ± 7.2% after 48 h).  With 1 mM AlCl3 significant 
decreases were observed at all time points (decrease to 77% ± 3.1% after 12 h, to 54% ± 
6.4% after 24 h, to 56% ± 5.6% after 36 h and to 54% ± 4.6% after 48 h). 
 The effect of increasing aluminium concentration on PP1γ1 expression in COS-1 
cells with time was a reduction in PP1γ1 expression, as verified for PC12 cells.  Although 
for COS-1 cells, 0.1 mM AlCl3 induced a small but statistically significant increase of 
PP1γ1 expression at all time points (120% ± 4.2% at 12 h, 121% ± 6.8% at 24 h, 125% ± 
5.7% at 36 h and 118% ± 9.7% at 48 h) (Fig. II.7).  Whereas 0.5 mM and 1 mM AlCl3 
produced decreases in PP1γ1 expression with time, statistically significant results were 
only obtained with 0.5 mM AlCl3 at 48 h of exposure (decrease to 55% ± 17.3%), but at all 
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time points for 1 mM AlCl3 (decrease to 72% ± 7.8% at 12 h, to 65% ± 5% at 24 h, to 59% 
± 8.1% at 36 h and to 41% ± 18.3% at 48 h). 
 
 
Fig. II.7 - Effect of aluminium on PP1α and PP1γ1 expression in COS-1 cells.  Cells were incubated with 
increasing aluminium concentrations for different periods of time.  The expression levels of PP1α and PP1γ1 
were monitored by immunobloting with specific antibodies (A).  β-Tubulin levels were also assessed as a 
control.  Results obtained from at least three independent experiments were quantified and are represented 
graphically (B) as percentage of control (absence of aluminium at each time).  Data are expressed as mean ± 
SEM (*, **, *** value statistically different from control; p < 0.05, p < 0.01, p < 0.001, respectively). 
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II.3.2.3. Effect of aluminium withdrawal on PP1α and PP1γ1 expression 
 
 A recovery study was also performed in relation to the expression of protein 
phosphatases, similar to that performed for cellular viability.  After 24 h incubation with 
0.5 mM and 1 mM AlCl3, both cell lines were allowed to recover by replacement of the 
experimental medium with medium without serum, with medium with serum or by the 
addition of 5% FBS plus 10% HS (for PC12 cells, but just 10% FBS for COS-1 cells) 
directly to the experimental medium.  Recovery was allowed for an additional 24 h of 
incubation.  Data is presented as % of control, i. e. 100% was the level of expression of 
protein phosphatases obtained for cells incubated without aluminium for 48 h.  Statistical 
differences are expressed in relation to the control. 
 In PC12 cells the expression of PP1α following recovery was generally higher than 
the control (Fig.II.8), revealing a statistically significant increase for all conditions tested, 
except for the substitution for medium without serum in cells incubated with 1 mM AlCl3 
that yielded an expression similar to the control.  The levels of PP1α expression were 
112% ± 4.4%, 129% ± 6.6% and 122% ± 6.8% for cells incubated with 0.5 mM AlCl3 for 
24 h and allowed to recover for another 24 h in medium without serum, in medium with 
serum or with the addition of FBS/HS to the medium, respectively.  For the cells incubated 
with 1 mM AlCl3 and allowed to recover in similar conditions, the levels of expression 
achieved were 106% ± 7.1%, 120% ± 7.1% and 116% ± 6.5%, respectively (Fig.II.8).  The 
highest level of PP1α expression was induced by medium with serum in cells previously 
incubated with 0.5 mM AlCl3 for 24 h. 
 On the other hand, for both aluminium concentrations, the substitution to medium 
without serum induced PP1γ1 expression levels similar to the control (93% ± 3.8% for 0.5 
mM AlCl3 and 93% ± 4.7% for 1 mM AlCl3) (Fig.II.8).  However, the substitution to 
medium with serum and the addition of FBS/HS to the medium yielded significant 
decreases in the expression levels of PP1γ1 for both aluminium concentrations (77% ± 
4.8% and 78% ± 5.4% respectively for 0.5 mM AlCl3, and 69% ± 5.5% and 66% ± 5.4% 
respectively for 1 mM AlCl3) (Fig.II.8). 
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Fig. II.8 – Effect of aluminium withdrawal on PP1α and PP1γ1 expression in PC12 cells.  Cells were 
incubated with 0.5 mM or 1 mM aluminium for 24 h in serum-free and phosphate-free medium, and allowed 
to recover for another 24 h by: substituting experimental medium with fresh medium without serum and 
phosphate (-S), or fresh complete medium with serum (+S), or by adding fresh 5% FBS and 10% HS to the 
experimental medium (+F).  The expression levels of PP1α and PP1γ1 were analysed by immunobloting with 
specific antibodies (A).  β-Tubulin levels were also assessed as a control.  Results obtained from at least three 
independent experiments were quantified and are represented graphically (B) as percentage of control (48 h 
without treatment) and expressed as mean ± SEM (*, **, *** value statistically different from control; p < 
0.05, p < 0.01, p < 0.001, respectively). 
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fact, for PP1α, that was the only condition that induced a significant increase in the 
expression, an effect that was observed with both aluminium concentrations (124% ± 8% 
for 0.5 mM and 129% ± 8.7% for 1 mM) (Fig.II.9). 
 
 
Fig. II.9 – Effect of aluminium withdrawal on PP1α and PP1γ1 expression in COS-1 cells.  Cells were 
incubated with 0.5 mM or 1 mM aluminium for 24 h in serum-free and phosphate-free medium, and allowed 
to recover for another 24 h by: substituting experimental medium with fresh medium without serum and 
phosphate (-S), or fresh complete medium with serum (+S), or by adding fresh 10% FBS to the experimental 
medium (+F).  The expression levels of PP1α and PP1γ1 were analysed by immunobloting with specific 
antibodies (A).  β-Tubulin levels were also assessed as a control.  Results obtained from at least three 
independent experiments were quantified and are represented graphically (B) as percentage of control (48 h 
without treatment) and expressed as mean ± SEM (**, *** value statistically different from control; p < 0.01, 
p < 0.001, respectively). 
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 The other experimental recovery conditions led to expression levels similar to the 
control (116% ± 7.9% and 109% ± 7.4% respectively, for 0.5 mM AlCl3 followed by 
medium without serum or addition of FBS to the experimental medium).  Also, the 
expression levels for cells treated similarly but pre-incubated with 1 mM AlCl3 were 105% 
± 11.2% and 106% ± 6%, respectively.  For PP1γ1 expression, the values observed, 
following recovery from aluminium exposure were significantly higher than the control for 
all conditions tested, except for cells incubated with 1 mM whose medium was substituted 
by medium without serum (138% ± 18.7%).  The levels of PP1γ1 expression for cells 
incubated with 0.5 mM AlCl3 for 24 h and whose medium was substituted by medium 
without serum, by medium with serum or to which FBS/HS was added, were 155% ± 
15.4%, 227% ± 12.5% and 177% ± 12.9%, respectively.  For cells incubated with 1 mM 
AlCl3 the expression levels reached 226% ± 13.1% after substitution for medium with 
serum, and reached 169% ± 8.6% by the addition of FBS to the experimental medium (Fig. 
II.9). 
 
II.3.3. Protein phosphatase activity 
 
 The effect of aluminium on PP1 activity was evaluated via different approaches.  
Either purified recombinant PP1α and PP1γ1 were incubated with a range of aluminium 
concentrations and the IC50 was determined, or PC12 and COS-1 cells were incubated with 
0.5 mM or 1 mM AlCl3 and PP1 activity was evaluated in the cell extracts.  In both 
approaches the 32P-phosphorylase a was used as a substrate. 
 
II.3.3.1. Effect of aluminium on recombinant PP1α and PP1γ1 activity 
 
 Purified recombinant PP1α and PP1γ1 were incubated with increasing aluminium 
concentrations (0.01 to 10 mM) and their activity was determined using phosphorylase a as 
a substrate.  Data is presented as percentage of inhibition (Fig.II.10). 
 The range of aluminium concentrations used induced a decrease in both PP1α and 
PP1γ1 activity, thus a characteristic aluminium inhibition curve was obtained.  The IC50 
was calculated using BioDataFit 1.02 software and approximate values were calculated for 
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both PP1 isoforms.  The experimental values determined were: 0.277 mM for PP1α and 
0.258 mM for PP1γ1, as shown in Fig.II.10. 
 
 
 
Fig. II.10 – Effect of aluminium on recombinant PP1α and PP1γ1 activity.  Purified recombinant PP1α 
and PP1γ1 were incubated with increasing aluminium concentrations (0.01 to 10 mM) and their activity was 
determined using phosphorylase a as a substrate.  Results obtained are presented as percentage of inhibition.  
Error bars are mean of duplicates of at least three independent experiments. 
 
 
II.3.3.2. Effect of aluminium on cellular PP1 activity 
 
 The total protein phosphatase activity was evaluated in PC12 and COS-1 cells 
extracts following incubation with 0.5 mM or 1 mM AlCl3 for 24 h.  PP2A activity was 
also determined by pre-incubating the cell extracts with I-2 (a PP1-specific inhibitor).  PP1 
activity in the cell extracts was calculated as the total activity minus the PP2A activity 
towards the 32P-phosphorylase a substrate.  Data is presented as percentage of control, i. e. 
the level of activity obtained for cells incubated without aluminium for 24 h was 
considered as 100% (Fig. II.11.A and Fig. II.12.A).  The partial contributions of PP2A and 
PP1 activities to the total activity was also calculated and data presented as percentage of 
total activity (Fig. II.11.B and Fig. II.12.B). 
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 Both aluminium concentrations yielded similar decreases in the total phosphatase 
activity (PP total), and in PP2A and PP1 activity, in both cell lines.  The decrease in PP 
total activity was to 75% ± 4.6% with 0.5 mM AlCl3 and to 76% ± 5.6% with 1 mM AlCl3 
in PC12 cells (Fig. II.11). 
 
 
Fig. II.11 – Effect of aluminium on PP1 and PP2A activity in PC12 cells.  Cells were incubated with 0.5 
mM or 1 mM aluminium for 24 h. The PPtotal, PP1 and PP2A activities were determined using 
phosphorylase a as a substrate.  Results obtained are presented as (A) percentage of control and (B) 
percentage of total activity.  Error bars are mean of duplicates of at least three independent experiments. **, 
*** Value statistically different from the control p < 0.01, p < 0.001, respectively. 
 
 
 Cellular PP2A activity was reduced to 73% ± 15% with 0.5 mM AlCl3 and to 68% 
± 11.8% with 1 mM AlCl3, whereas for PP1 activity a decrease to 75% ± 4.8% with 0.5 
mM AlCl3 and to 77% ± 5.4% with 1 mM AlCl3 was observed.  The decrease of about 
25% detected for the PP total activity was mainly due to the aluminium induced inhibition 
of PP1 activity, as shown in Fig. II.11.B.  The contribution of PP2A to the total 
phosphorylase phosphatase activity in PC12 cells was only about 6%, whereas that of PP1 
was approximately 94%. 
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 In COS-1 cells (Fig. II.12) the PP total activity decreased to approximately 60% 
with both 0.5 mM and 1 mM AlCl3. 
 
 
Fig. II.12 – Effect of aluminium on PP1 and PP2A activity in COS-1 cells.  Cells were incubated with 0.5 
mM or 1 mM aluminium for 24 h. The PP1 and PP2A activity was determined using phosphorylase a as 
substrate.  Results obtained are presented as (A) percentage of control and (B) percentage of total activity.  
Error bars are mean of duplicates of at least three independent experiments. *** Value statistically different 
from the control p < 0.001. 
 
 
 An inhibition similar to that previously shown for PC12 cells was also observed for 
COS-1 cells incubated with aluminium.  PP2A was inhibited to 70% ± 10.9% and to 80% 
± 10.2% respectively by 0.5 mM and 1 mM AlCl3, and PP1 to 61% ±3.1% and to 61% ± 
4.6% respectively by 0.5 mM and 1 mM AlCl3.  The observed 40% decrease for the total 
phosphorylase phosphatase activity was mainly due also to PP1 inhibition by aluminium, 
as verified for PC12 cells.  PP2A only contributed with about 10% of the total activity, 
whereas PP1 accounted for 90%. 
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II.4. SUMARY OF RESULTS 
 
 In this study it was observed that: 
 - Serum withdrawal alone, in both cell lines, can not account for the observed 
effects of aluminium. 
 - Aluminium induced a decrease of cellular viability in both cell lines, both with 
time of exposure and with the dose. 
 - Decreased cellular viability was seen to recover in both cell lines, following 
aluminium withdrawal. 
 - Aluminium induced a decrease in the expression of both PP1 isoforms, in both 
cell lines, with time and in a dose dependent manner. 
 - The decrease induced by aluminium was reverted following aluminium 
withdrawal, especially in medium with serum. 
 - The aluminium IC50 was similar for both recombinant PP1α and PP1γ1. 
 - Aluminium induced a decrease on the PP1 activity in vivo, in both cell lines. 
 This comparative study showed that globally aluminium provoked equivalent 
effects both in neuronal-like PC12 cells and in non-neuronal COS-1 cells, with similar 
effects on both PP1 isoforms. 
 
II.5. DISCUSSION 
 
 The neurotoxicity of aluminium has been shown to mimic many of the 
pathophysiological features of AD. Indeed, the accumulation of aluminium in the brain 
may contribute to the cholinergic deficiency observed in AD patients (Bielarczyk et al., 
1998).  By potentiating lipid peroxidation, aluminium affects the uptake of choline in nerve 
terminals (Amador et al., 2001), potentially contributing to the cholinergic dysfunction and 
neuronal cell degeneration known to occur in AD.  In this study, aluminium was shown to 
decrease PP1 expression levels.  Although the precise molecular link between aluminium 
toxicity and decreased PP1 expression remains to be elucidated, several lines of evidence 
provide interesting clues.  Chronic aluminium exposure impairs long-term potentiation and 
depression in the rat dentate gyrus in vivo, potentially suggesting that aluminium affects 
both presynaptic and postsynaptic mechanisms of synaptic transmission (Chen et al., 
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2002).  PP1 is not only highly enriched in dendritic spines (Ouimet et al., 1995) and 
necessary for maintaining long-term depression (Morishita et al., 2001), it was also linked 
to age-related memory and learning deficits (Genoux et al., 2002).  It might be 
hypothesized that the toxic effect of aluminium may be mediated via its effect on PP1. 
 In the recovery studies, the decrease in PP1 expression levels was reverted by 
aluminium withdrawal.  This suggests that toxicity induced by low levels of aluminium 
may be reversible.  Recovery effects from aluminium toxicity have been published by 
either using metal ion chelation or using antioxidants.  It was reported that aluminium-
induced enhanced expression of glial fibrillary acidic protein was attenuated by some 
chelators (Yokel and O'Callaghan, 1998).  Chronic aluminium exposure through drinking 
water was shown to induce overexpression of Abeta protein in the hippocampus of rats, but 
this effect was reverted by the herbal medicine Dipsacus asper extract and by vitamin E 
(Zhang et al. 2003).  Moreover, it was published that vitamin E protects against 
aluminium-induced neurotoxicity in rats by reducing the release of proinflammatory 
cytokines induced by aluminium (Nedzvetsky et al., 2006). 
 The use of a culture system offers appropriate conditions for continuous inspection 
of the cells during prolonged periods of exposure to aluminium, along with ability to 
control aluminium content in the extracellular medium and to examine its uptake into cells 
(Meiri et al., 1993).  It was reported that PC12 cells exposed to AlCl3 exhibited 
internalized aluminium, measured by atomic absorption spectrometry, linearly proportional 
to the extracellular aluminium concentration (Bosetti et al., 2001).  In this study both cell 
lines used responded similarly to aluminium exposure.  The cellular viability monitored by 
mitochondrial dehydrogenases activity decreased following aluminium treatment.  This 
finding was in agreement with the decrease in cell viability reported by Suarez-Fernandez 
et al. (1999) following prolonged exposure of cultured astrocytes and neurons to 
aluminium chloride.  In fact, an increasing amount of evidence reported in model studies 
using cultured cells and animals, has confirmed that aluminium can have a severe 
neurotoxic effect.  It is well known that aluminium has the ability to promote the pro-
oxidant properties of transition metals such as iron (Gutteridge et al., 1985; Oteiza, 1994; 
Xie et al., 1996).  It seams that the decrease of MTT reduction following aluminium 
exposure may reflect modification of mitochondrial function.  Alterations in the 
mitochondrial function may lead to the formation of excess ROS production, which in turn 
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can lead to oxidative injury.  Aluminium accumulation was found significantly increased 
in the nerve endings, in the presence of an oxidizing system, and a possible role was 
proposed for aluminium in the promotion and enhancement of oxidant-induced damage 
believed to occur in neuronal degeneration (Amador et al., 1999).  Besides the pro-oxidant 
effect, aluminium is also known to promote inflammatory events (Campbell et al., 2004; 
Becaria et al., 2006).  Aluminium induced a significant increase in lipid peroxidation and 
marked elevation of pro-inflammatory cytokines (Nedzvetsky et al., 2006).  Platt and co-
workers (2001), using histochemical and immunocytochemical studies, suggested that the 
enhancement of inflammation and the interference with cholinergic projections may be the 
mode of action through which aluminium causes learning and memory deficits.  
Additionally, an aluminium impairment of hippocampal long-term potentiation, a model 
for synaptic plasticity underlying some forms of learning and memory, has been reported 
in rats both in vivo and in vitro (Platt et al., 1995). 
 Under the experimental conditions used, a general decrease of the expression of 
both PP1 isoforms with time and in a dose dependent manner was observed.  However, for 
low aluminium concentrations, PP1γ1 expression in COS-1 cells appeared up-regulated, 
contrary to the down-regulation observed for higher aluminium concentrations.  The 
biological response upon exposure to a chemical can be biphasic.  A biphasic response is 
an increase in response at low-dosage levels and a decrease in response at high-dose levels.  
Aluminium is capable of producing biphasic effects in diverse cell systems.  A high dose 
of aluminium was observed to decrease protein synthesis, whereas a lower dose increased 
protein synthesis (Kumar, 1999).  Moreover, low aluminium concentrations have been 
shown to have an activating effect without causing cytotoxicity (Golub et al., 2002).  Other 
experimental conditions, such as brief or prolonged exposure to sodium azide also yielded 
a similar biphasic effect on PP1γ1 expression levels (Amador et al., 2004).  Besides the 
decrease of PP1 expression levels, aluminium also induced a reduction of PP1 activity, for 
both isoforms.  The contribution of aluminium to the reduction of endogenous phosphatase 
activity was previously reported and implicated in the hyperphosphorylation of 
neurofilament proteins (Shetty et al., 1992).  Moreover, following chronic aluminium 
treatment the levels of protein phosphatases were found to be depleted in the cerebral 
cortex (Kaur et al., 2006).  Indeed, it has been reported that the expression and/or activities 
of PP1 and other phosphatases are decreased in the affected areas of AD brains (Gong et 
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al., 1993, 1995; Lian et al., 2001; Liu et al., 2005a).  Reduced PP1 activity has been 
related to tau hyperphosphorylation (Baum et al., 1995; Merrick et al., 1997; Iqbal et al., 
2000).  Decreased PP1α and PP1γ1 mRNA expression was also reported in samples from 
AD patients (Mufson et al., 2002).  These findings suggest that PP1 activity, protein levels, 
as well as mRNA levels, are reduced in neurodegeneration.  It might be hypothesized that 
aluminium may contribute to this down-regulation and to that neurotoxicity. 
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III. EFFECT OF ALUMINIUM ON PRIMARY CORTICAL 
NEURONAL CULTURES 
 
III.1. INTRODUCTION 
 
 The phosphorylation state of neurofilaments (NF) is altered in neurodegenerative 
diseases.  As NF are confined to the nervous system, they might be one of the best markers 
reflecting neuronal pathogenic changes seen in some neurological disorders, such as AD.  
Neuronal accumulation of NF proteins has been seen in a number of neurodegenerative 
diseases.  In the AD brain, in addition to tau, NF are also hyperphosphorylated and 
accumulated.  In fact, the levels of all three neurofilament subunits have been found to be 
markedly increased and, at least NF-H and NF-M, to be significantly hyperphosphorylated 
at several sites (Wang et al., 2001; Hu et al., 2002).  Evidence points to the involvement of 
protein phosphatases in the regulation of the phosphorylation state of neurofilaments. 
 In this chapter a neuronal system (primary cortical cultures) was used to evaluate 
the effect of aluminium on the expression of both PP1 isoforms (PP1α and PP1γ1), and on 
both phosphorylated and nonphosphorylated NF (P-NF and nonP-NF, respectively).  The 
effect of aluminium on the expression of synaptophysin, a 50 kDa protein from synaptic 
vesicles membrane, was also studied as a nerve terminal marker.  A 10 day time course of 
the same proteins was also performed.  The level of expression of those proteins was also 
evaluated in cortex homogenates from 18 day embryos (E18) and from postnatal rats with 
4 (P4) and 7 (P7) days.  Time course of protein expression was compared during 
development in culture and in vivo.  The aim of this study was to evaluate the effect of 
aluminium on the expression of proteins in a neuronal system. 
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III.2. MATERIALS AND METHODS 
 
 The complete composition of all solutions and media used, as well as other relevant 
information, is presented in Appendix I.  All reagents were of cell culture grade or ultra 
pure.  Detailed methods are described in Appendix II.  Other technical information is also 
presented in Appendix III. 
 
III.2.1. Rat cortical primary cultures 
 
 Rat cortical neurons were dissociated from cortex of Wistar Hannover 18 day rat 
embryos whose mother was sacrificed by rapid cervical dislocation.  Tissues were treated 
with a solution of 0.45 mg/ml trypsin and 0.18 mg/ml deoxyribonuclease in Ca2+- and 
Mg2+-free Hank’s Balanced Salt Solution (HBSS) for 10 min at 37 ºC.  Cells were washed 
with HBSS supplemented with 10% fetal bovine serum to stop trypsinization, centrifuged 
at 200 x g for 3 min, and further washed and centrifuged with HBSS for serum withdrawal.  
Cells were pelleted and ressuspended with serum-free Neurobasal medium (Gibco), 
supplemented with 2% B27 supplement (Gibco), 25 µM glutamate (Sigma-Aldrich), 0.5 
mM L-glutamine (Gibco), 60 µg/ml gentamicine (Gibco) and 0.001% Phenol Red (Sigma-
Aldrich) (complete Neurobasal medium).  Viability and cellular concentration were 
assessed using Trypan Blue exclusion (0.4% Trypan Blue solution, Sigma-Aldrich).  Blue 
stained cells (dead) or unstained (living) were counted in a haemocytometer chamber, with 
cellular viability normally being greater than 95%.  These neuronal cells were finally 
plated at a density of 0.9x106 cells/well, in complete Neurobasal medium in poly-D-lysine 
(0.1mg/ml) pre-coated 6-well plates, and grown at 37 ºC in an atmosphere of 5% CO2.  
Seven days after plating, 500 µl of cultured medium was substituted by 500 µl of 
Neurobasal medium with B27, L-glutamine but lacking glutamate. 
 
III.2.2. Time course of protein expression 
 
 For an evaluation of the time course of PP1 (PP1α and PP1γ1), neurofilaments (NF) 
(phosphorylated and nonphosphorylated) and synaptophysin expression in primary 
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cultures, cortical neurons isolated and plated on 6-well plates at a density of 0.9x106 
cells/well in complete Neurobasal medium were incubated at 37 ºC and allowed to grow 
and differentiate for 1, 3, 5, 7, 10 and 11 days in vitro (DIV).  Extracts from the cells 
collected at 11 DIV were used as the control of 10 days time course.  At the specified time 
points (1 to 11 DIV), the cortical neurons were washed with PBS and harvested in boiling 
1% SDS.  Cell lysates were boiled for 10 min and sonicated for 30 sec, and the total 
protein concentration in each sample was determined using the BCA protein assay kit (see 
Appendix II).  Samples were separated by 7.5% SDS-PAGE and immunoblotting was 
performed with antibodies CBC2C (anti-PP1α), CBC3C (anti-PP1γ1), SMI31 (anti-P-NF), 
SMI32 (anti-nonP-NF) or anti-synaptophysin.  Anti-β-tubulin was also used as a control.  
The dilutions and the secondary antibodies used are presented in Table III.1.  Detection 
and analysis was performed as described previously in Chapter II. 
 For this study, samples from isolated cortex of 18 day embryos (E18) and from 
cortex of postnatal rats with 4 and 7 days of life (P4 and P7) were also used.  Those 
samples were collected and processed as previously described. 
 
 
Table III.1 List of antibodies used. 
Target Protein Primary Antibody Assay/Dilution 
Secondary Antibody 
Assay/Dilution 
PP1α CBC2C 
IB dilution: 1:2500 
Horseradish Peroxidase conjugated Rabbit IgG 
IB dilution: 1:5000 
PP1γ1 CBC3C 
IB dilution: 1:2500 
Horseradish Peroxidase conjugated Rabbit IgG 
IB dilution: 1:5000 
Phosphorylated NF SMI31 
IB dilution: 1:1000 
Horseradish Peroxidase conjugated Mouse IgG 
IB dilution: 1:5000 
Nonphosphorylated NF SMI32 
IB dilution: 1:1000 
Horseradish Peroxidase conjugated Mouse IgG 
IB dilution: 1:5000 
Synaptophysin Anti-Synaptophysin 
IB dilution: 1:7500 
Horseradish Peroxidase conjugated Mouse IgG 
IB dilution: 1:5000 
β-Tubulin Anti-β-Tubulin 
IB dilution: 1 µg/ml 
Horseradish Peroxidase conjugated Mouse IgG 
IB dilution: 1:5000 
IB – immunoblot. 
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III.2.3. Exposure of cortical neurons to aluminium 
 
 To study the effect of aluminium on the protein expression in cortical neurons, a set 
of plates were prepared as described above.  After 10 days in culture, cells were washed 
with serum-free and phosphate-free DMEM.  Cells were then incubated in this medium 
with AlCl3 at final concentrations of 0.01 mM and 0.05 mM for 24 h at 37 ºC.  A control of 
cells, washed and incubated only with serum-free and phosphate-free DMEM for 24 h, was 
also performed.  Cells with 11 DIV maintained in Neurobasal medium (NB) were kept as 
control for medium substitution as well.  The cortical neurons were washed with PBS, 
harvested in boiling 1% SDS and processed as described above to perform the 
immunodetection of PP1, NF and synaptophysin.  The cellular viability was also 
determined with the MTT assay (Mossman, 1983), as previously described in Chapter II. 
 
III.3. RESULTS 
 
III.3.1. Time course of protein expression 
 
 An evaluation of the time course of protein expression was performed in primary 
cortical cultures from 1 DIV to 11 DIV.  The proteins analysed were both PP1 isoforms 
(PP1α and PP1γ1), both phosphorylated and nonphosphorylated NF proteins, and 
synaptophysin.  The levels of expression of these proteins were also evaluated in cortex 
homogenates from 18 days embryos (E18), and postnatal day 4 (P4) and 7 (P7) rats.  Data 
is presented as percentage of control, with 100% of expression being defined as the level of 
protein at 11 DIV. 
 
III.3.1.1. Time course of PP1α and PP1γ1 expression 
 
 The expression of PP1α and PP1γ1 increased with time in culture in an analogous 
way for both proteins, as presented on Fig. III.1.  For PP1α the values of expression were 
41% ± 6.6% for 1 DIV, 55% ± 7% for 3 DIV, 73% ± 6.7% for 5 DIV, 94% ± 4.4% for 7 
DIV and 103% ± 4% for 10 DIV.  The expression of PP1γ1 achieved 49% ± 4.4% at 1 
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DIV, 58% ± 4.3% at 3 DIV, 61% ± 4% at 5 DIV, 75% ± 5.2% at 7 DIV and 97% ± 9.6% at 
10 DIV.  At 10 DIV both PP1 isoforms reached values of expression similar to the control 
(expression at 11 DIV). 
 
 
Fig. III.1 – Time course of PP1α and PP1γ1 expression in primary cortical neurons.  Cells were 
collected at different days in culture (1 to 11) and analysed.  Samples from cortex of 18 days embryos (E18) 
and from rats with 4 (P4) and 7 (P7) days were also analysed.  The expression levels of PP1α and PP1γ1 were 
analysed by immunobloting with specific antibodies (A).  β-Tubulin levels were also assessed as a control.  
Results obtained from at least three independent experiments were quantified and are represented graphically 
(B) as percentage of control (expression at 11 DIV) and expressed as mean ± SEM. 
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 The levels of expression obtained from E18 samples were 74% ± 6.9% for PP1α 
and reached 148% ± 19.6% for PP1γ1.  From P4 and P7 samples the expression values 
were quantified as being 24% ± 6.1% and 33% ± 4.1% for PP1α, and 20% ± 7.2% and 
20% ± 7.7% for PP1γ1.  Overall the expression of both PP1 isoforms was analogous in 
both samples, with expression levels decreasing dramatically on the first day of culture 
compared to the E18 samples, especially for PP1γ1, and thereafter recovering with time in 
culture up to 10-11 DIV.  Following birth, both PP1α and PP1γ1 levels decreased again, as 
see for the P4 and P7 samples. 
 
III.3.1.2. Time course of P-NF and nonP-NF expression 
 
 The antibody anti-P-NF (SMI31) reacts with high molecular weight neurofilament 
(NF-H) and, to a lesser extent, with medium molecular weight neurofilament (NF-M).  NF-
H is 200 KDa and NF-M is 160 KDa, and therefore both proteins were quantified 
separately.  The antibody anti-nonP-NF (SMI32) reacts only with NF-H but detects two 
bands of 200 and 180 KDa, both bands were quantified together. 
 The expression of both phosphorylated, NF-H and NF-M, increased with time of 
culture, as well as the expression of the nonphosphorylated NF (Fig.III.2).  The expression 
levels of NF-H (phosphorylated) were 17% ± 11.7%, 55% ± 18.7%, 83% ± 11.6%, 90% ± 
7.5% and 97% ± 4.9% for 1, 3, 5, 7 and 10 DIV, respectively.  And for NF-M 
(phosphorylated) were 3% ±1.4%, 16% ± 7%, 45% ± 11.1%, 69% ± 13% and 94% ± 
12.9%, respectively.  For the same time points the expression of nonphosphorylated NF 
reached 35% ± 6.2%, 48% ± 5.9%, 69% ± 6%, 84% ± 15.3% and 99% ± 3.7%.  At the 10th 
day of culture the expression of both P-NF and nonP-NF yielded values similar to the 
control (expression at 11 DIV).  The values of E18, P4 and P7 samples were 26% ± 19.1%, 
7% ± 2.6% and 5% ± 2.8% for NF-H (phosphorylated), 66% ± 28%, 29% ± 8.4% and 21% 
± 8.3% for NF-M (phosphorylated) and 61% ± 15.1%, 142% ± 24.5% and 27% ± 7.3% for 
nonP-NF, respectively. 
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Fig. III.2 – Time course of neurofilament expression in primary cortical neurons.  Cells were collected 
at different days in culture (1 to 11) and analysed.  Samples from cortex of 18 days embryos (E18) and from 
rats with 4 (P4) and 7 (P7) days were also analysed.  The expression level of neurofilaments phosphorylated 
(P-NF) and nonphosphorylated (nonP-NF) were analysed by immunobloting with specific antibodies (A).  
β-Tubulin levels were also assessed as a control.  Results obtained from at least three independent 
experiments were quantified and are represented graphically (B) as percentage of control (expression at 11 
DIV) and expressed as mean ± SEM. 
 
 
 
0
30
60
90
120
E18 1st 3rd 5th 7th 10th 11th P4 P7
Time course
%
 
o
f C
o
n
tr
o
l NF-H
NF-M
A. 
P-NF 
NonP-NF 
β-Tubulin 
200 
160 
KDa 
180 
200 
E18    1       3       5       7     10     11        P4    P7 
NF-H 
NF-M 
NF-H 
      1       3        5        7      10      1           P7 
DIV 
0
30
60
90
120
150
180
E18 1st 3rd 5th 7th 10th 11th P4 P7
Time course
%
 
o
f C
o
n
tr
o
l
NonP-NF levels 
DIV 
       1         3         5          7       10        1              
DIV 
P-NF levels 
B. 
Aluminium neurotoxicity and neuronal phosphorylation systems 
106 
 
III.3.1.3. Time course of synaptophysin expression 
 
 The expression of synaptophysin, a synaptic vesicle protein used as a marker, 
increased gradually with time in culture (Fig.III.3).  Starting only with 3% ± 1.3% at 1 
DIV, increased to 13% ± 3.5%, 36% ± 4.8%, 57% ± 4.8% and 90% 2.5% at 3, 5, 7 and 10 
DIV, respectively.  Only trace levels were detected in E18 samples, but levels similar to 
control were detected in the postnatal samples (73% ± 4.5% for P4 and 87% ± 6.5% for 
P7). 
 
 
Fig. III.3 – Time course of synaptophysin expression in primary cortical neurons.  Cells were collected 
at different days in culture (1 to 11) and analysed.  Samples from cortex of 18 days embryos (E18) and from 
rats with 4 (P4) and 7 (P7) days were also analysed.  The expression level of synaptophysin was analysed by 
immunobloting with specific antibody (A).  β-Tubulin levels were also assessed as a control.  Results 
obtained from at least three independent experiments were quantified and are represented graphically (B) as 
percentage of control (expression at 11 DIV) and expressed as mean ± SEM. 
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III.3.2. Effect of aluminium on cellular viability 
 
 The viability of cortical neurons was evaluated following aluminium exposure for 
24 h.  A significant decrease to 50% ± 12% was observed, but only with the higher 
aluminium concentration (0.05 mM) as shown in Fig. III.4.  The lower concentration, 0.01 
mM aluminium, did not affect significantly the viability of cortical neurons, yielding 90% 
± 4.5% in relation to the control (cells incubated in serum-free, phosphate-free DMEM for 
24 h in the absence of aluminium).  However, a significant decrease of 34% ± 9% in cell 
viability had already been induced by the change in medium from Neurobasal to serum-
free, phosphate-free DMEM. 
 
 
Fig. III.4 - Effect of aluminium on cellular viability in primary cortical neurons.  Cells with 10 days in 
culture were incubated with 0.01 mM or 0.05 mM aluminium for 24 h.  Cells with 11 DIV in Neurobasal 
medium (NB) were included for comparison.  Results are expressed as percentage of control (absence of 
aluminium) as mean ± SEM of triplicate determinations from at least three independent experiments.  ** 
Value statistically different from the control (p < 0.01). 
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III.3.3.1. Effect of aluminium on PP1α and PP1γ1 expression 
 
 No significant changes on the expression of both PP1α and PP1γ1 were observed 
following aluminium exposure, as shown on Fig. III.5.  The expression of PP1α was at 
103% ± 6.8% and 104% ± 9.1%, after exposure to 0.01 mM and 0.05 mM AlCl3 for 24 h.  
Similar values were also observed for PP1γ1 (97% ± 7.8% and 110% ± 8.9% after 
incubation with 0.01 and 0.05 mM AlCl3, respectively).  However, the expression of both 
isoforms decreased significantly by 41% ± 9% for PP1α and 30% ± 7.2% for PP1γ1 due to 
the medium change from Neurobasal to serum-free, phosphate-free DMEM. 
 
Fig. III.5 - Effect of aluminium on PP1 isoform expression in primary cortical neurons.  Cells with 10 
days in culture were incubated with 0.01 mM or 0.05 mM aluminium in serum-free phosphate-free DMEM 
for 24 h.  Cells with 11 DIV in Neurobasal medium (NB) were included for comparison.  The expression 
level of PP1α and PP1γ1 were analysed by immunobloting with specific antibodies (A).  β-Tubulin levels 
were also monitored as a control.  Results obtained from at least three independent experiments were 
quantified and are represented graphically (B) as percentage of control (absence of aluminium) and expressed 
as mean ± SEM. 
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III.3.3.2. Aluminium effect on P-NF and nonP-NF expression 
 
 As previously described, phosphorylated NF-H and NF-M were quantified 
separately; on the other hand, both nonphosphorylated NF-H isoforms were quantified 
together.  The higher aluminium concentration (0.05 mM) induced the virtual 
disappearance of both phosphorylated NF-H and NF-M (1% ± 1.3% and 0%, respectively) 
and a significant reduction of nonP-NF expression to 7% ± 3.3% (Fig. III.6).  In contrast, 
the lower aluminium concentration (0.01 mM) had no effect on the expression of both 
phosphorylated NF-H and NF-M (91% ± 9.4% and 85% ± 12.9%, respectively), but 
induced a significant decrease of nonP-NF expression to 57% ± 11.2%.  Cells with 11 DIV 
in Neurobasal medium (NB) globally presented no significant differences in the expression 
levels of both phosphorylated NF-H and NF-M (115% ± 13.9% and 143% ± 50.24%, 
respectively) or of nonP-NF (107% ± 31.1%). 
 
Fig. III.6 - Effect of aluminium on neurofilament expression in primary cortical neurons.  Cells with 10 
days in culture were incubated with 0.01 mM or 0.05 mM aluminium in serum-free phosphate-free DMEM 
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for 24 h. Cells with 11 DIV in Neurobasal medium (NB) were included for comparison.  The expression level 
of phosphorylated (P-NF) and nonphosphorylated (nonP-NF) neurofilaments were analysed by 
immunobloting with specific antibody (A).  β-Tubulin levels were also assessed as a control.  Results 
obtained from at least three independent experiments were quantified and are represented graphically (B) as 
percentage of control (absence of aluminium) and expressed as mean ± SEM (**, *** value statistically 
different from the control p < 0.01, p < 0.001, respectively). 
 
 
 
III.3.3.3. Effect of aluminium on synaptophysin expression 
 
 The expression of synaptophysin only decreased significantly following exposure 
to 0.05 mM AlCl3 for 24 h (88% ± 3.5% of the control).  Incubation with 0.01 mM AlCl3 
did not induce changes on this protein expression (97% ± 3%), as presented in Fig. III.7.  
Also, cells with 11 DIV in Neurobasal medium exhibited synaptophysin expression levels 
similar to the control (94% ± 4.9%). 
 
 
Fig. III.7 - Effect of aluminium on synaptophysin expression in primary cortical neurons.  Cells with 10 
days in culture were incubated with 0.01 mM or 0.05 mM aluminium in serum-free phosphate-free DMEM 
for 24 h. Cells with 11 DIV in Neurobasal medium (NB) were included for comparison.  The expression level 
of synaptophysin was analysed by immunobloting with specific antibody (A).  β-Tubulin levels were also 
assessed as a control.  Results obtained from at least three independent experiments were quantified and are 
represented graphically (B) as percentage of control (absence of aluminium) and expressed as mean ± SEM 
(** value statistically different from the control p < 0.01). 
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III.4. SUMARY OF RESULTS 
 
 In this study it was observed that: 
 - All proteins studied (both PP1 isoforms, both NF proteins and synaptophysin) 
increased their expression during the 10 day time course in primary cortical neurons. 
 - Only the higher aluminium concentration (0.05 mM) induced a decrease in 
cellular viability.  However, 11 DIV cells in Neurobasal medium exhibited cellular 
viability values higher than the control. 
 - The expression of both PP1 isoforms remained largely unchanged after aluminium 
exposure.  However, higher expression levels of both PP1 isoforms were observed in 11 
DIV cells in Neurobasal medium, compared to the control. 
 - Both aluminium concentrations induced a decrease in the expression of nonP-NF. 
 - The higher aluminium concentration (0.05 mM) abolished both medium and high 
molecular weight P-NF expression and decreased synaptophysin expression. 
 - On the other hand, no significant differences in the expression levels of 
neurofilaments or synaptophysin were observed in 11 DIV cells in Neurobasal medium. 
 
III.5. DISCUSSION 
 
 The primary culture system of dissociated neurons provides a useful tool that 
enables the observation of pharmacological, functional and morphological changes induced 
by a variety of agents, including aluminium.  Cultured neurons extend neurites, form 
synaptic contacts, show electrophysiological activities, can be maintained more than 1 
month, and exhibit morphological maturation of synapses during the culture period.  These 
features of cultured neurons are similar to those of neurons in vivo (Ichikawa et al., 1993).  
In this work the studied proteins were monitored with time to determine the time course of 
their expression.  The expression of all proteins analysed increased with time, denoting the 
good conditions of the culture and thus conducting to its maturation.  This observation was 
particularly important for synaptophysin expression, since this protein is the main protein 
of synaptic vesicles and hence a good marker for monitoring synaptogenesis.  Ichikawa et 
al. (1993) observed an increase in the number of synaptic vesicles per terminal with DIV, 
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which was correlated with the increase verified in synaptophysin expression with DIV.  
During cortical neuron maturation an increase in the expression levels of synaptophysin 
was observed during the first 15-20 days and then remained stable through 60 DIV 
(Lesuisse and Martin, 2002).  Also, increasing expression of NF with time may be 
correlated with the growth of neuronal processes and therefore with culture maturation. 
 In this chapter, the aluminium concentrations used were lower than those used in 
the previous studies, since cellular viability tests revealed cortical neurons to be more 
sensitive to aluminium than the cell lines previously used.  The previous concentration 
used (0.5 and 1 mM) induced high cytotoxicity to neurons, disrupting neurons and causing 
cells to die.  Thus, the lower concentrations used (0.01 and 0.05 mM) were determined to 
induce low and mild cytotoxicity levels.  However, these lower aluminium concentrations 
seemed not to be sufficient to induce a decrease in PP1 expression.  The expression of both 
PP1 isoforms was not affected by aluminium.  However, a decrease of synaptophysin and 
NF expression was observed following aluminium treatment.  Kawahara and co-workers 
(1992) also reported an impairment of synapse formation in cultured neurons of rat 
cerebral cortex following long-term aluminium exposure.  It was also reported that the in 
vitro formation of synaptic vesicles from PC12 membranes, containing the protein 
synaptophysin, was inhibited by aluminium (Cleves et al., 1997).  The aluminium-induced 
decrease of synaptophysin expression levels was correlated with the decrease verified on 
cellular viability.  This suggests that the observed decrease of synaptophysin expression is 
due to an increase of neuronal disruption induced by aluminium, especially on axons and 
nerve terminals.  Also, the decrease of both NFs levels might be due to the aluminium 
induced axon disruption.  The higher aluminium concentration induced a decrease of 
cellular viability, monitored by assaying mitochondrial enzyme activity, this suggesting the 
occurrence of mitochondria impairment induced by aluminium.  Mitochondria impairment 
is one of the factors that contribute to neurodegeneration.  Indeed, reduced expression of 
NF mRNA was found in human neurodegenerative diseases (AD and ALS) (Crapper et al., 
1988; Bergeron et al., 1994), as well as in aged animals (Parhad et al., 1995).  
Additionally, Munirathinam et al. (1996) observed that primary cortical cultures derived 
from newborn rats that were exposed on 6 DIV to 0.1-1 mM AlCl3, after 48 h of 
aluminium exposure, many nerve cell bodies were swollen; a beading of neurites and a 
disruption of the neuritic network were also observed suggesting neurodegeneration. 
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 In this study, using primary neuronal cultures, aluminium had no effect on the 
expression of both PP1 isoforms, in contrast to the aluminium-induced down-regulation 
seen in both cell lines used in the previous chapter.  These results may be explained by the 
different susceptibilities of the cells used.  In fact, glial cells have been reported to be a 
primary target of aluminium, rather than neurons.  Following aluminium treatment under 
the same conditions, oxidative events were observed in glioma cells, but no significant 
changes were observed in neuroblastoma cells, suggesting that glia may have a higher 
susceptibility to aluminium than neurons (Campbell et al., 1999).  It was reported that long 
exposure to aluminium induced accumulation of the metal both in neurons and astrocytes 
(Suarez-Fernandez et al., 1999).  Interestingly, aluminium neurotoxicity occurred in 
neuroglial cultures containing approximately 10% astrocytes but not in near-pure neuronal 
cultures containing only 1% astrocytes.  Apoptotic condensation and fragmentation of 
chromatin, found in aluminium-treated astrocytes but not in co-cultured neurons, suggests 
that aluminium can induce the apoptotic degeneration of astrocytes and that this toxicity is 
critical to neuronal degeneration and death (Suarez-Fernandez et al., 1999).  Moreover, 
extended impairment of astrocytic function following aluminium injection either 
intraperitoneally or stereotactically into the lateral cerebral ventricles of rats, suggests that 
these cells may be the primary targets of aluminium neurotoxicity (Guo-Ross et al., 1999). 
 On the other hand, besides the good culture maturation verified by the time course 
experiments, the medium substitution from B27-suplemented Neurobasal medium to 
serum-free, phosphate-free DMEM required for the aluminium experiments, induced some 
alterations in the culture.  These changes were evaluated by the differences verified 
between the 11 DIV cells in Neurobasal (used as the control of the time course 
experiments) and the cells with 10 DIV in Neurobasal plus 24h in serum-free, phosphate-
free DMEM without aluminium (the control of aluminium experiments).  A decrease in the 
cellular viability was observed, as well as a decrease in the expression levels of both PP1 
isoforms due to the medium substitution.  However, the medium substitution did not 
influence the expression levels of neurofilaments and of synaptophysin which did not alter; 
they only decreased following aluminium exposure.  The medium substitution induced 
different effects on different protein expression levels, probably because different 
mechanisms were involved conducting to this result.  Immunocytochemical studies were 
also intended to be performed to assess the aluminium induced alterations on the 
Aluminium neurotoxicity and neuronal phosphorylation systems 
114 
 
localization of those proteins and eventually apoptosis.  However, the entire medium 
substitution, from B27- supplemented Neurobasal to serum-free, phosphate-free DMEM, 
induced by itself changes in cell morphology that prevented these studies for being 
performed.  The medium exchange seemed to be injurious to the neuronal culture, 
probably due to the withdrawal of essential neurotrophic factors that were excreted to the 
medium during neuronal maturation or due to differences between media composition that 
compromised the culture.  In fact, B27-supplemented Neurobasal medium with lower 
osmolarity than DMEM medium and reduced cysteine and glutamine concentrations, led to 
higher survival of hippocampal neurons (Brewer et al., 1993). 
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IV. SELDI-TOF MS ANALYSIS OF ALTERED ALUMINIUM-
INDUCED PROTEOMIC PROFILING 
 
IV.1. INTRODUCTION 
 
 Aluminium may be implicated in the alteration of the expression of proteins other 
than those previously studied.  In this chapter we analysed the alteration in proteomic 
profiling induced by aluminium using in vitro and in vivo systems.  The in vitro system 
used consisted of two cell lines (PC12 and COS-1) treated with aluminium.  The in vivo 
analysis was carried out with mice injected with aluminium directly in the brain. 
 For proteomic evaluation, the ProteinChip technology and surface-enhanced laser 
desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry (MS) (Ciphergen 
Biosystems) was used.  ProteinChip technology coupled with SELDI-TOF MS is an 
effective tool that allows performing the separation and detection of the relative expression 
levels of proteins directly from biological samples under different conditions.  The system 
consists of three major components: the ProteinChip Array, the chip reader and the 
software, which allows the capture, purification, analysis and processing of individual 
proteins of interest from complex biological mixtures.  The ProteinChip System detects 
and accurately calculates the mass of compounds based on measured time-of-flight. 
 Protein discovery from the aluminium treated and control samples was performed 
by mass measurement, the ProteinChip Software provided a graphical comparison of 
multiple retentate maps allowing to identify proteins that were differentially expressed in 
the presence of aluminium. 
 
IV.2. MATERIALS AND METHODS 
 
 The complete composition of all solutions and media used, as well as other relevant 
information, is presented in Appendix I.  All reagents were of cell culture grade or ultra 
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pure.  Detailed methods are described in Appendix II.  Detailed chip characterization and 
other technical information are also presented in Appendix III. 
 
IV.2.1. In vitro and in vivo sample processing 
 
IV.2.1.1. PC12 and COS-1 sample preparation 
 
 To evaluate the effect of aluminium on protein expression in vitro, two cell lines 
were used.  PC12 and COS-1 cells were grown on 6-well plates, until 80% confluency was 
achieved, in complete RPMI or complete DMEM, respectively.  Cells were washed twice 
with serum-free and phosphate-free medium and incubated with AlCl3 solution at final 
concentration of 0.5 or 1 mM (in serum-free and phosphate-free medium) for 24 or 48 h.  
Control cells incubated with phosphate-free medium with serum (10% HS and 5% FBS for 
PC12 or 10% FBS for COS-1 cells, “with serum”) or serum-free and phosphate-free 
medium (“without serum”) for the same periods of time were also prepared.  After 
incubation, cells were washed with PBS, harvested in 1 ml PBS, centrifuged at 310 x g for 
5 min at 4 ºC and the pellet stored at -80 ºC.  Pellets were homogenized in 50 µl PBS/0.5% 
octyl glucopyranoside (OGP) solution and sonicated for 20 sec.  Protein concentration was 
estimated using the BCA protein assay and adjusted to 3 µg/µl with PBS/0.5% OGP 
solution in a final volume of 40 µl (120 µg of total protein).  Samples were diluted 1:3 in 
the respective binding buffers for each chip type used. 
 
IV.2.1.2. Mouse sample preparation 
 
 To evaluate the effect of aluminium on protein expression in vivo, C57BL/6J mice 
were used.  A group of mice, females with 9 months, were weighted and anaesthetized 
with Ketamine 150 mg/Kg (injected intramuscularly) and Xylazine 10 mg/Kg (injected 
intraperitoneally).  A few minutes later, a small incision in the skin from their head was 
performed and they were injected with one dose of aluminium lactate solution (1 µl 
containing 200 µg aluminium or 680 pmoles, 0.68 mM) in the left frontoparietal cortex 
area (1.5 mm deep).  Control groups of mice injected with saline solution (Saline) or 
punctured with a needle (Sham) in the same cortex area were also performed.  Each group 
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consisted of at least four animals.  After injection, the skin was stapled and the animals 
were allowed to recover for 3 h or 24 h before being sacrificed by decapitation.  The cortex 
was removed and area surrounding the puncture (4-5 mm3) was isolated, frozen in dry ice 
and stored at -80 ºC.  All samples were homogenized in 50 µl PBS/0.5% OGP and 
sonicated for 20 sec.  Protein concentration was estimated with the BCA protein assay and 
adjusted to 3 µg/µl in PBS/0.5% OGP solution in a final volume of 40 µl (120 µg of total 
protein).  Samples were diluted 1:3 in the respective binding buffers for each type of chip 
used. 
 
IV.2.2. ProteinChip array analysis 
 
 In this work, chips with different matrices (precoating) were used (ProteinChip 
Arrays, Ciphergen Biosystems), namely: strong anion-exchange (SAX2), weak cation-
exchange (WCX2), reverse phase (H4), normal phase (NP20) and immobilized affinity 
capture (IMAC3).  The coating “enhances” the surface to bind preferentially a particular 
class of proteins based on their physicochemical properties.  Each chip has appropriate 
binding and washing buffers that are used to equilibrate the chips, to dilute samples and to 
wash after incubation (for details see Appendix II).  The use of chips with different coating 
and treated with different buffers with different pH allows sample proteins to bind to the 
chip matrix with different affinities, depending on their pI (isoelectric point).  An 
assortment of chips and buffers allows to identify a wide range of proteins. 
 
IV.2.2.1. Bioprocessor method 
 
 Chips were equilibrated (pre-washed) with 10 ml of the respective binding and 
washing buffer, in a 15 ml sterile tube, with vigorous shaking for 5 min.  Chips were 
removed from the tubes, allowed to air dry and assembled in the bioprocessor (Ciphergen 
Biosystems) (see Appendix II).  Samples (5 µl), diluted in the correspondent binding and 
washing buffer (1µg/µl), were loaded into appropriate wells and incubated for 90 min at 
RT with vigorous shaking.  After incubation a quick wash was performed by pipetting 100 
µl/well of the respective binding and washing buffer.  The buffer was removed and the 
chips were also removed from the bioprocessor.  Chips were washed with 10 ml of binding 
and washing buffer three times for 5 min each in a 15 ml conical centrifuge tube with 
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vigorous shaking.  They were briefly rinsed with 10 ml of HPLC grade water and allowed 
to air dry.  Fresh EAM (Energy Absorbing Molecule) solution (see Appendix I) was loaded 
in each spot (2 µl/spot) and allowed to air dry for 10 min, this caused the entire mixture to 
crystallize as it dried.  Chips were then analyzed by SELDI-TOF MS as described below. 
 
IV.2.2.2. Direct spot method 
 
 A NP20 chip was loaded with known molecular weight peptide and protein 
standards.  The chip was washed with HPLC water and incubated with 1 µl/spot of a 
mixture of peptides or protein standards and 3 µl EAM solution, loaded directly into the 
chip (direct spot).  EAM alone was also loaded as a control.  The chip was allowed to air 
dry for 15 min before being analysed. 
 
IV.2.3. SELDI-TOF MS analysis 
 
 The chips with samples were placed into the vacuum chamber of the Ciphergen 
SELDI-TOF MS equipment and the crystals in each spot were hit with a laser, causing the 
proteins to desorb and ionize when the matrix absorbs the energy produced at the 
wavelength of the nitrogen laser.  This results in ionized protein molecules in the gas 
phase.  A brief electric field was then applied to accelerate the ions down a flight tube and 
a detector at the end of the tube recorded the time of flight.  Given the time of flight, the 
known length of the tube and the voltage applied, the mass-to-charge ratio (m/z value) of 
the protein was derived.  The typical spectrum obtained consisted of the sequentially 
recorded numbers of ions arriving at the detector (the intensity) coupled with the 
corresponding m/z value.  The output from the system was then a full profile of proteins 
that bound to the chip and were detected.  The mass spectrum contained peaks 
corresponding to proteins in the sample.  The peak areas are proportional to the measured 
concentrations of the corresponding proteins.  The proteins with altered expression (peaks 
with increased/decreased area) were selected and their molecular weight (MW) 
determined.  To simplify, in this work peptides were considered to have MW < 7500 Da 
and proteins to have MW ≥ 7500 Da.  Using the ExPASy software the putative proteins for 
a specified molecular weight and pI (the pI range was dependent on the pH of the buffer 
used) were tentatively identified. 
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IV.3. RESULTS 
 
 Mixtures of standard peptides and proteins were analysed.  No protein peaks were 
visualised for EAM alone, as expected, and similar peaks were obtained in duplicates 
(Fig.IV.1).  The molecular weights determined were used to calibrate the system. 
 
 
Fig. IV.1 - Peptide and protein standards SELDI-TOF MS spectra.  Peptide standards, all-in-1 protein 
standards and EAM alone were loaded onto a NP20 chip by direct spotting and analysed.  In the upper panel 
are presented the peptides  obtained: Vasopressin - 1084.247 Da; Somatostatin - 1637.903 Da; Bovine insulin 
- 3495.941 Da; Human insulin - 5807.653 Da;, Hirudin - 7033.614 Da.  In the lower panel are presented the 
proteins detected: Bovine Ubiquitin - 8564.8 Da; Bovine cytochrome c - 12230.9 Da; Bovine SOD - 15591.4 
Da; Bovine β-Lactoglobulin - 18363.3 Da. 
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IV. 3.1. Aluminium-induced altered expression of proteins in vitro 
 
 The in vitro study was performed using PC12 and COS-1 cells.  Quadruplicates of 
samples from PC12 or COS-1 cells incubated in medium “with serum”, “without serum”, 
in medium with 0.5 mM and 1 mM aluminium for 24 h or 48 h were loaded in different 
types of chips: H4 with PBS/25% ACN; NP20 with 50 mM HEPES (pH 7.4); SAX2 with 
50 mM Tris (pH 9.0); SAX2 with 50 mM sodium acetate (NaOAc) (pH 4.5); WCX2 with 
50 mM Tris (pH 9.0) and WCX2 with 50 mM NaOAc (pH 4.5).  Full profiles of each were 
obtained.  Proteins or peptides with altered expression are presented in detailed profiles in 
which the altered ones are labelled with the correspondent molecular weight. 
 For PC12 cells, no changes were observed in the expression of proteins detected 
with chips NP20 and SAX2 with NaOAc (pH 4.5).  A full profile of the proteins detected 
using the SAX2 chip with Tris (pH 9.0) is presented on Fig. IV.2.  In this profile a peptide 
of 6710.6 Da was detected exhibiting altered expression due to a serum effect, i. e., “with 
serum” samples revealed smaller peak areas than the others, for both 24 h and 48 h profiles 
(Fig. IV.3).  Serum withdrawal apparently induced an increase in the expression of this 
peptide.  Altered expression of 3250.2 Da, 3780 Da peptides and 9940.4 Da protein were 
detected by WCX2 with NaOAc (pH 4.5).  The change in the expression was also 
apparently due to a serum effect.  The 3250.2 Da and 3780 Da peptides (Fig. IV.4) 
revealed bigger peak areas for “with serum” samples, indicating a decrease in expression 
possibly due to serum withdrawal.  A similar pattern of altered expression, albeit less 
marked, was also observed for a protein peak of 9940.4 Da (Fig. IV.5). 
 The expression of proteins in PC12 cells was also evaluated using a WCX2 chip 
and 50 mM Tris buffer (pH 9.0).  A decrease of the expression of a protein with a 
molecular weight of 20245.5 Da due to aluminium was observed (Fig. IV.6).  Samples 
from cells treated with 0.5 mM and 1 mM aluminium for 24 h and 48 h showed smaller 
peaks than the others.  The putative protein found in the database corresponding to this 
molecular weight and to an expected pI>9.0 (dependent of the chip and pH buffer used) 
was the metalloproteinase inhibitor 1 precursor (MW: 20240.35, pI: 9.06).  Although this 
was the strongest candidate, other hypothesis were the peptidyl-prolyl cis-trans isomerase 
B precursor (MW: 20218.15, pI: 9.42), the 60S ribosomal protein L11 (MW: 20152.21, pI: 
9.64) and the microsomal signal peptidase 23 kDa subunit (MW: 20146.43, pI: 9.61). 
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Fig. IV.2 – Examples of SELDI-TOF MS spectra.  The full profiles of proteins (peaks) were detected 
using SAX2, 50 mM Tris buffer (pH 9.0).  Left profiles are from 24 h samples and right ones from 48 h 
samples.  The upper group of 4 spectra are from quadruplicates of “with serum” samples, the other groups of 
4 spectra are from quadruplicates of “without serum”, “0.5 mM Al” and “1 mM Al” samples, respectively.  
The Y-axis is a relative intensity scale and the X-axis is a mass-to-charge ratio (m/z) scale (Da). 
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Fig. IV.3 - Altered expression of 6710.6 Da peptide due to serum withdrawal in PC12.  The peptide was 
detected using SAX2, 50 mM Tris buffer (pH 9.0).  Altered peaks are labelled with the corresponding 
calculated molecular weight. 
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Fig. IV.4 – Serum withdrawal induced decreased expression of 3250.2 Da and 3780 Da peptides in 
PC12 cells.  The peptides were detected using WCX2, 50 mM NaOAc buffer (pH 4.5).  The 24 h spectra 
were cut to better show both altered peptides, as indicated by the vertical double lines. 
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Fig. IV.5 - Altered expression of a 9940.4 Da protein due to serum withdrawal in PC12 cells.  The 
protein was detected using WCX2, 50 mM NaOAc buffer (pH 4.5). 
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Fig. IV.6 - Aluminium induced change in protein expression in PC12 cells.  A protein with 20245.5 Da 
was detected using a chip WCX2 and Tris (pH 9.0). 
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 In COS-1 cells full profiles of proteins were also detected using different types of 
chips: H4 with PBS/25% ACN; NP20 with 50 mM HEPES (pH 7.4); SAX2 with 50 mM 
Tris (pH 9.0); SAX2 with 50 mM NaOAc (pH 4.5); WCX2 with 50 mM Tris (pH 9.0) and 
WCX2 with 50 mM NaOAc (pH 4.5).  No alterations in protein expression were detected 
on proteins captured in the chips NP20, SAX2 with 50 mM Tris (pH 9.0) and WCX2 with 
50 mM Tris (pH 9.0). 
 A few proteins were detected whose expression altered apparently due to serum 
withdrawal.  The proteins with 7840.6 Da and with 8200.7 Da detected with the chip 
SAX2 with 50 mM NaOAc (pH 4.5) revealed decreases in their expression, but only in the 
48 h profile (Fig. IV.7).  Another peak, not identified in the figure, with a molecular weight 
of 7967.1 Da was also detected exhibiting the same expression pattern of the others. 
 The chip WCX2 with 50 mM NaOAc (pH 4.5) allowed the detection of two 
peptides with altered expression.  The peptides with 4377.8 Da and 4776.4 Da showed a 
double effect in their expression, a first decrease due to serum withdrawal and an extra 
decrease due to aluminium exposure.  Those effects were only verified in the 48 h profiles, 
as presented in Fig. IV.8A and Fig. IV.8B, respectively. 
 Two proteins were detected with altered expression due to aluminium exposure.  A 
protein of 9501.4 Da was discovered using a chip WCX2 with 50 mM NaOAc (pH 4.5).  
Its expression exhibited a decrease induced by aluminium, in both 24 h and 48 h profiles 
(Fig. IV.9).  The search in the database for putative proteins revealed the most probable to 
be Stannin (MW: 9497.10, pI: 5.19).  Other less likely candidates were Glycoprotein J 
(MW: 9510.33, pI: 9.13) and the ATPase inhibitor, mitochondrial precursor (MW: 
9516.56, pI: 7.21). 
 The other, was a protein of 10825.4 Da detected using a H4 chip with PBS/25% 
ACN buffer.  An increase in its expression was verified in samples treated with aluminium 
(Fig. IV.10).  However, this effect was transient, since it was only verified in the 24 h 
profile.  The putative protein found in the database as being the most probable was the 
genome polyprotein (MW: 10823.66, pI: 5.28).  Other less likely possibilities include the 
leukocyte specific transcript 1 protein (MW: 10822.42, pI: 8.43), the polyprotein (MW: 
10819.82, pI: 8.83), the E7 protein (MW: 10819.14, pI: 4.02), Calgranulin A (MW: 
10834.51, pI: 6.51) and the E7 protein (MW: 10837.13, pI: 4.33). 
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Fig. IV.7 – Detection of altered protein expression in COS-1 cells.  The proteins with 7840.6 Da, 7967.1 
Da and with 8200.7 Da were detected using the chip SAX2 with 50 mM NaOAc (pH 4.5).  Decreases in their 
expression were only verified in the 48 h profiles.  The 24 h panel was cut to better show altered proteins, as 
indicated by the double vertical lines. 
7500 7750
7500 7750
0
2.5
5
7.5
10
7843.7+H
0
2.5
5
7.5
10
7835.9+H
0
2.5
5
7.5
10
7847.5+H
0
5
10
7838.0+H
0
2.5
5
7.5
7845.4+H
0
5
10
7846.2+H
0
5
10
15
7842.6+H
0
2.5
5
7.5
10
7842.3+H
0
2.5
5
7.5
7848.8+H
0
5
10
15
7842.5+H
0
2.5
5
7.5
7848.3+H
0
2.5
5
7.5
7838.2+H
0
2.5
5
7.5
7837.5+H
0
2.5
5
7.5
10
7844.6+H
0
2.5
5
7.5
10
7842.9+H
0
5
10
7846.0+H
7750 8000 8250 8500
7750 8000 8250 8500
24h w / Serum
24h w / Serum(2)
24h w / Serum(3)
24h w / Serum(4)
24h w /o Serum
24h w /o Serum(2)
24h w /o Serum(3)
24h w /o Serum(4)
24h 0.5 mM Al
24h 0.5 mM Al(2)
24h 0.5 mM Al(3)
24h 0.5 mM Al(4)
24h 1 mM Al
24h 1 mM Al(2)
24h 1 mM Al(3)
24h 1 mM Al(4)
7843.7+H
8192.5+H
7835.9+H
8185.9+H
7847.5+H
8199.7+H
7838.0+H
8195.9+H
7845.4+H
8202.2+H
7846.2+H
8202.5+H
7842.6+H
8199.9+H
7842.3+H
8203.8+H
7848.8+H
8193.8+H
7842.5+H
8199.8+H
7848.3+H
8195.6+H
7838.2+H
8198.6+H
7837.5+H 8192.1+H
7844.6+H
8197.1+H
7842.9+H
8200.7+H
7846.0+H
8201.0+H
7500 7750 8000 8250 8500
7500 7750 8000 8250 8500
48h w / Serum
48h w / Serum(2)
48h w / Serum(3)
48h w / Serum(4)
48h w /o Serum
48h w /o Serum(2)
48h w /o Serum(3)
48h w /o Serum(4)
48h 0.5 mM Al
48h 0.5 mM Al(2)
48h 0.5 mM Al(3)
48h 0.5 mM Al(4)
48h 1 mM Al
48h 1 mM Al(2)
48h 1 mM Al(3)
48h 1 mM Al(4)
0
10
20
30
7840.2+H 8203.7+H
0
10
20
30
7838.2+H
8199.8+H
0
10
20
30
7840.6+H
8197.1+H
0
10
20
30
7838.1+H
8200.7+H
0
10
20
30
7838.1+H
8197.8+H
0
10
20
30
7844.3+H
8199.7+H
0
10
20
30
7832.7+H 8190.5+H
0
10
20
30
7843.3+H
8200.8+H
0
10
20
30
7848.3+H 8187.3+H
0
10
20
30
7852.5+H
8196.6+H
0
10
20
30
7841.5+H
8193.0+H
0
10
20
30
7840.6+H
8189.3+H
0
10
20
30
7846.0+H 8186.5+H
0
10
20
30
7841.4+H 8192.1+H
0
10
20
30
7835.8+H 8197.1+H
0
10
20
30
7837.6+H 8191.0+H
With serum 
Without serum 
0.5 mM Al 
1 mM Al 
48 h 24 h 
Aluminium neurotoxicity and neuronal phosphorylation systems 
130 
 
 
Fig. IV.8A – Altered peptide expression in COS-1 cells.  The expression of a peptide of 4377.8 Da showed 
a double effect strongly evident in the 48 h panel.  The chip used was WCX2 and 50 mM NaOAc (pH 4.5). 
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Fig. IV.8B – Altered peptide expression in COS-1 cells.  A peptide of 4776.4 Da was detected using the 
chip WCX2 and 50 mM NaOAc (pH 4.5) whose altered expression is more evident in the 48 h profile. 
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Fig. IV.9 - Aluminium induced altered expression of a 9501.4 Da protein in COS-1 cells.  The protein 
was identified using a WCX2 chip with 50 mM NaOAc (pH 4.5).  The decrease in the expression induced by 
aluminium may be observed in both 24 h and 48 h profiles. 
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Fig. IV.10 – Detection of a protein with altered expression due to aluminium in COS-1 cells.  The 
protein of 10825.4 Da was detected using a H4 chip with PBS/25% ACN buffer.  The increase in the 
expression was only verified in the 24 h profile. 
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IV. 3.2. Aluminium-induced altered expression of proteins in vivo 
 
 For the in vivo study, mice were injected with aluminium lactate and sacrificed after 
3 h or 24 h.  Duplicates of “sham” and triplicates of “saline” and “aluminium” samples 
were loaded in different matrix chips and treated with different buffers: H4 with PBS/0.5 
M NaCl; IMAC3 with PBS/0.5 M NaCl; NP20 with 50 mM HEPES (pH 7.4); SAX2 with 
50 mM Tris (pH 9.0); SAX2 with 50 mM NaOAc (pH 4.5); WCX2 with 50 mM Tris (pH 
9.0) and WCX2 with 50 mM NaOAc (pH 4.5).  Full profiles of each were obtained. 
 No changes were observed in the expression of proteins detected by the chips 
SAX2 treated with 50 mM Tris (pH 9.0) or with 50 mM NaOAc (pH 4.5) and by WCX2 
with 50 mM Tris (pH 9.0).  However, with the chip H4 and PBS/0.5 M NaCl, a protein of 
9805.9 Da was discovered which showed increased expression due to aluminium, but only 
in animals treated for 24 h (Fig. IV.11). 
 
Fig. IV.11 - Increased expression of a 9805.9 Da protein in mice after 24 h aluminium treatment.  The 
protein was detected using a H4 chip with PBS/0.5 M NaCl buffer.  Profiles are from 3 h samples (left) and 
from 24 h samples (right).  The upper group of 2 spectra are duplicates of “sham” samples, the other groups 
of 3 spectra are from triplicates of “saline” and “aluminium” samples, respectively.  The Y-axis is a relative 
intensity scale and the X-axis is a mass-to-charge ratio (m/z) scale (Da).  Altered peaks are labelled with the 
correspondent molecular weight. 
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 The search for putative proteins in the database revealed the main candidate to be 
the U6 snRNA-associated Sm-like protein LSm5 (MW: 9806.3 Da, pI: 4.42).  Other 
putative candidates were the Anaphase promoting complex subunit 11 (MW: 9817.56 Da, 
pI: 7.99) and the Small inducible cytokine B13 precursor (MW: 9790.65 Da, pI: 10.52). 
 The chip IMAC3 (with PBS/0.5 M NaCl) was only used to analyse the 24 h 
samples.  A peptide of 6160.8 Da was detected with decreased expression in the aluminium 
treated samples.  A 7660.2 Da protein was also found exhibiting decreased expression due 
to aluminium.  Both profiles are presented in Figure IV.12. 
 
 
Fig. IV.12 - Aluminium-induced altered expression of a peptide and of a protein.  The peptide with 
6160.8 Da and the protein with 7660.2 Da were detected with the chip IMAC3 with PBS/0.5 M NaCl.  Only 
the 24 h profiles are shown. 
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6115.22 Da, pI: 8.23).  For the 7660.2 Da protein, the putative proteins identified from the 
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database were the Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-13 subunit 
(MW: 7651.95 Da, pI: 5.38), the Insulin-like growth factor I precursor (Somatomedin) 
(MW: 7676.88 Da, pI: 8.31) and the DNA-directed RNA polymerase II 7.6 kDa 
polypeptide (MW: 7645.12 Da, pI: 7.65). 
 Two peptides were detected with altered expression using the chip NP20 with 50 
mM Hepes (pH 7.4).  A peptide of 6556.9 Da exhibited a decrease in its expression in 
aluminium treated samples.  This effect was more obvious on the 3 h profiles than on the 
24 h profiles (Fig. IV.13).  The expression of a 6896.6 Da peptide also decreased in 
aluminium treated samples but, only on the 24 h profiles, although in relation to the 3 h 
profiles, in the 24 h profiles an increase in the expression of this peptide was verified on 
sham and saline samples, indicating a saline effect. 
 
 
Fig. IV.13 – Detection of two peptides with altered expression in mice.  The peptides of 6556.9 Da and 
6896.6 Da were detected using the chip NP20 with 50 mM Hepes (pH 7.4). 
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6.4 kDa protein (MW: 6538.64 Da, pI: 9.81), the Beta-defensin 29 precursor (MW: 
6541.71 Da, pI: 9.5) and the Cytochrome c oxidase polypeptide VIIa-liver/heart, 
mitochondrial precursor (MW: 6572.66 Da, pI: 9.11).  For the 6896.6 Da peptide the Small 
EDRK-rich factor 2 (4F5rel) (MW: 6899.85 Da, pI: 10.44) and the APP gamma-secretase 
C-terminal fragment 59 (MW: 6834.89 Da, pI: 7.03) were identified as possible candidates. 
 Also, with the chip NP20 and with 50 mM Hepes (pH 7.4), a protein of 13821.5 Da 
was detected with altered expression.  The expression decreased due to aluminium on both 
animal groups (3 h and 24 h), with the effect being more pronounced in the 24 h profile 
(Fig. IV.14). 
 
 
Fig. IV.14 – Detection of a 13821.5 Da protein exhibiting aluminium induced altered expression.  The 
protein was detected using the chip NP20 with 50 mM Hepes (pH 7.4). 
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precursor (MW: 13802.83 Da, pI: 8.25), and the Small inducible cytokine A2 (MW: 
13847.89 Da, pI: 9.81). 
 Using the chip WCX2 with 50 mM NaOAc (pH 4.5) two peptides of 4845.3 Da and 
5232.4 Da were detected exhibiting a decrease in their expression due to aluminium, but 
only in the 24 h profiles (Fig. IV.15). 
 
 
Fig. IV.15 – Detection of peptides with altered expression due to aluminium in mice.  Peptides of 4845.3 
Da and 5232.4 Da were detected using the chip WCX2 with 50 mM NaOAc (pH 4.5).  The 3 h panel was cut 
to better show both peptides, as indicated by the double vertical lines. 
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4800 5000 5200 5400
4800 5000 5200 5400
3h Sham 1
3h Sham 2
3h Saline 1
3h Saline 2
3h Saline 3
3h Al 1
3h Al 2
3h Al 3
0
20
40
60
4846.2+H
5232.4+H
0
20
40
60
4853.4+H 5231.6+H
0
20
40
60
4846.9+H 5235.3+H
0
20
40
60
4851.1+H 5227.9+H
0
20
40
60
4846.6+H
5225.2+H
0
20
40
60
4844.3+H
5218.4+H
0
20
40
60
4845.3+H 5230.7+H
0
20
40
60
4837.7+H
5215.9+H
5200 5400
5200 5400
3h Sham 1
3h Sham 2
3h Saline 1
3h Saline 2
3h Saline 3
3h Al 1
3h Al 2
3h Al 3
5232.4+H
5231.6+H
5235.3+H
5227.9+H
5225.2+H
5218.4+H
5230.7+H
5215.9+H
4800 5000 5200 5400
4800 5000 5200 5400
24h Sham 1
24h Sham 2
24h Saline 1
24h Saline 2
24h Saline 3
24h Al 1
24h Al 2
24h Al 3
0
20
40
60
4845.3+H
5232.5+H
0
20
40
60
4848.9+H
5237.7+H
0
20
40
60
4846.3+H
5232.4+H
0
20
40
60
4856.2+H 5241.6+H
0
20
40
60
4850.1+H
5239.0+H
0
20
40
60
4849.6+H
5232.0+H
0
20
40
60
4843.9+H
5230.9+H
0
20
40
60
4841.9+H 5230.1+H
Sham 
Saline 
Aluminium 
24 h 3 h 
Chapter IV 
Centro de Biologia Celular                                                                                                                             139 
Universidade de Aveiro 
 With the same chip WCX2 and also with 50 mM NaOAc (pH 4.5), two other 
proteins were also detected with altered expression (Fig. IV.16). The expression of a 
protein with 7103.1 Da slightly increased due to aluminium at 3 h and more evidently at 24 
h.  The expression of a protein with 7219.2 Da also increased due to aluminium, but only at 
24 h. 
 
 
Fig. IV.16 – Detection of two proteins with aluminium-induced increased expression.  The mouse 
proteins of 7103.1 Da and 7219.2 Da were detected using the chip WCX2 with 50 mM NaOAc (pH 4.5). 
 
 The putative proteins identified from the database search for the 7103.1 Da protein 
was the Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-7 subunit (G-protein) 
(MW: 7140.2 Da, pI: 8.71), and for the 7219.2 Da protein was the FXYD domain-
containing ion transport regulator 4 precursor (Channel inducing factor) (MW: 7168.35 
Da, pI: 8.43). 
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 Two more proteins, of 11168.1 Da and 11644.5 Da, were also noticed exhibiting 
aluminium-induced increased expression after 24 h, using the same chip [WCX2 with 50 
mM NaOAc (pH 4.5)] (Fig. IV.17). 
 
 
Fig. IV.17 – Detection of increased expression of two proteins induced by aluminium in mice.  The 
proteins of 11168.1 Da and 11644.5 Da were detected using the chip WCX2 with 50 mM NaOAc (pH 4.5).  
The 3 h panel was cut to better show both altered proteins, as indicated by the double vertical lines. 
 
 The putative proteins identified from the database search for the 11168.1 Da protein 
were the Ig heavy chain V region 1B43 precursor (MW: 11168.41 Da, pI: 7.97), the Ig 
heavy chain V region M315 precursor (MW: 11167.42 Da, pI: 8.6), the S100 calcium-
binding protein A13 (MW: 11157.8 Da, pI: 5.89) and the Death-associated protein 1 (MW: 
11154.53 Da, pI: 9.35).  For the 11644.5 Da protein the putative proteins identified were 
the Transmembrane protein 14C (MW: 11641.7 Da, pI: 9.7), the Stefin 1 (MW: 11640.34 
Da, pI: 5.86), the U6 snRNA-associated Sm-like protein LSm7 (MW: 11636.41 Da, pI: 
5.1) and the FK506-binding protein 1B (MW: 11666.37 Da, pI: 8.64). 
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 Using the same chip [WCX2 with 50 mM NaOAc (pH 4.5)] a protein of 14972.0 
Da also exhibited an increase in expression due to aluminium on the 24 h profile (Fig. 
IV.18). 
 
 
Fig. IV.18 – Detection of increased expression of a protein due to aluminium.  The protein of 14972.0 Da 
was detected using the chip WCX2 with 50 mM NaOAc (pH 4.5). 
 
 Several putative proteins were identified in the database for this protein.  The best 
candidate was the Glial cell line-derived neurotrophic factor precursor (MW: 14974.00 Da, 
pI: 9.44).  Other possibilities were the Potassium voltage-gated channel subfamily E 
member 1-like protein (MW: 14968.21 Da, pI: 5.28), the Interleukin-17 precursor (MW: 
14978.16 Da, pI: 8.84), the bone morphogenetic protein 5 precursor (MW: 14978.93 Da, 
pI: 7.77), the Interleukin-21 precursor (MW: 14964.48 Da, pI: 9.79) and the CD160 
antigen precursor (MW: 14979.70 Da, pI: 6.39). 
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 A protein of 15613.6 Da was also observed with increased aluminium-induced 
expression, but only at 24 h (Fig. IV.19). 
 
 
Fig. IV.19 - Aluminium-induced increased expression of a 15613.6 Da protein in mice.  The protein was 
detected using the chip WCX2 with 50 mM NaOAc (pH 4.5). 
 
 Three putative proteins were identified in the data base for this protein: the SPUF 
protein precursor (secreted protein of unknown function) (MW: 15612.35 Da, pI: 4.79), the 
Microfibrillar-associated protein 5 precursor (MW: 15603.56 Da, pI: 5.61) and the 60S 
ribosomal protein L28 (MW: 15602.28 Da, pI: 12.02). 
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peptides (3250.2 Da and 3780 Da, Fig. IV.4) and one protein (9940.4 Da, Fig. IV.5) 
revealed lower expression levels] and one protein (20245.5 Da, Fig. IV.6) exhibited 
decreased expression due to aluminium. 
- In COS-1 cells, three proteins (7840.6 Da, 7967.1 Da and 8200.7 Da, Fig. IV.7) were 
discovered with decreased expression due to serum and two with altered expression due to 
aluminium [one with increased levels (10825.4 Da, Fig. IV.10) and the other with lower 
levels (9501.4 Da, Fig. IV.9)].  Two peptides (4377.8 Da and 4776.4 Da, Fig. IV.8A and 
8B, respectively) were also identified with altered expression, apparently due to a double 
serum and aluminium decreasing effect. 
- In vivo studies: 
- In mice, five peptides were detected with decreased levels of expression due to 
aluminium (6160.8 Da, Fig. IV.12; 6556.9 Da and 6896.6 Da, Fig. IV.13; 4845.3 Da and 
5232.4 Da, Fig. IV.15) and nine proteins with aluminium-induced altered expression [two 
with lower levels (7660.2 Da, Fig. IV.12; 13821.5 Da, Fig. IV.14) and seven with 
increased levels of expression (9805.9 Da, Fig. IV.11; 7103.1 Da and 7219.2 Da, Fig. 
IV.16; 11168.1 Da and 11644.5 Da, Fig. IV.17; 14972 Da, Fig. IV.18; 15613.6 Da, Fig. 
IV.19)]. 
- The putative proteins identified were very diverse with quite different functions. 
- Aluminium may be implicated in a wide range of mechanisms. 
 
IV.5. DISCUSSION 
 
 Surface-enhanced laser desorption/ionization (SELDI) time of flight (TOF) is a 
mass spectrometry technology for measuring the composition of a sampled protein 
mixture.  Protein profiling has been applied to a variety of samples including plasma, 
urine, cerebrospinal fluid, saliva and solid tissue (Kasthuri et al., 2006).  This new 
proteomic technology has been useful providing information about the pathogenesis of 
many central and peripheral nervous system diseases (Johnson et al., 2006), including AD 
by, for instance, monitoring Abeta peptides in cerebrospinal fluid of AD patients 
(Maddalena et al., 2004) or finding biomarkers for schizophrenia (Lakhan et al., 2006).  
Protein profile analysis is also increasingly used for identification of biomarkers of non-
Aluminium neurotoxicity and neuronal phosphorylation systems 
144 
 
neurological diseases as diverse as cancer (Ciordia et al., 2006), diabetes (Puricelli et al., 
2006) or chronic lymphoid malignancies (Miguet et al., 2006). 
 The form and speciation of aluminium is critical to its biological actions (Golub et 
al., 2002).  AlCl3 is the most common inorganic aluminium salt used for in vitro studies.  
In solution, AlCl3 dissociates and Al3+ is free to associate with a ligand from the culture 
medium, increasing its bioavailability.  In the in vivo experiments a biological form of 
aluminium, aluminium lactate, was used for intraperitonial injections.  Lactate, as well as 
citrate, maltolate or ascorbate, is one of the best aluminium ligands that allows aluminium 
to cross membranes in vivo.  Indeed, it was reported that the uptake of aluminium was 
higher in mice injected intraperitonialy when it was administered in a complex form 
(aluminium-maltolate) than in an ionic form (AlCl3) (Kaneko et al., 2006). 
 One of the earliest reports of aluminium neurotoxicity was published by Scherp and 
Church (1937).  These investigators described a characteristic neurological syndrome 
induced in experimental animals by a single injection of a minute amount of aluminium 
salt into the central nervous system.  Within 20 days of injection, motor malfunction 
developed which was soon followed by severe convulsions and by subsequent death of the 
animal.  In the terminal state, pathological examination revealed widespread cellular 
degeneration in various parts of the CNS accompanied by elevated levels of aluminium 
(Meiri et al., 1993).  Altered protein expression due to aluminium neurotoxicity has been 
reported.  Strong and colleagues (1994) observed altered neurofilaments mRNA levels 
following acute aluminium neurotoxicity.  Elevation of cerebral proteases after systemic 
administration of aluminium was also reported (Guo-Ross et al., 1998).  Infant rabbits 
exposed to aluminium maltolate in milk (lactating mother received aluminium injections) 
exhibited changes in brain protein synthesis which resemble those in infants injected 
directly with aluminium (Nicholls et al., 1995). 
 In this study, various peptides and proteins were found to be up or down-regulated.  
However, due to unsolved technical problems related to the SELDI-TOF technology used 
it was only possible to detect peptides and low molecular weight proteins.  In the in vitro 
studies some proteins were detected with altered expression due to serum withdrawal.  
Serum deprivation may induce changes conducting, for instance, to cell death.  It was 
reported that serum deprivation induces cell death of PC12 cells (Kwon et al., 2002) or of 
primary neuronal cultures (Hugon et al., 2000).  Thus, in this process, or others, some 
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proteins may be up or down-regulated.  However, more interestingly, various proteins were 
discovered with altered expression due to aluminium.  Several putative proteins for those 
discovered proteins have known functions in the most variable systems.  Some of the 
putative proteins are related with mechanisms in which aluminium seems to induce 
toxicity.  A putative protein for an aluminium up-regulated protein with 9.8 kDa (Fig. 
IV.11) is a cytokine B13 precursor.  Putative proteins for a 14.9 kDa protein up-regulated 
by aluminium (Fig. IV.18) are the precursors of interkeukin-17 and interleukin-21.  The 
aluminium-induced increase of other interleukin family members has been previously 
reported.  The levels of interleukin-1alpha increased in the brains of animals following 
chronic aluminium exposure (Campbell et al., 2004).  Aluminium treatment of human 
glioblastoma cells caused an increase in the levels of interleukin-6 (Campbell et al., 2002).  
The activity of apopain, an interleukin 1beta converting enzyme (ICE)-like cysteine 
protease was found increased following dosing with aluminium (Guo-Ross et al., 1998).  
Elevation in the levels of pro-inflammatory cytokine interleukin-1beta induced by 
aluminium was also reported (Nedzvetsky et al., 2006).  Interleukins are a group of 
cytokines which are signalling compounds that, like hormones and neurotransmitters, are 
used extensively for inter-cell communication.  Cytokines play a major role in a variety of 
immunological, infectious and inflammatory diseases.  Chronic up-regulation of the innate 
immune responses in the central nervous system may jeopardize neuronal integrity through 
the prolonged production of toxic inflammatory mediators.  Environmental exposures that 
further enhance the innate immune response may accelerate neurodegeneration.  
Environmental factors such as aluminium can trigger inflammatory events in the central 
nervous system (Campbel, 2004; Campbell et al., 2002; Campbell et al., 2004). 
 A putative protein for the 11.1 kDa protein which is up-regulated by aluminium 
(Fig. IV.17) is a death-associated protein 1 that may be related to apoptosis.  This finding 
suggests that aluminium contributes to the augmenting of proteins leading to apoptosis.  
Indeed, apoptosis is known to be one of the consequences of aluminium toxicity (Savory et 
al., 1999; Ghribi et al., 2001b; Yang et al., 2004; Johnson et al., 2005).  Interestingly, a 
putative protein for the 4.8 kDa peptide found down-regulated by aluminium (Fig. IV.15) 
is the cytochrome c oxidase polypeptide VIII-liver, mitochondrial precursor.  This suggests 
a possible involvement of aluminium in mitochondria impairment.  In fact, it was reported 
that following chronic aluminium exposure the enzymatic activity of the terminal enzyme 
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of the electron transport chain cytochrome oxidase was found significantly decreased 
(Kaur and Gill, 2006).  Moreover, mitochondrial cytochrome c oxidase subunit III was 
detected selectively down-regulated by aluminium exposure (Bosetti et al., 2001).  
Mitochondrial dysfunction has been implicated in neuronal cell death, namely the opening 
of the mitochondrial permeability transition pore and the cytochrome c release which are 
associated with apoptosis.  Aluminium has been related with this mitochondrial 
impairment leading to apoptosis (Ghribi et al., 2001a; Savory et al., 2003; Griffioen et al., 
2004; Johnson et al., 2005).  APP gamma-secretase C-terminal fragment 59 is a putative 
protein for the 6.89 kDa protein down-regulated by aluminium.  Gamma-secretase cleaves 
APP leading to the formation of the Abeta peptide.  It seems that aluminium down-
regulation of this enzyme might inhibit APP processing.  In fact, APP accumulation in 
damaged neuronal processes and microglia was observed following intracerebral 
administration of aluminium salts in rat brain (Shigematsu and McGeer, 1992).  All these 
aluminium-induced altered proteins are associated with mechanisms through which 
aluminium exerts toxicity leading to neurodegeneration. 
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V. CONCLUDING REMARKS 
 
 Excessive aluminium exposure impairs neurocognitive function in humans and 
animals (Gotow et al., 1995; Savory et al., 1999; Miu et al., 2003; Roig et al., 2006).  
Epidemiologic studies have shown a potential link between chronic aluminium exposure 
and neurodegenerative diseases, such as dialysis encephalopathy (Alfrey et al., 1976; 
Savory and Wills, 1984; Kerr and Ward, 1988), ALS/PD complex of Guam (Perl et al., 
1982; Kurland, 1988) or AD (Perl and Brody, 1980; Perl, 1988; Xu et al., 1992a).  Indeed, 
aluminium exposure and apoptotic cell death have been implicated in neurodegeneration.  
The mechanisms by which this metal affects the nervous system are poorly understood, but 
it is known to influence gene expression, alter protein phosphorylation and inhibit some 
cellular enzymes (Li et al., 1998).  There is also evidence for aluminium-induced 
chromosomal aberrations, micronuclei in human lymphocytes (Banasik et al., 2005), DNA 
damage and inhibition of DNA repair (Lankoff et al., 2006).  Aluminium was shown not 
only to induce apoptosis via generation of DNA damage, but also through activation of 
several apoptotic signalling mechanisms including nuclear translocation of gadd153, 
triggering NF-kB signalling, up-regulation of pro-apoptotic factors such as Bax, down-
regulation of the anti-apoptotic factor Bcl-2 and activation of caspase-3 and caspase-12 
(Ghribi et al., 2001b, Savory et al., 2003; Yang et al., 2004; Johnson et al., 2005).  Thus, 
apoptosis seems to be the final consequence of aluminium toxicity. 
 It is well known that aluminium, a trivalent cation unable to undergo redox 
reactions, has the ability to promote the pro-oxidant properties of transition metals such as 
iron (Gutteridge et al., 1985; Oteiza, 1994; Xie et al., 1996).  In parallel, the decrease of 
MTT reduction following aluminium exposure suggests modification of mitochondrial 
function.  Alterations in mitochondrial function may lead to excess ROS production, which 
in turn can lead to oxidative injury.  Since mitochondria are rich in iron one may speculate 
that the iron-dependent lipid peroxidation potentiated by aluminium-induced ROS 
production is one of the mechanisms at the onset of aluminium toxicity.  These 
observations are supported by several reports.  Indeed, subcellular analysis revealed that 
aluminium injections into rat brain resulted in its significant enrichment in the 
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mitochondrial fraction (Ogasawara et al., 2003).  Additionally, following neuronal 
aluminium exposure, mitochondrial ultrastructure analysis showed that aluminium appears 
to impair the mitochondrial membrane and cristae, as increased cell death rate, enhanced 
ROS, decreased mitochondrial membrane potential, and decreased enzyme activity in 
mitochondria (MTT reduction) were observed (Niu et al., 2005).  Furthermore, following 
chronic aluminium exposure the enzymatic activity of cytochrome oxidase (the terminal 
enzyme of the electron transport chain) was significantly decreased (Kaur and Gill, 2006).  
Thus, a potential mechanism through which aluminium exerts neurotoxicity involves 
mitochondria impairment and consequently oxidative damage and cell death.  Interestingly, 
cell death due to oxidative injury is strongly suspected to be a contributory factor in many 
neurological diseases. 
 The most significant effect of aluminium on the central nervous system of 
experimental animals is neurodegeneration, related to neurofibrillary degeneration.  The 
latter is characterized by the accumulation of neuronal perikarial aggregates of 
hyperphosphorylated neurofilaments.  Erasmus and co-workers (1993) suggested that 
aluminium binds to soluble monomeric or oligomeric neurofilament proteins via a 
phosphate group, resulting in abnormal neurofilament assembly, impaired axonal transport, 
and subsequent aggregation.  Reduction of neurofilament axonal transport during 
aluminium neurotoxicity (Shea et al., 2003) may have serious implications for memory and 
learning.  In fact, aluminium-induced impairment of hippocampal long-term potentiation, a 
model for synaptic plasticity underlying some forms of learning and memory, has been 
reported in rats both in vivo and in vitro (Platt et al., 1995), suggesting that aluminium can 
lead to memory impairment. 
 PP1, the “forgetfulness molecule”, is necessary for maintaining long-term 
depression (Morishita et al., 2001) and has been associated with age-related memory and 
learning deficits (Genoux et al., 2002).  It is possible that some of the toxic effect of 
aluminium might also be mediated via its effect on PP1 and/or neurofilaments.  In this 
work, we observed that aluminium induced down-regulation of the expression and activity 
of both PP1 isoforms studied.  As protein phosphatases are key players in the intracellular 
signal transduction pathways, this alteration may lead to an imbalance in cellular protein 
phosphorylation systems and subsequently to neurodegeneration.  Up to now, aluminium 
has been shown to impair intracellular signal transduction involving G-protein-mediated 
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pathways and phosphoinositide-producing systems (Shafer et al., 1994; Golub et al., 
2002), as well as to interfere with intracellular calcium homeostasis (Shi and Haug, 1992; 
Haug et al., 1994; Kaur and Gill, 2005).  Furthermore, as this cation induces 
conformational changes in proteins and strongly binds to the phosphate groups of proteins, 
phosphorylated proteins, such as protein phosphatases and specially their regulatory 
subunits, constitute excellent aluminium targets.  Using different approaches, we have also 
demonstrated that aluminium also induced alterations in the expression of other proteins.  
However, those aluminium-induced changes probably occurred through different 
mechanisms of action. 
 In this work we demonstrated aluminium-induced toxicity in two cell lines of 
different lineage and in primary neuronal cultures, with concomitant down-regulation of 
protein phosphatase expression and activity.  The specificity of these effects was suggested 
by their reversion following aluminium withdrawal.  Moreover, in primary neurons 
aluminium exposure resulted in reduced expression of synaptophysin and neurofilaments, 
although it did not alter protein phosphatase levels.  Furthermore, our in vivo studies 
involving injection of aluminium directly into mouse brains led to alterations in the 
expression levels of several peptides.  Interestingly, bioinformatics analysis indicates that 
some of these putative proteins are associated with apoptosis, mitochondria impairment 
and inflammatory mechanisms. 
Various interconnected hypotheses have been advanced that underscore different 
events as a rationale for the initiation of the aluminium toxic insult to the brain.  
Nonetheless, no single unifying mechanism of aluminium neurotoxicity has been 
identified.  Although the relation between aluminium and the pathogenesis of 
neurodegenerative diseases remains controversial, new lines of evidence make it difficult 
to contradict and numerous studies support an “aluminium hypothesis” (Flaten, 2001; Zatta 
et al., 2003; Gupta et al., 2005; Kawahara, 2005).  Furthermore, it is widely accepted that 
aluminium is a powerful neurotoxicant, and can cause cognitive deficiency and dementia 
when it enters the brain.  The results presented here may predict that this metal induces 
cellular toxicity through mechanisms that lead to apoptosis, most probably via 
mitochondrial impairment.  In addition, the hypothesis that aluminium may be a cause of 
neuritic degeneration and neuronal loss was supported by the observed alterations in 
neuronal morphology and simultaneous down-regulation of neurofilament proteins and 
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synaptophysin.  Concomitantly, aluminium impaired PP1 activity and expression, an 
enzyme that is a central player in many neuronal signal transduction pathways, 
contributing therefore to abnormal neuronal protein phosphorylation.  To date more than 
twenty primary neuronal signaling cascades have been shown to be under the regulation of 
the PP1/DARPP-32 system in the striatum or the PP1/I1 system in other brain regions. 
Interestingly, PP1 has also been suggested to play a key central role in the molecular 
mechanisms underlying the actions of several drugs of abuse.  Finally, by altering the 
expression of proteins associated with mechanisms as diverse as apoptosis and 
inflammation, aluminium may also induce substantial cellular toxicity via different 
pathways, further underscoring the difficulty in defining a single mechanism to explain 
aluminium neurotoxicity. 
 The major contribution of this work was to provide evidence that aluminium 
neurotoxicity is linked to the down-regulation of PP1 expression and activity, an effect that 
may ultimately lead to alterations in neuronal phosphorylation systems and thus to the 
abnormal hyperphosphorylation of key proteins. From the data presented in this 
dissertation it may be concluded that the study of aluminium neurotoxicity remains current 
and of major importance concerning its implications for human exposure. 
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APPENDIX 
 
APPENDIX I - Solutions 
 
CELL LINES AND RAT CORTICAL PRIMARY CULTURES 
 
Cells seeding, maintenance and experiments: 
 
Complete RPMI 1640 medium (PC12 cells) 
For a final volume of 1 L, dissolve one pack of RPMI 1640 powder (Gibco, Invitrogen) in 
deionised H2O and add: 
- NaHCO3 (Sigma-Aldrich)   0.85 g 
- Horse Serum (HS)    100 ml (10% v/v) 
- Foetal Bovine Serum (FBS)  50 ml (5% v/v) 
- Antibiotic/antimycotic solution  10 ml (1% v/v) 
Adjust to pH 7.4, sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
 
Notes: 
- Antibiotic/antimycotic solution (100x) (Gibco, Invitrogen) contains 10,000 U/ml 
Penicillin, 10,000 µg/ml Streptomycin, 25 µg/ml Amphotericin B in 0.85% saline. 
- HS and FBS (Gibco, Invitrogen) are heat inactivated for 30 min at 56 ºC. 
 
RPMI 1640 without phosphates medium (PC12 cells) 
Using one bottle of 500 ml RPMI 1640 without phosphates (liquid) (Biosource) add: 
- Antibiotic/antimycotic solution  10 ml 
Sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
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Complete DMEM medium (COS-1 cells) 
For a final volume of 1 L, dissolve one pack of DMEM powder (with L-glutamine and 
4500 mg glucose/L, Sigma-Aldrich) in deionised H2O and add: 
- NaHCO3     3.7 g 
- Foetal Bovine Serum (FBS)  100 ml (10% v/v) 
- Antibiotic/antimycotic solution  10 ml 
Adjust to pH 7.4, sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
 
DMEM without phosphates medium (COS-1 cells) 
For a final volume of 1 L, dissolve one pack of DMEM powder (Sigma-Aldrich) in 
deionised H2O and add: 
- NaHCO3     3.7 g 
- 20 mM HEPES (Sigma-Aldrich)  5.2 g 
- Antibiotic/antimycotic solution  10 ml 
Adjust to pH 7.4, sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
 
PBS (1x) 
For a final volume of 500 ml, dissolve one pack of BupH Modified Dulbecco’s Phosphate 
Buffered Saline Pack (Pierce) in deionised H2O. Final composition: 
- Sodium Phosphate    8 mM 
- Potassium Phosphate   2 mM 
- NaCl      140 mM 
- KCl      10 mM 
Sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
 
Complete Neurobasal medium (primary neuronal cultures) 
This serum-free medium (Neurobasal, Gibco, Invitrogen) is supplemented with: 
- B27 supplement (Gibco, Invitrogen) 2% 
- L-glutamine (Gibco, Invitrogen)  0.5 mM 
- Glutamate (Gibco, Invitrogen)  25 µM 
- Gentamicine (Gibco, Invitrogen)  50 µg/ml 
- Phenol Red (Sigma-Aldrich)  0.001% 
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Adjust to pH 7.4, sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
 
Hank’s Balanced Salt Solution (HBSS) (primary neuronal cultures) 
This salt solution is prepared with deionised H2O. Final composition: 
- NaCl      137 mM 
- KCl      5.36 mM 
- KH2PO4     0.44 mM 
- Na2HPO42H2O    0.34 mM 
- NaHCO3     4.16 mM 
- Glucose     5 mM 
- Sodium Pyruvate    1 mM 
- HEPES     10 mM 
Adjust to pH 7.4, sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
 
 
Aluminium solutions: 
 
Aluminium solution (for cells exposure) 
Aluminium solution is prepared fresh for each experiment. 
Prepare 10 mM stock solution by dissolving 0.12 mg AlCl3.6H2O (Sigma-Aldrich) in 5 ml 
50 mM HEPES, pH 7.4. 
Dilute 10x with the same buffer and filter (0.2 µm) to sterilize. 
Dilute 10 mM aluminium stock solution in RPMI or DMEM without phosphates to the 
experimental concentrations. 
 
Aluminium solution (for recombinant PP activity assays) 
Prepare 1 mM AlCl3.6H2O in Tris, pH 9. 
Dilute in 50 mM Tris-HCl, pH 7.5 containing 0.1 mM EGTA, 0.03% (v/v) Brij-35 and 
0.1% (v/v) 2-mercaptoethanol to the working concentrations. 
 
 
 
Aluminium neurotoxicity and neuronal phosphorylation systems 
198 
 
Cells Fixation: 
 
1 mg/ml Poly-L-ornithine stock solution (10x) (100 ml) 
To a final volume of 100 ml, dissolve in deionised H2O 100 mg of poly-L-ornithine 
(Sigma-Aldrich). Sterilize by filtering through a 0.2 µm filter and store at -20 ºC. 
Prior to use, dilute the stock solution 10x with deionised H2O. 
 
10 mg/ml Poly-D-lysine stock solution (100x) (10 ml) 
To a final volume of 10 ml, dissolve in borate buffer 100 mg of poly-D-lysine (Sigma-
Aldrich). Sterilize by filtering through a 0.2 µm filter. 
 
Poly-D-lysine solution (100 ml) 
To a final volume of 100 ml, dilute 1 ml of the 10 mg/ml poly-D-lysine stock solution in 
borate buffer. 
 
Borate buffer (1 L) 
To a final volume of 1 L, dissolve in deionised H2O 9.28 g of boric acid (Sigma-Aldrich). 
Adjust to pH 8.2, sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
 
 
PROTEINS MANIPULATION 
 
SDS-PAGE: 
 
LGB (Lower gel buffer) (4x) (1 L) 
- Tris       181.65 g 
- SDS       4 g 
Dissolve in deionised H2O, adjust the pH to 8.9 with HCl and adjust the volume to 1 litre. 
 
UGB (Upper gel buffer) (5x) (1 L) 
Dissolve 75.7 g of Tris base in deionised H2O, adjust the pH to 6.8 with HCl and adjust the 
volume to 1 litre. 
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30% Acrylamide/0.8% Bisacrylamide solution (100 ml) 
- Acrylamide      29.2 g 
- Bisacrylamide     0.8 g 
Dissolve in deionised H2O and adjust the volume to 100 ml. Filter through a 0.2 µm filter 
and store at 4ºC. 
 
10% APS (ammonium persulfate) (10 ml) 
In 10 ml of deionised H2O dissolve 1g of APS. Note: prepare fresh before use. 
 
10% SDS (sodium dodecilsulfate) (10 ml) 
In 10 ml of deionised H2O dissolve 1g of SDS. 
 
Loading (sample) gel buffer (4x) (10 ml) 
- 1M Tris solution (pH 6.8)   2.5 ml (250mM) 
- SDS      0.8 g (8%) 
- Glicerol     4 ml (40%) 
- β-Mercaptoetanol    2 ml (20%) 
- Bromofenol blue    1 mg (0.01%) 
Adjust the volume to 10 ml with deionised H2O. Store in darkness and at RT. 
 
1M Tris (pH 6.8) solution (250 ml) 
Dissolve 30.3 g of Tris base in deionised H2O, adjust pH to 6.8 and adjust final volume to 
250 ml. 
 
Running buffer (10x) (1 L) 
- Tris      30.3 g (250 mM) 
- Glycine     144.2 g (2.5 M) 
- SDS      10 g (1%) 
Dissolve in deionised H2O, adjust the pH to 8.3, and adjust the volume to 1 litre. 
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15 cm gels: 
 
Resolving (lower) gel solution (60 ml) 7.5%  12% 
- H2O      29.25 ml 20.7 ml 
- 30% Acryl/0.8% Bisacryl solution  15.0 ml 24.0 ml 
- LGB (4x)     15.0 ml 15.0 ml 
- 10% APS     300 µl  300 µl 
- TEMED     30 µl  30 µl 
 
Stacking (upper) gel solution (20 ml) 3.5% 
- H2O      13.2 ml 
- 30% Acryl/0.8% Bisacryl solution  2.4 ml 
- UGB (5x)     4.0 ml 
- 10% SDS     200 µl 
- 10% APS     200 µl 
- TEMED     20 µl 
 
 
Immunoblotting solutions: 
 
Electrotransfer buffer (1x) (1 L) 
- Tris      3.03 g (25 mM) 
- Glycine      14.41 g (192 mM) 
Dissolve in deionised H2O, adjust the pH to 8.3 with HCl and adjust the volume to 800 ml 
with deionised H2O. Just prior to use add 200 ml of methanol (20%). 
 
TBS (Tris Buffered Saline) (10x) (1 L) 
- Tris      12.11 g (10 mM) 
- NaCl      87.66 g (150 mM) 
Dissolve in deionised H2O, adjust the pH to 8.0 with HCl and adjust the volume to 1 litre. 
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TBS-T (Tris Buffered Saline + Tween) (10x) (1 L) 
- Tris      12.11 g (10 mM) 
- NaCl      87.66 g (150 mM) 
- Tween 20      5 ml (0.05%) 
Dissolve in deionised H2O, adjust the pH to 8.0 with HCl and adjust the volume to 1 litre. 
 
Blocking solution (100 ml) 
- TBS-T stock solution (10x)   10 ml 
- non-fat milk (dry powder)   5 g 
Dissolve in deionised H2O and adjust volume to 100 ml. 
 
Antibody solution (25 ml) 
- TBS-T stock solution (10x)   2.5 ml 
- non-fat milk (dry powder)   0.75 g 
Dissolve in deionised H2O and adjust volume to 25 ml. Add antibody, mix gently without 
vortex, and store at -20 ºC. 
 
Alkaline Phosphatase (AP) reaction solution (1 L) 
- Tris-HCl (pH 9.5)     12.11 g (100 mM) 
- NaCl      5.85 g (100 mM) 
- MgCl2      1.02 g (5 mM) 
Dissolve Tris base in deionised H2O and adjust solution to pH 9.5 with HCl. Dissolve the 
other solutes and adjust volume to 1 litre. 
 
AP stop solution (1 L) 
- Tris-HCl (pH 9.5)    2.42 g (20 mM) 
- EDTA     1.86 g (5 mM) 
Dissolve Tris base in deionised H2O and adjust with HCl to pH 9.5. Add EDTA after and 
adjust volume to 1 litre. 
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ASSAY OF PROTEIN PHOSPHATASES 
 
50 mM Tris / 0.1 mM EDTA solution 
For a final volume of 15 ml add to deionised H2O from respective stocks: 
   Final concentration Stock  Volume (15 ml) 
- Tris-HCl pH 7.5  50 mM 250 mM 3 ml 
- EDTA   0.1 mM 1 mM  1.5 ml 
- H2O        10.5 ml 
 
Homogenization buffer 
For a final volume of 4 ml add to deionised H2O from respective stocks: 
  Final concentration Stock  Volume (4 ml) 
- Tris-HCl pH 7.5 50 mM 250 mM 800 µl 
- EDTA  0.1 mM 1 mM  400 µl 
- EGTA  0.1 mM 1 mM  400 µl 
- NaCl   150 mM 1.5 M  400 µl 
- DTT   0.1 mM 2 mM  200 µl 
- Benzamidine 1 mM  200 mM 20 µl 
- PMSF  0.1 mM 100 mM 4 µl 
- Leupeptin  5 µg/ml 0.5 mg/ml 4 µl 
- dH2O       1772 µl 
 
Preparation of 32P-labelled phosphorylase a 
Buffer A 
- Na-2-glycerophosphate, pH 7.5 50 mM 
- Glycerol    10% (v/v) 
- EGTA    0.1 mM 
- 2-mercaptoethanol   0.1% (v/v) 
- Microcystin    0.1 µM 
Add 2-mercaptoethanol to buffers just before use. For 1 ml of buffer A, add 2 µl of 50 µM 
microcystin and 1 µl of 2-mercaptoethanol to 997 µl of pre-prepared buffer containing the 
remaining components. 
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Buffer B 
- 125 mM Na-2-glycerophosphate, pH 8.6 
 
Buffer C      Buffer D 
- 50 mM Tris-HCl, pH 7.0    - 10 mM Tris-HCl, pH 7.0 
- 0.1% (v/v) 2-mercaptoethanol   - 0.1% (v/v) 2-mercaptoethanol 
 
 
Buffer E 
- 50 mM Tris-HCl, pH 7.0 
 
Phosphorylase kinase (20 mg/ml in buffer A) 
Phosphorylase b (100 mg/ml in buffer A) 
 
90% saturated ammonium sulphate 
Add 475 g per litre, adjust pH to 7.0 with NH4OH. The ammonium sulphate is added to the 
water slowly in order to dissolve till saturation. 
 
50 µM Microcystin 
Prepare in DMSO and keep aliquots in -20ºC. 
 
Assay of phosphorylase phosphatase (PP1 and/or PP2A) activity 
Buffer A      Buffer B 
- Tris-HCl, pH 7.5 50 mM   - Tris-HCl, pH 7.5 50 mM 
- EGTA  0.1 mM   - EGTA  0.1 mM 
- 2-mercaptoethanol 0.1%    - 2-mercaptoethanol 0.1% 
- BSA   1 mg/ml   - Brij-35  0.03% 
- MnCl2  1mM 
 
Buffer C 
As buffer A, but without BSA. 
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75 mM Caffeine 
Adjust pH to 7.0 and store in the dark at RT (caffeine is degraded by light and will 
crystallize if stored at 4 ºC). 
 
 
CIPHERGEN PROTEINCHIP SOLUTIONS 
All solutions are prepared with HPLC water. 
 
Aluminium lactate solution (mice injections) 
Dissolve in 1 ml saline solution 200 mg of Aluminium lactate (Sigma-Aldrich). 
 
0.5% OGP/PBS solution 
Prepare 10% OGP (n-octyl glucopyranoside, Sigma-Aldrich) in deionised H2O by 
dissolving 1 g OGP in 10 ml H2O. Dilute 20x by adding 500 µl 10% OGP to 9.5 ml PBS. 
 
100 mM Cupric sulfate (CuSO4) solution 
To a final volume of 25 ml, add 0.399 g to 25 ml HPLC H2O. 
 
50 mM HEPES pH 7.4 
To a final volume of 100 ml, add 1.19 g HEPES to 80 ml HPLC H2O, adjust to pH 7.4 and 
adjust the volume to 100 ml. 
 
50% Acetonitrile (ACN) 
To a final volume of 50 ml, add 25 ml 100% ACN to 25 ml HPLC H2O. 
 
PBS 
Dissolve 1 package (PBS, Pierce) in 1000 ml HPLC H2O. 
 
PBS/0.5 M NaCl 
To a final volume of 500 ml, add 14.61 g NaCl to 400 ml PBS.  Mix and adjust volume to 
500 ml. 
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PBS/25% ACN 
To a final volume of 500 ml, add 125 ml ACN (100%) to 375 ml PBS. 
 
50 mM Tris pH 9.0 
To a final volume of 500 ml, add 25 ml from stock 1 M pH 8.0 to 475 ml HPLC H2O, 
adjust to pH 9.0. 
 
50 mM Sodium acetate solution pH 4.5 
To a final volume of 500 ml, add 2.05 g sodium acetate to 500 ml HPLC H2O, adjust to pH 
4.5. 
 
EAM molecule solution 
 The solvent system for EAM (Energy Absorbing Molecule) and the EAM solution 
itself must be prepared fresh every day.  Acetonitrile (ACN) volatilizes rapidly and EAMs 
break down significantly within 24 hours in solution at RT. 
 A saturated solution is prepared so some pellet can be visualized, use only the 
supernatant. 
- Weight 5 mg Sinapinic acid (SPA, Sigma) in a microfuge tube (preferably brown or 
covered with foil, to protect from light). 
- Add 100 µl of a freshly prepared 1:1 solution of 100% ACN and 1% trifluoroacetic acid 
(TFA) (final concentration: 50% ACN and 0.5% TFA) and strongly vortex. 
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APPENDIX II – Kits and methods 
 
CELL CULTURE 
 
PC12 cell culture maintenance 
 PC12 cells were cultured in RPMI 1640 medium (Gibco, Invitrogen) supplemented 
with 10% (v/v) heat-inactivated horse serum (Gibco, Invitrogen), 5% (v/v) heat-inactivated 
fetal bovine serum (Gibco, Invitrogen), 1% (v/v) antibiotic-antimycotic solution (100 U/ml 
Penicillin, 100 µg/ml Streptomycin, 0.25 µg/ml Amphotericin B) (Gibco, Invitrogen) and 
0.85 g/L NaHCO3.  Routinely, cells were plated in 100 mm plates and maintained at 37 ºC 
in an atmosphere of 5% CO2.  Cells were subcultured whenever ∼95% confluency was 
reached (every 3-5 days).  For experimental procedures, cells were collected, counted and 
plated onto 6-well plates that were previously treated with 100 µg/ml poly-L-ornithine 
(Sigma-Aldrich) for 10 minutes and washed 3 times with sterile deionised water. 
 
COS-1 cell culture maintenance 
 COS-1 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, 
Sigma-Aldrich) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Gibco, 
Invitrogen), 1% (v/v) antibiotic-antimycotic solution and 3.7 g/L NaHCO3.  Cells were 
routinely plated in 100 mm cell culture dishes and grown in a humidified incubator at 37 
ºC and 5% CO2.  Whenever ∼95% confluency was reached (every 3-5 days) cells were 
subcultured and for successful dissociation trypsin-EDTA (Gibco, Invitrogen) was used.  
For experimental procedures, cells were collected, counted and seeded onto 6-well plates. 
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ANIMAL PROCEDURES 
 
Rat cortical primary cultures 
 Rat cortical neurons were dissociated from cortex of Wistar Hannover 18 days rat 
embryos whose mother was killed by rapid cervical dislocation.  After cortex dissection, 
tissues were treated for 10 min at 37 ºC with a 0.45 mg/ml trypsin/0.18 mg/ml 
deoxyribonuclease solution in Ca2+- and Mg2+-free HBSS, supplemented with BSA 
(Merck, VWR International).  Cells were washed with HBSS supplemented with 10% FBS 
to stop trypsinization, centrifuged at 200 g for 3 min, and further washed and centrifuged 
with HBSS for serum withdraw.  Cells pellet was ressuspended in complete Neurobasal 
medium, which is supplemented with 2% B27..  Viability and cellular concentration were 
assessed by using the Trypan Blue excluding dye (0.4% Trypan Blue solution, Sigma-
Aldrich), and cells with (dead) or without (living) intracellular blue staining were counted 
in a hemocytometer chamber.  Cellular viability was calculated and normally higher than 
95%.  These neuronal cells were finally plated at 0.9 x 106 cells/well in 100 µg/ml poly-D-
lysine pre-coated six-well plates.  Cells were maintained in 2 ml of complete Neurobasal 
medium in a humidified incubator at 37 ºC and 5% CO2.  Three and seven days after 
plating, 500 µl of cultured medium was replaced with 500 µl of glutamate-free complete 
Neurobasal medium.  For epifluorescence analyzis, cells were plated on 100 µg/ml poly-D-
lysine pre-coated glass coverslips in six-well plates. 
 
Mice aluminium injected samples 
 C57BL/6J mice, females with 9 months, were weighted and anaesthetized with 
Ketamine 150 mg/Kg (injected intramuscularly) and Xylazine 10 mg/Kg (injected 
intraperitoneally).  A few minutes after, the skin from their head was cut and they were 
injected with one dose of aluminium lactate solution (1 µl containing 200 µg aluminium or 
680 pmoles, 0.68 mM) in the left frontoparietal cortex area (1.5 mm deep).  Control groups 
of mice injected with saline solution (Saline) or just touched with a needle (Sham) in the 
same cortex area were also preformed.  Each group had at least four animals.  After 
injection, the skin was stapled and the animals were allowed to recover for 3 or 24 hours 
before being sacrificed by decapitation.  The cortex was removed and the puncted 
surrounding area (4-5 mm3) was isolated and frozen in dry ice and stored at -80 ºC.  All 
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samples were homogenized in 50 µl PBS/0.5% OGP and sonicated for 20 seconds.  Protein 
concentration was estimated with BCA protein assay and adjusted to 3 µg/µl in PBS/0.5% 
OGP solution in a final volume of 40 µl (120 µg of total protein).  Samples were diluted 
1:3 in respective binding buffers. 
 
VIABILITY ASSAYS 
 
Trypan blue assay 
 This method is based on the exclusion dye Trypan blue (Sigma-Aldrich).  Cells that 
became blue after incubated with the dye are dead cells (the cellular membrane is affected 
and allows the dye to go inside) on the other hand, cells that remains uncoloured are living 
cells.  From the cellular suspension 90 µl was removed, added to 10 µl of 0.4% Trypan 
blue solution and mixed for 1 minute.  Ten µl of that mixture was loaded onto a 
hemocytometer chamber and cells were counted using an inverted optical microscope. 
 
MTT assay 
 This method is based on the reduction of MTT, a water soluble tetrazolium salt, by 
mitochondrial dehydrogenase, to an insoluble intracellular purple formazan.  The extent of 
reduction of MTT was measured spectrophotometrically at 570 nm, according to Mossman 
(1983).  After cells treatment, the conditioned medium was removed and 0.5 mg/ml MTT 
(Sigma-Aldrich) solution (in serum-free RPMI or serum-free DMEM) was added and 
incubated for 3 hours at 37 ºC.  The resulting insoluble formazan precipitates were 
solubilized with 0.04 M HCl/Isopropanol.  The absorbance of the converted dye was 
measured at a wavelength of 570 nm in a Cary 50 spectrophotometer.  The cellular 
viability was expressed as a percentage of O.D. values of control cells, meaning that 90% 
of viability denotes a decrease of 10% on viability. 
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PROTEINS MANIPULATION 
 
Protein Assay kit (BCA) 
 Samples total protein measurements were performed with BCA protein assay kit 
(Pierce), following the manufacturer’s instructions.  The method combines the reduction of 
Cu2+ to Cu+ by protein in an alkaline medium (the biuret reaction) with a sensitive 
colorimetric detection of the Cu+ cation using a reagent containing bicinchoninic acid 
(BCA).  BCA complexes with Cu+ and produces a purple colour, which exhibit a strong 
absorbance at 562 nm. 
 The total protein from each sample was measured using 50 µl of cell lysate in 1% 
SDS (or 25 µl of cell lysate plus 25 µl of 1% SDS).  Standards were prepared with 
different volumes of 2 mg/ml bovine serum albumin (BSA) solution (Pierce) (with known 
final concentrations of 2-80 µg) and final volumes adjusted to 50 µl with 1% SDS.  One ml 
of working reagent (WR) was added to each sample or standard, and mixed well.  WR was 
previously prepared with 50:1 of reagent A (sodium carbonate, sodium bicarbonate, BCA 
and sodium tartrate in 0.2 N sodium hydroxide) and reagent B (4% cupric sulfate).  
Samples and standards were incubated at 37 ºC for 30 minutes.  Temperature from samples 
and standards was let to cool to RT and absorbance was read at 562 nm in a 
spectrophotometer Cary 50 (Varian).  A standard curve was prepared by plotting BSA 
standard absorbance vs. BSA concentration and used to determine the total protein 
concentration of each sample. 
 
SDS-PAGE (for Western blotting) 
 SDS polyacrylamide gel electrophoresis (SDS-PAGE) separations were carried out 
using well established methods (Laemmli, 1970), where proteins are separated by their 
molecular weight and negative charge due to SDS-amino acid binding.  The gels 
percentage and size chosen depend on the molecular weight of the proteins to be separated 
in the gel. Gels were prepared by mixing several components (Appendix I).  The resolving 
gel solution was immediately and carefully pipetted down the spacer into the gel sandwich, 
leaving free space for the stacking gel.  Water was carefully added to cover the top of the 
gel and the gel was allowed to polymerize for 1 h.  Stacking gel solution was prepared 
according to Appendix I.  The water was poured out and the stacking gel was added to the 
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gel sandwich; a comb was inserted and the gel allowed to polymerize for 1 h.  In parallel, 
samples were prepared by adding to the protein sample solution ¼ volume of 4x LB 
(Loading Buffer).  Samples microtubes were boiled and spinned down, the combs removed 
and the gels wells filled with Tris-Glycine running buffer.  The samples were carefully 
loaded into the wells, and electrophoretically separated using a 90 mA electric current.  
Molecular weight markers (Kaleidoscope Prestained Standards or Prestained SDS-PAGE 
Standards – Broad Range, BioRad) were also loaded and resolved side-by-side with the 
samples.  In some experiments, as the number of samples was more than the number of 
wells, samples were loaded into two similar gels and a control sample was loaded in both 
gels. 
 
Proteins electrotransfer 
 Western blotting was carried out by direct electrotransfer the proteins, that were 
electrophoretically separated by SDS-PAGE, from the gel to a nitrocellulose membrane, 
while keeping their position (Burnette, 1981).  3MM blotter papers and a nitrocellulose 
membrane were used to build up the transfer sandwich.  The gel was removed from the 
electrophoresis device and the stacking gel discarded.  A transfer sandwich was assembled 
under transfer buffer, in the following order: sponge, 3MM blotter paper, gel, 
nitrocellulose membrane, 3MM paper, sponge.  The cassette was placed in the transfer 
device, previously filled with transfer buffer, oriented so that the negatively charged 
proteins migrate towards the anode.  Electrotransfer was let to proceed for 18 h at 200 mA, 
after what the membrane was allowed to dry on a clean paper. 
 
Immunological detection 
 Proteins electrotransfered to nitrocellulose membrane can be immunologically 
detected.  Initially, membranes were soaped in 1x TBS for 5 min.  Blocking of possible 
non-specific binding sites of the primary antibody was performed by immersing the 
membrane in 5% (w/v) non-fat dry milk (Johnson et al., 1984) in 1x TBS-T solution for 1 
h.  Further incubation with primary antibody was carried out for the specified times, 
ranging from 2 h to overnight incubation at 4 ºC with agitation.  After three washes with 1x 
TBS-T, of 10 min each, the membrane was further incubated with the appropriate 
secondary antibody for 2 h with agitation.  All primary and secondary antibodies used were 
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diluted in 1x TBS-T/non-fat dry milk (3% w/v) at the dilutions specified in Chapter II and 
III (Table II.1 and III.1).  Membranes were additional washed three times with 1x TBS-T, 
before being submitted to one of the following detection methods. 
 
 Enhanced chemiluminescence detection (ECL and ECL+ kits) 
 Enhanced chemiluminescence (ECL) (Amersham Pharmacia) is a light emitting 
non-radioactive method for detection of immobilised specific antigens, conjugated directly 
or indirectly with horseradish peroxidase-labelled antibodies.  The ECL reaction is based 
on the oxidation of the cyclic diacylhydrazide luminal (Whitehead et al., 1979).  In a dark 
room, the membrane was incubated for 1 min at RT with the ECL detection solution or for 
5 min with the ECL+ detection solution.  These solutions were prepared fresh following 
the manufacturer’s instructions.  The membrane was wrapped in cling-film and exposed to 
an autoradiography film (X-Omat, Kodak, Sigma-Aldrich) inside a film cassette (Kodak, 
Sigma-Aldrich).  The film was developed in a developing solution (Kodak, Sigma-
Aldrich), washed in water and fixed in a fixing solution (Kodak, Sigma-Aldrich). 
 
 Colorimetric detection (NBT/BCIP) 
 The substrate 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium 
(NBT/BCIP) (Promega) is converted in situ into a dense purple compound by immuno-
localized alkaline phosphatase.  Each 15 cm membrane was developed by adding to it a 
solution of 66 µl of NBT and 33 µl of BCIP in 10 ml of Alkaline Phosphatase (AP) 
reaction buffer.  When a coloured signal was achieved, the developing reaction was 
stopped by adding 20 ml of AP stop solution.  Membrane was washed twice with deionised 
water and air dried at RT. 
 
Quantification of protein expression and data analysis 
 The films from ECL detection or the membranes developed with NBT/BCIP were 
scanned using a GS-710 calibrated imaging densitometer (BioRad) and the intensity of the 
bands was quantified.  Data are expressed as mean ± SEM of triplicate determinations 
from at least three independent experiments.  Statistical significance analysis was 
conducted by one way analysis of variance (ANOVA).  Unless otherwise noted, a level of 
statistical significance is considered * p < 0.05 versus control. 
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ASSAY OF PROTEIN PHOSPHATASES 
 
Preparation of [γ-32P]ATP 
 Fifty µl of [γ-32P]ATP (250µCi - 3000 Ci/mmol, Amersham Pharmacia) were 
transferred to a 1.5 ml screw cap microcentrifuge tube, shielded in a Plexiglas box.  The 
original vial was washed out with part of 445 µl of water and the washings transferred to 
the [γ-32P]ATP tube.  The remainder of water plus 5 µl of 100 mM ATP (pH was adjusted 
to 7.0 with NaOH and aliquots were kept at -20 ºC; 1/1000 dilution should have A260 of 
1.54) was added to the container and mixed by pipetting up and down.  Duplicates of 10 µl 
aliquots of 1/100 dilution in water were counted in a scintillation counter.  Dilutions up to 
1/1000 were also performed to measure A260 to check concentration and to determine 
specific activity. 
 
Preparation of 32P-labelled phosphorylase a 
 Phosphorylase kinase and phosphorylase b prepared solutions were incubated at 30 
ºC for 10 min.  The following components were mixed together, ATP was the last to be 
added: 
Phosphorylase kinase   16 µl 
100 mM Mg acetate   32 µl 
100 mM CaCl2   2 µl 
Microcystin    3 µl 
Phosphorylase b   200 µl 
Buffer B    847 µl 
[γ-32P]ATP    500 µl 
Total     1600 µl 
 
 Incubation took place for 2 h at 30 ºC.  An equal volume of ice-cold 90% saturated 
ammonium sulphate was added.  The mixture was left on ice for 30 min to precipitate 
protein, and centrifugated at 19000 g for 15 min at 4 ºC.  The pellet was ressuspended 
gently in buffer C (not more than 5 ml per 100 mg of phosphorylase) using a pipette.  An 
equal volume of ice-cold 90% saturated ammonium sulphate was added and the steps of 
precipitation on ice and centrifugation were repeated, to remove excess of ATP.  The 
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suspension was dialysated for 24 h at 4 ºC against 4x 1 L of buffer D, to remove residual 
ATP.  The dialysis buffer was monitored for radioactivity at each change.  During dialysis 
the phosphorylase a crystallized forming a cream-coloured suspension.  The contents of 
the dialysis bag were carefully empty into a microcentrifuge tube, left on ice for 2 h to 
ensure complete crystallization, centrifuged at 19000 g for 15 min at 4 ºC and the obtained 
crystals gently ressuspended in not more than 500 µl of buffer E.  A sample was taken and 
diluted 100x in buffer E to determine the specific radioactivity.  The concentrated solution 
was swirled before sampling to ensure complete ressuspension, and the diluted sample 
warmed at 30 ºC to dissolve the crystals.  The A280 of 1/100 dilution was determined to 
estimate protein content (A280 is 1.31 for a 1 mg/ml solution), and triplicates of 10 µl 
aliquots were counted to determine the radioactivity.  The specific radioactivity should 
correspond to 1 mole of phosphate per mole of 97.4 kDa subunit.  Aliquots were pipetted 
into 1.5 ml microcentrifuge tubes and stored at 4 ºC (were not freeze as this denatures 
phosphorylase).  The size of each aliquot varied depending on the exact protein 
concentration of the preparation, and was adjusted so the concentration of phosphorylase a 
was 3 mg/ml after the addition of 0.5 ml of buffer C and caffeine (see below). 
 
Assay of phosphorylase phosphatase (PP1 and/or PP2A) activity 
 0.1 ml of caffeine and 0.4 ml of buffer C were added to one vial of [32P]-
phosphorylase a to give a 3 mg/ml (30 µmol/L) solution, and stored on ice.  Occasionally, 
the redissolved phosphorylase a substrate showed slight cloudiness due to trace 
denaturation.  When it occurred the vial was simply warmed for 1-2 min at 30 ºC and the 
precipitated spined out at 12000 g for 2 min and vial kept at RT (returned to storage at 4 ºC 
after being used).  The protein phosphatase sample (crude extract or purified PP1 or PP2A) 
was diluted in buffer A.  Several dilutions were checked to find the one that released 5-
10% of the total counts.  Microcentrifuge tubes (1.5 ml) were labelled, duplicates for each 
sample and two more for blanks.  Blanks were included as the first and last tubes in every 
set of assays: in this way, any phosphatase carry-over due to contaminated pipette tip being 
accidentally inserted into the vial substrate was noticed.  Using phosphorylase a as 
substrate, the blank should be <1% of the total counts: if the blank value rose above 5% of 
the total, the batch of substrate in use was discarded and a fresh aliquot was made.  Into 
each sample tube, 10 µl of diluted protein phosphatase were pipetted and 10 µl of buffer A 
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(no enzyme) into blank tubes, and tubes were placed on ice.  To each tube, 10 µl of buffer 
B (containing inhibitor/activator as required) was added, and tubes were placed on ice.  
Sample and blank tubes were removed from ice and placed in a water bath at 30 ºC.  The 
phosphatase assay was started by adding 10 µl of [32P]phosphorylase a at 10 or 15 sec 
intervals.  The mix was vortexed and incubated at 30 ºC for 10 min.  The reactions were 
stopped at 10 or 15 sec intervals by adding 100 µl of 20% (w/v) TCA to each tube, and the 
suspensions vortexed.  Tubes were centrifuged at 12000 g for 2 min at RT in a 
microcentrifuge to sediment the precipitated protein.  From each clear TCA supernatant, 
100 µl were transferred to a second equally labelled set of tubes and the scintillations 
counted in a scintillation counter.  A tube with 10 µl of [32P]phosphorylase a (labelled 
“Total”) was included.  The calculation was made as follows: one unit (U) of protein 
phosphatase activity releases 1 µmol phosphatase from phosphorylase a per minute in a 
standard assay.  Therefore the calculation for 10 min assay is: 
 
c.p.m. released = Sample c.p.m. – Blank c.p.m. 
 
Activity (mU/ml) = c.p.m. released x 0.3 x 130 
                                   c.p.m. Total       10    100 
 
0.3 is the number of nanomoles of phosphorylase in the assay, 10 is the incubation time in 
minutes, 100 is to convert the results for 1 ml rather than 10 µl of enzyme, and 130/100 is 
the fraction of the TCA supernatant that is counted. 
 
 
SELDI-TOF MS ANALYSIS 
 
Chip pretreatments 
 IMAC3 chip: 
 Draw an outline for each spot with a hydrophobic pen.  Load 10 µl of 100 mM 
cupric sulfate (CuSO4) solution and incubate in humid chamber for 15 min.  Do not allow 
solution to dry.  Rinse chip under running deionised water for 10 sec.  Repeat loading 
cupric sulfate solution for another 10 min.  Rinse chip under running deionised water for 
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10 sec.  Equilibrate chip with 10 ml of the respective binding buffer for 10 min (in a 15 ml 
sterile tube) at RT with vigorous shaking.  Transfer chip to bioprocessor. 
 
 H4 chip: 
 Pre-treat chip with 10 ml of 50% Acetonitrile (ACN) for 2 min.  Remove ACN 
solution and add 10 ml of PBS for 2min.  Equilibrate chip with 10 ml of the respective 
binding buffer for 10 min (in a 15 ml sterile tube) at RT with vigorous shaking.  Transfer 
chip to bioprocessor. 
 
 NP20, SAX2 and WCX2 chips: 
 Equilibrate chip with 10 ml of the respective binding buffer for 10 min (in a 15 ml 
sterile tube) at RT with vigorous shaking.  Transfer chip to bioprocessor. 
 
Binding buffers 
 Each chip has appropriate binding buffers that are used to equilibrate the chips 
before being assembled into bioprocessor, to dilute samples and to perform the washes 
after incubation.  After decide which chip and buffer are going to be used, always use the 
same buffer in each step. 
 
IMAC chip: PBS/0.5 M NaCl 
 
H4 chip: PBS/0.5 M NaCl 
  PBS/25% ACN 
 
NP20 chip: 50 mM HEPES pH 7.4 
 
SAX2 chip:  50mM Tris pH 9.0 (low stringency) 
  50mM Sodium acetate pH 4.5 (high stringency) 
 
WCX2 chip:  50mM Tris pH 9.0 (high stringency) 
  50mM Sodium acetate pH 4.5 (low stringency) 
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Bioprocessor assembly 
 Bioprocessor consists on a metal device (the bracket) were chips (1 to12 chips) are 
assembled side by side and a plastic 96-well plate (the top) that is tightly assembled over 
the chips.  A plastic gasket is assembled between the bracket and the top to avoid any 
leaks.  When using less than 12 chips, dummy chips must be used to fill the empty slops in 
the 96-well bioprocessor.  Do not use gloves or just use powder-free ones for handling 
chips and bioprocessor. 
 Equilibrate the chips with 10 ml of respective binding buffers (in 15 ml sterile tubes 
for 10 min at RT with vigorous shaking), assemble them in the bracket side by side and 
putting all with the same orientation (the chip has 8 spots identified from A to H, put A to 
the top, H to the bottom).  Connect the gasket to the top and assemble them to the bracket 
with the chips.  Close tightly.  Load the samples avoiding touch the spot surface and 
surrounding coating of the chip.  Incubate at RT for 90 min with vigorous shaking.  Wash 
quickly each well with 100 µl of corresponding binding buffer.  Remove the chips from the 
bioprocessor.  Wash the chips with 10 ml of binding buffer 3 times for 5 min each in 15 ml 
conical centrifuge tubes with vigorous shaking.  Rinse briefly with 10 ml of HPLC grade 
water and let to air dry.  Load fresh EAM molecule solution (2 µl/spot) and allow to air dry 
for 10 min.  Analyze chips by SELDI-TOF analysis using the ProteinChip System. 
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APPENDIX III – Technical information 
 
CIPHERGEN PROTEINCHIP TECNOLOGY 
 
ProteinChip Arrays 
 The ProteinChip Array consists of a metal base with 8 chemically active sites or 
“spots” where the actual sample binding occurs. 
 
ProteinChip Arrays provide a variety of surface chemistries that allow researchers to 
optimize protein capture and analysis.  The surface chemistries of the arrays include a 
series of classic chromatographic chemistries and specialized affinity capture surfaces.  
Classic chromatographic surfaces include normal phase for generic protein binding; 
hydrophobic surfaces for reversed-phase capture; cation and anion exchange surfaces; and 
immobilized metal affinity capture (IMAC) for metal-binding proteins.  Specific proteins 
of interest can be covalently immobilized on pre-activated surface arrays, enabling 
customized experiments to investigate antibody-antigen, DNA-protein, receptor-ligand and 
other molecular interactions. 
 
H4 Arrays 
Hydrophobic surface arrays, are used for capturing proteins through hydrophobic 
interactions. The active spots chains of 16 methylene groups that can bind proteins through 
reverse phase chemistry via alanine, valine, leucine, isoleucine, phenylalanine, tryptophan, 
or tyrosine. 
 
IMAC3 Arrays 
Immobilized Metal Affinity Capture arrays, can be used to capture molecules that bind 
divalent cationic metals such as nickel, gallium, copper and zinc. 
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NP1 and NP2 Arrays 
Normal phase arrays, are used for general binding of proteins for analysis.  The chemistries 
on the active spots of both arrays contain silicon oxide which allows proteins to bind via 
serine, threonine or lysine. NP1 and NP2 arrays can be used to calibrate using peptides or 
proteins of known molecular weight. 
 
PS1 and PS2 Arrays 
Preactivated surface chip arrays, are used to covalently immobilize biomolecules for the 
subsequent capture or proteins from complex biological samples. 
 
SAX2 Arrays 
The Strong Anion Exchange arrays, can be used to analyze molecules with a negative 
charge on the surface.  The active spots contain cationic, quaternary ammonium groups 
that interact with the negative charges on the surface of target proteins, e.g., aspartic acid 
or glutamic acid. 
Uses for SAX2 arrays include: selective analysis of proteins with low pI’s and for 
biomarker discovery. 
 
WCX2 Arrays 
The Weak Cation Exchange arrays, can be used to analyze molecules with a positive 
charge on the surface.  The active spots contain weak anionic carboxylate groups that 
interact with the positive charges on the surface of the analyte, e.g., lysine, arginine or 
histidine. 
Uses for WCX2 arrays include: selective analysis of proteins with low pI’s and for 
biomarker discovery. 
 
EAM molecule 
 EAM (Energy Absorbing Molecule) are the molecules that assist in the desorption 
and ionization of the analyte (protein or peptide).  The EAM is applied in organic solvent, 
solubilizing many proteins on the chip surface.  As the EAM solution dries, the proteins 
co-crystallize with the EAM.  These crystals absorb the laser energy and generate the 
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ionized proteins detected by the ProteinChip Reader.  In general, the EAM is chosen based 
on the molecular weight of the analyte of interest. 
 
 
Isoelectric point 
 The isoelectric point of a protein (pI) is simply the pH value at which the protein 
has no net charge.  The pI of a protein results from the charges of all the amino acid groups 
on the protein, plus the N-terminus and C-terminus.  Acidic amino acid residues (e.g., 
aspartic acid, glutamic acid) decrease the pI of a protein. Basic amino acid residues (lysine, 
arginine, histidine) increase the pI of a protein. 
The isoelectric point of a protein will strongly influence how well it binds to the ionic 
ProteinChip Arrays.  Proteins with a low pI bind strongly to the anion exchange surface 
(SAX2).  If the buffer solution is lowered below the pI of the protein, the protein will begin 
to bear a net positive charge and will bind more weakly to the surface of the array.  
Proteins with a high pI bind strongly to the cation exchange surface (WCX2).  If the buffer 
solution is increased above the pI of the protein, the protein will begin to bear a net 
negative charge and will bind more weakly to the surface of the array.   
 
The ProteinChip Reader (Series PBS II) 
 The ProteinChip Reader is a laser desertion/ionization time-of-flight mass 
spectrometer that uses state-of-the-art ion optic and laser optic technology. The laser optics 
maximize ion extraction efficiency over the greatest possible sample area, and thus 
increase analytical sensitivity and reproducibility.  The Reader’s ion optics incorporate a 
four-stage, time-lag-focusing ion lens assembly that provides precise, accurate molecular 
weight determinations with excellent mass sensitivity. 
 
The ProteinChip Software 
 Ciphergen’s ProteinChip Software controls all aspects of the ProteinChip Reader 
and facilitates data collection and analysis. 
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